Diabetic peripheral neuropathy and retinal tissue thickness by Srinivasan, Sangeetha
 
 
 
DIABETIC PERIPHERAL NEUROPATHY 
AND RETINAL TISSUE THICKNESS 
 
 
Sangeetha Srinivasan 
M.Phil (Optometry)  
 
Supervisors 
Professor Nathan Efron 
Dr. Nicola Pritchard 
 
 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
School of Optometry and Vision Science 
Institute of Health and Biomedical Innovation 
Faculty of Health 
Queensland University of Technology 
2014
 
 
 
 
 
 
 
 
 
 
 
I 
 
Keywords 
Diabetic peripheral neuropathy 
Diabetic retinopathy 
Ganglion cell complex 
Neuropathy disability score 
Retinal nerve fibre layer 
Retinal thickness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II 
 
Abstract 
Diabetic peripheral neuropathy is a major cause of foot ulceration and lower 
limb amputation (Boulton, 2005). Recent studies demonstrated compromised 
neuroretinal anatomy (Shahidi et al., 2012), retinal function (Lövestam-Adrian 
et al., 2012) and mid-peripheral visual field sensitivity (Sampson et al., 2012) in 
relation to diabetic peripheral neuropathy. In view of the fact that macular and 
the foveal integrity are crucial for central vision, the structural integrity of the 
retina in the macular area deserves particular attention. To date, there is no 
information regarding the integrity of the macula in relation to diabetic 
peripheral neuropathy. Therefore, this research program examined retinal 
tissue thickness in relation to diabetic peripheral neuropathy. Full retinal 
thickness, inner retinal thicknesses at the macula (Ganglion Cell Complex, GCC) 
and that around the optic nerve head (Retinal Nerve Fibre Layer, RNFL) were 
examined.  
Collective evidence from the past suggests key variables such as diabetic 
retinopathy (DR), age, sex of the individuals, duration of diabetes and HbA1c 
levels may influence retinal tissue thickness. Therefore, this research program 
took into account the above key variables for all experiments.  
The diabetic cohort comprised of individuals with type 1 or type 2 diabetes. 
However, it was unclear if the two cohorts can be combined to represent one 
group of individuals with diabetes. Therefore, as a preliminary step, the 
relationship between type of diabetes and retinal tissue thickness was explored. 
It was observed that individuals with type 2 diabetes had a tendency for 
reduced retinal thicknesses when compared to those with type 1 diabetes; 
however, this association was not statistically significant. Therefore, the groups 
with type 1 and type 2 diabetes were combined into one cohort. Subsequently, 
the primary research questions were explored.    
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Neuropathy status was defined using the Neuropathy Disability Score (NDS). 
The NDS involved neurological evaluation of three sensory modalities in the 
feet, namely, vibration sensation, hot and cold sensation, sharp and blunt 
sensation and also the Achilles tendon reflex; the outcome was recorded on a 
continuous scale from 0-10. An NDS ≥ 3 was defined as neuropathy, with higher 
NDS scores indicating advanced degrees of neuropathy. Thus, the association 
between retinal tissue thickness and the severity of neuropathy was assessed. 
It was observed that the perifovea (outer macula) is thinner in relation to the 
severity of neuropathy. On the other hand, the parafovea (inner macula) is 
thinner in the presence of retinopathy.  
As far as the inner retinal thickness is concerned, the RNFL is thinner in 
individuals with advanced degrees of neuropathy.  The GCC thickness also 
showed a tendency to be reduced in relation to the severity of neuropathy; 
however, the relationship did not reach statistical significance.  Interestingly, 
neither RNFL nor GCC thickness showed a significant relationship to DR, thus 
demonstrating that neuroretinal degeneration in diabetes is related to 
peripheral neuropathy rather than retinopathy.  
A thinner perifovea may be associated with changes in the outer retinal layers 
and more specifically the photoreceptor layer. A thinner RNFL may be 
associated with loss in visual field sensitivity. Therefore, this necessitates 
investigation of visual function. 
Examination of pattern-based GCC parameters revealed that individuals with 
diabetes have pockets of loss in GCC volume that is related to the severity of 
neuropathy and a generalized loss in GCC volume that is related to age. These 
findings were not related to DR, duration of diabetes, or the HbA1c levels.  
In conclusion, this research program has contributed to new knowledge 
regarding the retinal anatomy in relation to diabetic peripheral neuropathy.  
The full retinal tissue thickness, the macular and peripapillary nerve fibre layer 
thickness is decreased in individuals with diabetic peripheral neuropathy. The 
results of this research provide a better understanding of these changes in 
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relation to neural pathology occurring elsewhere in the body in individuals with 
diabetes. These findings have important implications to visual function, mobility 
and quality of life issues. More specifically, the retinal compromise documented 
here may pose a threat to the visual integrity of individuals with neuropathy, 
and hence investigation of the functional correlates of these structural changes 
(i.e. assessment of visual function) is warranted.  
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Thesis outline 
The thesis is organized as follows: 
Chapter 1 reflects on the natural history of diabetic neuropathy, the risk factors 
involved and the traditional tests used in the assessment of neuropathy. The 
final section of this chapter presents the ophthalmic complications in relation to 
diabetic neuropathy. The purpose of this chapter is to provide an in-depth 
understanding of the signs and symptoms in diabetic neuropathy and the tests 
involved in the detection of neuropathy.  
Chapter 2 discusses in detail, retinal degeneration in diabetes. The intention of 
this chapter is to offer a fundamental insight into the vascular and neural 
involvement in diabetes. The chapter begins with a brief introduction to retinal 
anatomy and the factors influencing retinal anatomy. Following this a detailed 
discussion of the features of diabetic retinopathy is presented. The literature 
that investigated retinal thickness in individuals with diabetes has been 
reviewed and debated in the later sections of Chapter 2.  
Chapter 3 presents the general methodology used in this research. Methodology 
specific to each individual experiment has been provided in respective chapters. 
The experiments constitute Chapters 4 to 6. A series of cross-sectional studies 
examined the relationship between diabetic peripheral neuropathy and the 
retinal tissue thickness in a group of individuals with type 1 or type 2 diabetes. 
The full retinal and the inner retinal thicknesses were examined in relation to 
diabetic neuropathy. Further study involved examination of pattern-based 
ganglion cell complex parameters in relation to diabetic neuropathy and is 
discussed in Chapter 5. Chapter 6 presents an analysis of the retinal tissue 
thickness in individuals who had undergone laser treatment for diabetic 
retinopathy, in comparison to those with retinopathy but no laser treatment. 
 
VI 
 
Finally, Chapter 7 summarizes the findings from all the experiments, including a 
discussion of the strengths, limitations and the implications of this work.  
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Chapter 1: Diabetic peripheral neuropathy 
Diabetes is the leading cause of non-traumatic lower limb amputation (Siitonen 
et al., 1993). Diabetic peripheral neuropathy (DPN) predominantly affecting the 
sensory nerves of the feet and lower limbs can be particularly problematic as it 
can lead to foot ulceration and eventually amputation (Boulton, 2005). Corneal 
sensory nerve networks have been shown to be compromised in relation to the 
degree of peripheral neuropathy (Malik et al., 2003)  (Quattrini et al., 2004) 
(Tavakoli et al., 2010). This link between diabetic peripheral neuropathy and 
the eye has been also demonstrated by alterations to retinal anatomy (Shahidi 
et al., 2012) and visual fields (Sampson et al., 2012). These two studies 
demonstrated peri-papillary nerve fibre layer thickness reduction and mid-
peripheral visual field sensitivity reduction in people with neuropathy 
compared to people without neuropathy. In view of the fact that macular and 
the foveal integrity are crucial for central vision, the structural integrity of the 
retina in the macular area deserves particular attention. Therefore, this 
research project was designed to explore retinal tissue thickness in people with 
and without diabetic neuropathy in relation to other factors that affect the 
retinal thickness. Further rationale is discussed in Chapter 3. As it is important 
to gain an in-depth understanding of diabetic neuropathy and the risk factors 
involved, this chapter begins with an introduction to diabetic neuropathy, 
followed by a review of pathogenesis in neuropathy. Subsequently, the natural 
history of diabetic neuropathy, risk factors, and the diagnostic tests for diabetic 
neuropathy are described. Ocular changes in association with diabetic 
neuropathy are subsequently discussed. 
 1.1 Introduction 
Peripheral neuropathy can affect  up to 50% of individuals with diabetes 
(Tesfaye et al., 1996). The aetiology has been linked to prolonged raised blood 
glucose levels and compromised blood supply in diabetes. Initially, the 
Diabetic peripheral neuropathy 
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peripheral nerves are involved with the first sign of nerve damage occurring in 
the feet (Reiber et al., 1998). If left untreated, it can affect other body parts.  
A person with neuropathy can have symptoms such as numbness or tingling at 
one end of the spectrum or painful symptoms at the other end of the spectrum 
(Boulton et al., 1998). Loss of sensation in the foot can increase the risk of foot 
injury. This when combined with poor wound healing in diabetes, can lead to 
foot ulcers and may require amputation.  
Neuropathic pain can be mild or severe but can worsen especially at night 
(Archer et al., 1983). This causes the person to seek medical attention. It can 
also cause unsteadiness while walking and can interfere with daily activities. 
Symptoms can also include poor bladder control, bowel movement or impaired 
movement of one or more toes. Since no effective treatment exists, screening for 
the disease and early intervention becomes vital, in arresting the development 
or in preventing or delaying the progression of neuropathy.  
1.2 Pathogenesis  
Several mechanisms such as hyperglycaemia, polyol pathway, ischaemia and 
oxidative stress have been identified in the pathogenesis of diabetic neuropathy 
(Tomlinson, 2002). A schematic has been shown in Figure 2. A combination of 
the above pathways has been proposed in the pathogenesis of diabetic 
peripheral neuropathy.  
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Figure 2. Hyperglycaemia, polyol pathway, ischaemia and oxidative stress are some of the pathways 
identified in the pathogenesis of diabetic neuropathy 
 
A chain of events is involved, that lead to eventual axonal degeneration and a 
functional breakdown.  
There is a more direct damage to the neurons from hyperglycaemia and 
ischaemia. Neurons need a constant supply of glucose; glucose uptake depends 
on extracellular glucose concentration. In the presence of hyperglycaemia, there 
can be up to a four-fold increase in the uptake of glucose. When this condition 
occurs long-term or occurs more frequently, the nerves are damaged.  
The enzyme aldose reductase, catalyses the conversion of glucose to sorbitol. 
Peripheral nerve damage has been reported to be associated with over-
expression of aldose reductase inhibitor enzyme in animal models (Yagihashi et 
al., 2001). High extracellular glucose increases oxidative metabolism of glucose 
in the mitochondria, which releases free radicals (Glock et al., 1955). There is 
Schwann cell damage and a reduction in a range of factors such as free radical 
scavengers and nerve growth factors, along with a decrease in the regenerative 
Diabetic peripheral neuropathy 
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capacity of axons. These changes can ultimately damage cellular properties 
resulting in direct damage to the nerve axons. 
Nerves depend on small blood vessels for their nutrition and oxygen supply. 
High blood glucose levels affect the blood vessels that supply the nerves and 
consequently the nerves are damaged. Focal nerve lesions have been observed 
with severe blood vessel damage. However, neuronal function improved with 
improvement in blood supply thus indicating a strong association (Cameron et 
al., 2001) and also a potential to improve with intervention. There is also an 
overall reduction in neurotrophic factors like nerve growth factor and a 
subsequent decrease in the ability to repair nerves and degeneration of 
Schwann cells, followed by a complete neuronal functional breakdown.  
Certain other factors such as C-peptides, VEGF, immune mechanisms and 
insulin-like growth factors have also been reported to be involved in the 
pathogenesis of diabetic neuropathy (Boulton et al., 2004). It is encouraging that 
neuropathy is responsive to modifications in the glycaemic levels and 
improvement in blood supply thus demonstrating a potential for improvement.  
1.3 Natural history of diabetic neuropathy 
The natural history of diabetic peripheral neuropathy is not well defined 
because the criteria for diagnosis and the methods for detection varied between 
studies and therefore the prevalence. Diabetic neuropathy can be thought to 
present in two ways: a gradually progressive type that worsens with the 
duration of diabetes and the other acute type that can be treated. Neuropathy 
may present as 1) Peripheral neuropathy 2) autonomic neuropathy (Vinik, 
2008) 3) focal neuropathy 4) proximal neuropathy or a combination of these. 
The following sections examine in depth, the type of nerve fibre involvement, 
the symptoms in neuropathy and the traditional tests used in the detection of 
neuropathy. Peripheral neuropathy and autonomic neuropathy are the 
commonly occurring types and are therefore discussed in detail in the following 
sections. 
Diabetic peripheral neuropathy 
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1.3.1 Types of nerve fibres 
Presentation of neuropathy can largely depend on the type of nerve fibres 
involved. The nerve fibres can be broadly classified as large, medium and small 
fibres (Brown et al., 2004). The features are summarized below.  
Large nerve fibres 
• Heavily myelinated 
• A-alpha fibres (motor strength) 
• A-beta fibres (vibratory, touch sensation) 
Medium nerve fibres 
• Myelinated 
• A-gamma fibres (information to muscle spindles) 
Small nerve fibres 
• Myelinated A-delta fibres 
• Unmyelinated or myelinated C fibres 
• Both innervate skin (somatic fibres), involuntary muscles (cardiac, 
smooth muscles, autonomic fibres) 
A-alpha fibres are large and heavily myelinated and are responsible for motor 
strength and proprioception. A-beta fibres are also heavily myelinated but carry 
vibratory and touch sensations. A-delta fibres are small myelinated fibres that 
carry sensory information about pain and cold sensation. A-gamma fibres carry 
information to muscle spindles. 
C-fibres are small fibres that may be myelinated or unmyelinated and carry 
sensation of warmth and pain and also regulate autonomic reflexes such a blood 
pressure, heart rate regulation and sweating. 
Figure 3 is a representation of the type of neuropathy and the corresponding 
regions affected. 
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Figure 3. (A) Peripheral neuropathy (B) Autonomic neuropathy. Adapted from Diabetic 
neuropathies: The nerve damage of diabetes, National Diabetes Information Clearinghouse 
 
1.3.2 Peripheral neuropathy  
This is also referred to as distal polyneuropathy; the most common neuropathic 
presentation in both type 1 and type 2 diabetes, characterised by a length-
dependent process that involves distal nerves first and then progresses to 
involve proximal nerves; also called as glove-stocking distribution.  Figure 3A is 
a representation of regions involved. By the time, knees are affected, symptoms 
progress to the tips of fingers (Veves et al., 2007, p.251). Impaired sensation can 
progress to involve the skin of the chest.  
Neuropathic symptoms 
Symptoms are primarily sensory with tingling or numbness and tend to be 
symmetrical (Boulton et al., 2009) thus indicating large nerve fibre involvement. 
Symptoms such as burning sensation or pain in the lower extremities (Lacomis, 
2002) suggests small fibre involvement. Patients can have abnormal or 
impaired thermal sensation but essentially normal vibration perception.  
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Paradoxically, individuals with painful neuropathy may have only a minimal 
neurological deficit but individuals with loss of sensation in the foot can have 
very advanced stage of nerve damage (Boulton, 2005) thus emphasizing the 
need for a more comprehensive neuropathy evaluation. However, the presence 
of pain in neuropathy is thought to be protective (Boulton, 2012) where 
individuals can have heightened awareness of the problem and can approach 
the health practitioner and have their diabetes status monitored. 
1.3.3 Autonomic neuropathy 
Cardiac neuropathy and postural hypotension are some of the features of 
autonomic neuropathy and are explained below. Resting tachycardia (where an 
indi idua ’s  eart rate during rest is a n r a     ig   r   re t an 100  eats 
per minute) is generally the first clinically detectable sign of cardiac neuropathy 
(Stewart et al., 1992). A fall in systolic blood pressure of 20 mmHg or more, 
when switching from lying to standing position, without any increase in heart 
rate is defined as postural hypotension (Stewart et al., 1992). There can be a 
risk of silent ischemia and myocardial infarction in people suffering from 
cardiac autonomic neuropathy. Gastroparesis (signs of fullness or vomiting), 
diabetic diarrhoea (watery diarrhoea after food especially at night), bladder 
atony (large residual volume after microurition), impotence and premature 
ejaculation are some disconcerting symptoms in autonomic neuropathy (Said, 
2007). Figure 3B is shows regions involved in autonomic neuropathy. 
Ophthalmic manifestations of autonomic neuropathy may involve a sudden 
painful ophthalmoplegia (extra ocular muscle paresis), abnormal pupillary light 
reflexes or miosis (Lanting et al., 1990). 
Non-diabetic causes of neuropathy 
Other causes of peripheral neuropathy include autoimmune diseases like 
r eu at id art ritis ( a  is et a .  19  )  infe ti ns su   as Hansen’s disease 
(Charosky et al., 1983), AIDS (Simpson et al., 2000), certain toxic substances like 
alcohol (Hillbom et al., 1984), vitamin deficiency (McCombe et al., 1984), and 
chronic exposure to radiation, trauma, and tumours exerting pressure on the 
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spinal cord. A detailed history can therefore play a vital role in differential 
diagnosis.  
1.4 Risk factors for diabetic neuropathy 
Prolonged duration of diabetes, poor glycaemic control, advancing age, systemic 
hypertension, smoking, higher body mass index, abnormal lipid profile and 
alcohol intake have been reported as risk factors for DPN (Adler et al., 1997; 
Forrest et al., 1997; Partanen et al., 1995; Tesfaye et al., 2005; Van De Poll-
Franse et al., 2002). Of these, poor glycaemic control and prolonged duration of 
diabetes have been reported as strong risk factors.     
In another study (described below), the proportion of people with neuropathy 
was higher among those with prolonged duration of diabetes. The prevalence of 
neuropathy was 12% among those with duration of diabetes less than 7 years 
and the percentage increased to 42% for duration of 15 years and greater. A 
similar trend was also observed for higher HbA1c values. The proportion of 
people with diabetic neuropathy was 26% for a HbA1c level of 5.4-6.4%, and the 
percentage increased to 40% for a HbA1c value greater than 7.8% (Tesfaye, et 
al., 1996). In addition, treatment of chronic hyperglycaemia led to improvement 
or reversal of neurological abnormalities and symptomatic relief from pain, thus 
suggesting a strong association between hyperglycaemia and diabetic 
neuropathy (Boulton, 1982).  
Tesfaye et al (1996) examined the frequency of diabetic neuropathy in a cohort 
of people with type 1 diabetes. The authors observed the prevalence of diabetic 
neuropathy to be lower (19%) in the younger age group 15-29 years, as 
compared to that in the age group 45-61 years (57%), when adjusted for 
duration of diabetes and HbA1c suggesting that advancing age is an important 
risk factor in diabetic neuropathy.  
The relative risk for developing neuropathy has been reported to be 3.92, 95% 
CI [2.23, 6.91] for the presence of systemic hypertension; 1.74, 95%CI [1.07, 
2.83] for positive history of smoking and 2.6, 95% CI [1.6, 4.3] for HbA1c levels 
 f ≥ 10% (F rrest et a .  2002). 
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The question whether the type of diabetes is related to neuropathy is not well 
understood. Prevalence of neuropathy has been reported to be slightly higher in 
people with type 2 diabetes (32.1%) compared to that in type 1 diabetes 
(22.7%) in a multicentre study conducted in hospital population in the UK 
(Young et al., 1993). In experimental animal models, neuropathy has been 
reported to differ between the two types of diabetes. Kamiya et al (2004) and 
Sima et al (2006) observed greater extent of axonal degeneration in type 1 form 
of rats than the type 2 form of rats, (Kamiya et al., 2005) (Sima et al., 2006). 
Therefore, the relationship between type of diabetes and neuropathy is not well 
understood and requires further investigation.  
For the purposes of this research project, risk factors namely age, duration of 
diabetes, HbA1c levels, systemic hypertension, smoking, body mass index and 
lipid profile have been analysed in individuals with and without neuropathy.  
1.5 Diagnostic tests for diabetic neuropathy 
Traditional tests for diabetic neuropathy include nerve conduction studies, 
quantitative sensory testing (QST) and autonomic nerve function testing 
(Tesfaye et al., 2009). The nerve conduction studies, 128-Hz tuning fork, ankle 
reflex tests and monofilament generally test for the large nerve fibres 
involvement; temperature sensation assessment using hot and cold rods and 
pinprick sensation evaluation using Neurotip® device (as a part of NDS) are 
generally used in the assessment of small nerve fibre involvement. Neuropathy 
symptoms are evaluated using the diabetic neuropathy symptom score (DNSS).  
The QST, NDS, monofilament test and the DNSS are subjective in nature in that, 
the participants are required to respond; whereas, skin biopsy, nerve 
conduction studies, Neuropad and heart rate variability are objective tests for 
neuropathy. Evaluation of postural changes in blood pressure, the heart rate 
variability and sweating response is a part of autonomic neuropathy testing. 
The following sections describe in detail, the tests involved in the assessment of 
neuropathy.  
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1.5.1 Skin biopsy  
Skin biopsy involves excising a 3mm section on the skin of the distal leg and 
thigh (Polydefkis et al., 2001). This allows for a direct and a quantitative 
evaluation of the peripheral nerve fibres but requires qualified medical 
personnel. In addition, only small fibre involvement can be assessed. 
Nevertheless, skin biopsy can also reveal information about morphological 
changes such as swelling and pathological changes in the intraepidermal nerve 
fibres (IENF) such as branched patterns, which are difficult to visualize 
otherwise. The IENF also inversely correlates with duration of diabetes and 
elevated warm sensation threshold (Shun et al., 2004). Despite the advantage 
over other techniques, skin biopsy can still be debated as a minimally invasive 
technique. However, several other non-invasive techniques (described below) 
have emerged that involve non-invasive assessment of both small and large 
fibre involvement and can be performed in a clinical scenario with minimal 
training or specialization. 
1.5.2 Diabetic neuropathy symptom score (DNSS)   
Diabetic neuropathy symptom score is a validated questionnaire for symptom 
assessment that contains four general questions regarding unsteadiness while 
walking, experience of burning and aching pain or tenderness sensation in legs 
or feet, prickling sensation in legs or feet and places of numbness in legs or feet. 
A score of 1 is given for the presence of symptom and 0 for the absence of 
symptom. A score of 1 or more out of 4 is abnormal (Meijer et al., 2002).  
1.5.3 The 10g Monofilament test 
This is a sensitive, reproducible and a rapid screening method to assess 
touch/pressure sensation in large nerve fibres (Smieja et al., 1999) (Dros et al., 
2009) (Perkins et al., 2010). The 10g monofilament test enables the clinician to 
map the areas of reduced pressure perception by exerting a specific repeatable 
bending force on test site (Figure 4) and by having the participant respond 
whether they felt it or not (Valk et al., 1997). The outcome is recorded as 
number of points detected out of three. 
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Figure 4. Monofilament test: Circles showing tested sites 
(David et al., 2005) 
 
1.5.4 Neuropathy disability score (NDS)  
The NDS test involves neurological examination of three sensory modalities 
namely, sharp and blunt sensation, hot and cold sensation and vibration 
sensation. In addition, the ankle reflex is also tested. Figure 5 shows the 
instruments used for NDS assessment.  
Sharp and blunt sensation is tested using a Neurotip® device for both touch and 
pain sensation. A neurotip device has two ends: one end with a sharper tip to 
test for pain sensation and a blunt tip to test for blunt sensation. The other end 
has the monofilament (described earlier). The individual is asked to identify if 
the type of stimulus is sharp or blunt (Figure 5A). 
The temperature sensation is assessed in the arch of the feet using rods 
immersed in hot and cold water (Figure 5B). 
Vibration perception is tested with a 128-Hz tuning fork on the plantar aspect of 
the great toe and the patient responds with a ‘ es’  r ‘n ’ if t e  fe t it  r n t 
(Figure 5C). 
A score of 0 is given for correct response and 1 for incorrect identification for 
each individual test component in the above three tests. 
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The ankle reflex is assessed using a reflex hammer, with the scores being 0 for 
normal, 1 for reinforcement and 2 for absent (Figure 5D). 
Each foot can have maximum score of 5 resulting in a total score of 10 for both 
feet. NDS scores 0-2 is classified as no neuropathy, 3-5 indicates mild 
neuropathy, 6-8, moderate neuropathy and 9-10 indicates severe neuropathy. 
NDS score of six or greater predicts foot ulceration (Young et al., 1993). The NDS 
criterion of neuropathy has been utilized in the current study.  
 
 
Figure 5. Equipment used in NDS testing (A) Neurotip® device (B) Hot and cold rods (C) Tuning 
fork (D) Reflex hammer 
 
 
1.5.5 Nerve conduction studies 
The nerve conduction studies involve electrophysiological assessment of 
peroneal, tibial or sural nerve conduction velocities (CV) and amplitudes in the 
lower limb of the participants (Figure 6), in order to assess the degree of 
damage to the nerve fibres in relation to neuropathy. Nerve conduction 
B C A 
D 
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velocities and amplitudes are then compared with the age-related normal 
values. Nerve conduction studies (NCS) have been reported as a sensitive 
method for detecting peripheral neuropathy (Valensi et al., 1997). However, 
NCS essentially tests the large nerve fibre involvement and therefore are not 
very helpful in detecting small fibre neuropathy (Jamal et al., 1987); in addition, 
the testing requires trained examiners.  
 
Figure 6. Electrophysiology testing 
 
1.5.6  Quantitative sensory testing  
Quantitative sensory testing (QST) is a set of valid quantitative psychophysical 
methods for evaluating sensory nerve function. QST measures the threshold in 
response to a range of stimuli such as vibration and thermal stimuli and pain 
thresholds in response to heat and cold (Young et al., 1994).  
Figure 7 shows the Neurosensory Analyser Model TSA-II utilized in the current 
study.  
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Figure 7. The Neurosensory Analyser Model TSA-II  (A) Neurosensory analyser (B) Thermode (C) 
Vibratory sensory analyser (D) Patient response button (E) Vibration stimulator (Image: courtesy Dr. 
Ayda M Shahidi) 
 
The threshold values are then compared with age and gender-based normative 
values. With the variation in the type of stimulus used, QST can detect large and 
small fibre deficits. (Vinik et al., 1995). In the presence of sensory deficit, the 
threshold will be elevated. However, QST requires the use of sophisticated 
equipment and may be time consuming in a clinical environment. In addition, 
the subjective nature of the test requires the person to be cooperative and 
attentive.  
Since QST involves quantitative evaluation of small and large nerve fibres, QST 
can be of great value in assessing neuropathic progression (Zaslansky et al., 
1998). The current research program has analysed neuropathy variables as 
assessed using QST measures.  
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It is to be noted that there is an ongoing debate regarding the best method to 
detect neuropathy. For small fibre neuropathy, however, skin biopsy is accepted 
as the standard technique. There is currently no accepted gold standard test for 
detecting diabetic peripheral neuropathy (Horowitz, 2002).  
1.5.7 Tests for autonomic neuropathy 
Assessment for postural hypotension (Ewing et al., 1982) (as previously 
described in section 1.3.3), heart rate variability and NeuropadTM are some of 
the tests used in autonomic nervous system testing.  
Heart rate variability (HRV) involves assessing beat-to-beat alterations in heart 
rate during deep breathing with the use of electrocardiograph equipment 
(Osterhues et al., 1998).  
The NeuropadTM (miro Verbandstoffe GmbH, Wiehl, Germany) is a simple, rapid 
and an inexpensive test for autonomic neuropathy that assesses small fibre 
dysfunction, by assessing the sympathetic cholinergic innervations to the skin. 
Sympathetic nerve fibres supply sweat glands. NeuropadTM, an adhesive pad 
containing cobalt salts, is attached to plantar aspect of the foot. The pad changes 
colour from blue to pink within 10 mins if sudomotor and hence the cholinergic 
sympathetic function is normal (Stewart, et al., 1992). An abnormal neuropad 
response is associated with sympathetic dysfunction and clinical neuropathy 
(Quattrini et al., 2008). 
For the purposes of this thesis, measures of HRV and Neuropad are not 
included. 
It is to be noted that there is an ongoing debate regarding the best method to 
detect neuropathy. To date, there is no accepted gold standard for detecting 
diabetic peripheral neuropathy (Horowitz, 2002).  
Diabetic neuropathy has been reported to be associated with neuronal 
complications in the eye. The following section discusses the studies reporting 
this association. 
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1.6 Corneal and retinal changes in relation to diabetic neuropathy 
1.6.1 Corneal nerve structure and corneal sensitivity compromise  
Various corneal nerve structural and functional deficits have been reported in 
relation to diabetic neuropathy. Corneal sensitivity and vibratory perception in 
the distal leg were found to be reduced in people with diabetes and has been 
attributed to diabetic polyneuropathy (Nielsen, 1978). Corneal nerve fibre 
density and nerve fibre branching (Edwards et al., 2012; Edwards et al., 2012; 
Efron et al., 2010) are significantly reduced in people with diabetes when 
compared to people without diabetes (Malik, et al., 2003; Quattrini, et al., 2004). 
Corneal nerves are tortuous in people with severe neuropathy when compared 
to mild and moderate degrees of neuropathy as well as the group without 
diabetes (Kallinikos et al., 2004). A corneal sensitivity threshold of 0.66 
millibars or higher with non-contact corneal aesthesiometry most likely 
indicates neuropathy (Pritchard et al., 2012; Pritchard et al., 2010). Corneal 
nerve fibre growth has been demonstrated after pancreatic transplantation 
(Mehra et al., 2007). Corneal nerve fibre density improved after a 25-month 
metabolic control (Iqbal et al., 2005), suggesting improvement in nerve 
structure with intervention. This emphasizes the importance of early detection 
for timely referral so as to prevent further damage. These studies suggest an 
association between a generalised form of diabetic neuropathy and nerve fibre 
changes in the cornea (Edwards et al., 2012, Edwards et al., 2012; Efron et al., 
2010; Pritchard et al., 2011). Apart from the corneal compromise, retinal 
investigations also revealed compromised retinal structure, function and visual 
field sensitivity in association with diabetic neuropathy. The following studies 
report this finding.  
1.6.2 Retinal structure and visual functional compromise  
Sampson et al (2012) analysed the visual field sensitivities in people with type 2 
diabetes with neuropathy (defined using NDS), in comparison to people with 
diabetes without neuropathy. Visual field sensitivities were analysed by 
quadrant and at eccentricities 0-10, 11-20 and 21-30 degrees using standard 
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automated perimetry. The authors noted similar visual sensitivities in the two 
groups for smaller degrees of eccentricity. However, for eccentricities beyond 7 
degrees, there was a steep relative decline in visual field sensitivity in the 
neuropathy group. Also at eccentricities beyond 15 degrees, the groups with 
and without DPN were statistically shown to be separated. The difference 
between groups was greatest for eccentricity 21-30 degrees (Sampson et al., 
2012). 
A previous pilot study by Shahidi et al (2012) assessed the relationship between 
retinal nerve fibre layer (RNFL) thickness and peripheral neuropathy in a group 
comprising of 82 individuals with type 2 diabetes and compared with 24 
healthy individuals. Participants were in the age group 45-77 years, with no 
difference in age or male to female ratio in either group. The diabetes cohort 
consisted of 23 people with no neuropathy (NDS 0-2), 32 with mild neuropathy 
(NDS 3-5), 16 with moderate neuropathy (NDS 6-8) and 11 with severe 
neuropathy (NDS 9-10). An NDS s  re ≥   was used f r defining  e   e at ris   f 
foot ulceration (Abbott et al., 1998). There were 36 individuals without DR, 16 
with minimal DR, 25 mild DR, and 1 moderate DR (Shahidi et al., 2012). Global 
and sectoral RNFL thicknesses were examined with a spectral domain OCT in 
people stratified according to neuropathy disability score. The authors noticed 
no difference in RNFL global or sectoral thicknesses between people with 
diabetes with and without neuropathy. However, for people at risk of foot 
u  erati n (NDS ≥  )  t e inferi r  NFL t i  ness was signifi ant   redu ed. 
Multivariable regression models were used to determine the relationship 
between neuropathy and RNFL thickness. There was no effect of retinopathy or 
interaction between retinopathy and neuropathy on RNFL thickness. The study 
observed that the RNFL thickness reduced with the severity of neuropathy 
defined using NDS criteria. The reduction in RNFL thickness was not explained 
by age, glycaemic levels or the retinopathy status, in a cohort of people with 
type 2 diabetes.  
Another recent study observed significantly reduced multi-focal visually evoked 
potential (mfVEP) amplitudes in the lower nasal visual field quadrant, in people 
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with neuropathy, compared to those without neuropathy (Lövestam-Adrian et 
al., 2012). The mfVEP is an objective method for assessing neuroretinal function 
(Jiang et al., 2011). It is interesting to note that both the groups had similar 
percentage of people with DR; however the group with neuropathy were 
significantly older (mean difference = 12 years) than the group without 
neuropathy. For the reason that advancing age is a risk factor for neuropathy in 
people with diabetes, the differences in age may have confounded the results to 
a certain extent. Nevertheless, this could also suggest a local response of a 
generalised polyneuropathy that might be exerting subtle neuroretinal changes 
in the eye that is not explained by DR.  
In addition to the inner retinal layer compromise, it is likely that the other 
retinal layers may be involved in diabetic neuropathy. Therefore, with the 
 n w edge   tained fr   S a idi’s stud   t e  urrent study was designed to 
explore the full retinal thickness, macular and the peripapillary nerve fibre layer 
thickness in individuals with and without neuropathy. Collective evidence from 
previous studies indicate that several factors such as DR, age, sex, duration of 
diabetes and HbA1c levels influence the retinal tissue thickness. In the current 
research project, multivariable regression models have been utilized to adjust 
for the known confounding factors, for example, age and DR.  
Having discussed the features associated with diabetic neuropathy, Chapter 2 
will focus on retinal degeneration in diabetes.  
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Chapter 2: Retinal degeneration in diabetes 
2.1 Introduction  
Several studies (described below) have attributed neuroretinal degeneration in 
diabetes to diabetic retinopathy. However, other studies have observed 
degeneration in retinal layers even in the absence of DR. More recently,  
compromised RNFL thickness (Shahidi et al., 2012), decreased visual field 
sensitivity (Sampson et al., 2012), and visual function in the inferior quadrant 
(Lövestam-Adrian et al., 2012) in individuals with diabetes have been attributed 
to diabetic neuropathy rather than DR. This leads to the further hypothesis that 
the retinal tissue thickness in diabetes reported in previous studies may have 
been confounded by diabetic peripheral neuropathy. With this knowledge, the 
current research program has been structured around the hypothesis that DPN 
may be related to retinal tissue thicknesses and therefore may confound 
estimates of retinal tissue thickness in studies that fail to account for the 
possible impact of DPN.  
This chapter presents a review of the retinal anatomy, and discusses the factors 
that influence retinal tissue thickness. Subsequently, studies that have examined 
retinal anatomy and function in the presence and the absence of diabetic 
retinopathy are reviewed.   
2.2 Retinal anatomy 
The macula is located between the superior and the inferior arcades temporal to 
the optic nerve head, and slightly below the horizontal meridian (Antonetti et 
al., 2006). Spitznas M (1973) (as cited by Apple, 1981) reported that the entire 
macula measures about 5.5 mm in diameter; the centre of the macula the fovea, 
measures approximately 1.5 mm in diameter and has a bright foveal reflex at 
the centre due to the concavity of the foveal pit that allows it to act as a concave 
mirror (Rose, 1988). The central  500 µm of the fovea is called the foveal 
avascular zone (FAZ) and is totally devoid of blood vessels and therefore 
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dependent on the choriocapillaris for its nutrient supply (Tombran-Tink et al., 
2007.pg.18). The foveola (centre of the fovea, measuring about 0.2 mm 
diameter) has sloping walls called clivus which is seen as an annular ring reflex 
in children and young adults (Hildebrand et al., 2010). The foveola has the 
highest density of cone photoreceptors, where the rods are essentially absent. 
The long axons of the photorece t rs t at f r  t e Hen e’s  a er fan  ut fr   
the centre (also called the parafovea) (Chan et al., 2006).  
Polyak (1941) was the first to describe the macula as fovea, parafovea and 
perifovea (Polyak, 1941). A schematic of this has been shown in Figure 8A. The 
fovea lies within the imaginary circle of diameter 1mm; the parafovea is the 
region outside the 1.5 mm and within 2.5 mm diameter. The parafovea 
comprises of several layers of ganglion cells. On the other hand, the perifovea 
marks the periphery of the macula where the density of ganglion cells is 
comparatively lesser and is the region outside the 2.5 mm zone but within 5.5 
mm circle. The peripheral retina purportedly lies outside the temporal arcades 
where the ganglion cell layer is essentially single layer in thickness. 
 
 
Figure 8. (A) Concentric retinal zones namely central zone, parafovea, perifovea (B) Histology of 
retina near fovea.  (Image adapted from the University of Delaware Image Library) 
 
Bending of neural layers 
A 
B 
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The retina comprises of 10 layers. The retinal pigment epithelium (RPE) which 
is the outermost retinal layer (Figures 8B and 9), adjacent to the choroid, is a 
single layer of cuboidal epithelium containing melanin, and is densely packed 
with mitochondria, endoplasmic reticulum and ribosomes (Fantes et al., 1989). 
Lipofuscin, which is a product of degradation of outer segments of 
photoreceptors, is also present in the RPE cells. Photoreceptors (rods and 
cones) are specialized neuronal cells that convert light impulses to nerve signal 
by a process called transduction. 
 
Figure 9. Retinal layers as seen on SD-OCT (Werner et al., 2011) 
The human retina contains 3-6 million cones and 75-107 million rods. Electron-
microscopic structure of a photoreceptor comprises of an outer segment that 
contains photopigment, an inner segment, a filament that resembles an axon 
and an end terminal that connects to the outer plexiform layer. The 
ter in   gies  ‘r ds’ and ‘  nes’ are deri ed fr   t e s a e  f the outer 
segments of photoreceptors. The photoreceptor nuclei constitute the outer 
nuclear layer, which is the thickest in the foveolar region (Figure 9).  
The retina is composed of three layers of nerve cell bodies and two layers of 
synapses (Figure 9).  
The layers comprising of the nerve cell bodies are: 
(i) Outer nuclear layer (ONL) (consisting of nerve cell bodies of rods and 
cones) 
(ii)  Inner nuclear layer (INL) (consisting of nerve cell bodies of amacrine 
cells, horizontal cells and bipolar cells) 
(iii) Ganglion cell layer (GCL) (consisting of nerve cell bodies of ganglion 
cells) (Lens et al., 2008) 
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The two layers of synapses are, the 
(i) Outer plexiform layer (OPL) (has synapses between endplates of rods 
and cones with that of the dendrites of amacrine, horizontal and 
bipolar cells) 
(ii) Inner plexiform layer (IPL) (has synapses between the axons of bipolar 
cells and the dendrites of ganglion cells (Figure 9). This also has 
interspersed network of vertically and horizontally directed 
amacrine cells that integrate with ganglion cells (Krebs et al., 1991). 
The photoreceptor terminals interact with each other via the horizontal and 
bipolar cells (also called interneurons). These interneurons which also include 
amacrine cells, connect the photoreceptor layer to the ganglion cells and hence 
the nerve fibre layer. Bipolar cells connect as little as one cone with that of 
ganglion cell, whereas, they connect many rods with each ganglion cell more 
peripherally. The fibres (axons) of the ganglion cells constitute the retinal nerve 
fibre layer. There are four types of glial cells in the retina; Muller cells, 
astrocytes, microglia and oligodendrocytes (Bringmann et al., 2013). Muller 
cells extend to the outer and deeper layers of the retina, to form the outer and 
inner limiting membranes respectively. Endothelial cells, pericytes, astrocytes 
and amacrine cells also occupy the inner retinal layers. Research reports twenty 
or more different ganglion cell types (Shabana et al., 2003). The axons of the 
ganglion cells travel towards the optic nerve head. However, due to their 
convergence at the optic nerve head (ONH), the nerve fibre layer is the thickest 
around the ONH (Curcio et al., 1990).  
2.3 Factors influencing the full retinal thickness  
The full retinal thickness is essentially the thickness from the retinal pigment 
epithelium up to the vitreoretinal layer (Sadda et al., 2006) (Figure 10). The full 
retinal tissue thickness is influenced by factors such as age, gender, refractive 
error and ethnicity. The following section provides a review of those findings. 
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Figure 10. Factors affecting the full retinal thickness (indicated by black line) 
 
The studies cited in this entire review used optical coherence tomography 
(OCT) technique unless otherwise stated.  
2.3.1 Retinal thickness and age 
Total macular volume (volume data of the macular area) as well as the macular 
thickness has been found to decrease with age (Fraser-Bell et al., 2005).   
The Early Treatment Diabetic Retinopathy Study (ETDRS) observed that the 
thickness in the nine zones thicknesses reduced at the rate of 0.26-0.46 µm per 
year increase in age (Eriksson et al., 2009). Figure 8A shows a schematic of 
ETDRS zones. 
Retinal thickness reduces at the rate of 0.53 µm per year increase in age 
(Alamouti et al., 2003). In contrast, a group of authors observed no relationship 
with age (Wong et al., 2004). Differences in the scan protocols could explain the 
variations in study results. Alamouti et al used a vertical scan line of 2.3 mm 
aligned at temporal disc margin. However, Wong et al observed thickness 
measured at the central 1 mm macula to have no relationship with age. In 
general, the reduced macular thickness with age might possibly be related to 
Full retinal thickness – influenced by 
1. Age 
2. Gender 
3. Ethnicity 
4. Refractive error and other clinical parameters 
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age-related ganglion cell loss and hence the axons (RNFL). For the reason that 
the neural layers are essentially pushed away from the foveal centre, any 
changes in the neural layers with age may not be noticeable in the foveal centre. 
Ooto et al (2011) noticed the thickness between inner-outer segment of 
photoreceptor till the inner border of photoreceptors were positively correlated 
with age meaning that the foveal thickness increased with age; the authors 
hypothesized that increase in foveal thickness with age may be due to reduced 
RPE phagocytosis (Ooto et al., 2011). Therefore, the current study has taken into 
account, the effect of age.  
2.3.2 Retinal thickness in males and females  
It is unclear if the sex of the individual is related to retinal thickness. Studies in 
the past have observed thickness in the macular area to be greater in healthy 
men than women (Massin et al., 2002) (Wang et al., 2004) (Bressler et al., 2008) 
(Huang et al., 2009) whereas other studies found that macular thickness was 
similar in male and female participants (Lattanzio et al., 2002) (Chan et al., 
2006). Foveal thickness has been reported to be greater in males than females 
(Adhi et al., 2012) but in another study, the foveal thickness has been reported 
to be similar between men  and women (Chan et al., 2006). Although there is 
some disagreement in the literature regarding the effect of sex of an individual 
and the retinal thickness, it is likely that sex of the individuals does play a role in 
retinal thickness; therefore the current project has taken into account the sex of 
the individuals, with respect to full retinal and inner retinal thicknesses. 
2.3.3 Retinal thickness and ethnicity 
Asians and African-Americans (Kashani et al., 2010) have thinner macula 
compared to Caucasians  (Kelty et al., 2008). African-Americans have a tendency 
for reduced foveal thickness and significantly reduced macular thickness 
compared to Caucasians (Asefzadeh et al., 2007). Interestingly, RNFL thickness 
(described in section 2.4) has been reported to be thicker in Hispanics and in 
Asians compared to Caucasians (Bundez et al., 2007). The current study 
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examined the ethnic composition in the cohort of people with and without 
diabetes for the retinal thickness assessments.  
2.3.4 Retinal thickness, refractive error and other clinical parameters 
Fraser-Bell et al (2005) reported reduced total macular volume for myopia 
greater than -5.00 D. Intraocular pressure and keratometry readings were not 
associated with retinal thickness (Fraser-Bell, et al., 2005). However, longer 
axial lengths and larger body mass index were associated with thicker retina 
within the central 1 mm (Wong et al., 2004). Foveal thickness was positively 
associated with the axial length (Sato et al., 2010) but the macular thickness 
measurements in all quadrants were inversely correlated to the axial length 
(Lam et al., 2007).  
In the current research program, the relative effects of the known confounding 
variables have been adjusted by utilising multiple regression models. 
2.4 Factors influencing the inner retinal thickness  
The inner retinal layers that include the RNFL and GCC thickness (Figure 11) are 
influenced by certain variables and are described in the following section.  
 
 
 
 
 
Figure 11. Factors affecting inner retinal thickness 
 
 
Inner retinal thickness – influenced by 
1. Age 
2. Axial length 
3. Ethnicity 
4. Gender  
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RNFL and GCC thicknesses reduce with advancing age. The RNFL reduces at the 
rate of 2 µm, 95% CI [1.2, 2.8 µm] per decade in Caucasians (Budenz et al., 2007) 
and Indian eyes (Malik et al., 2012). It has been reported that GCC thickness 
reduces at the rate of 1.59 µm per decade increase in age in a group of Korean 
adults (Kim et al., 2011) (Koh et al., 2012).  
The RNFL thickness is related to axial length. RNFL thickness has been found to 
decrease by 2.2 µm (Bundez et al., 2007) and 1.27 µm (Koh et al., 2012) for 
every 1 mm increase in axial length. RNFL thickness has been reported to be 
related to the optic disc size. For every 1 square mm increase in optic disc area, 
the RNFL thickness has been observed to increase by 3.3 µm (Budenz, et al., 
2007).  
The RNFL thickness also varies across different ethnic groups. Bundez et al 
(2007) observed thicker RNFL in Asian adult eyes compared to those of 
Hispanics or Caucasian adults.  
Difference in RNFL thicknesses between males and females has not been 
observed so far. However, a recent study (described below) observed females to 
have thinner GCC when compared to males. Koh et al (2012) observed the 
ganglion cell complex-inner plexiform layer thickness to be thinner in females 
(2.3 µm thinner GCC than males).  
Variations in retinal thickness have been reported in people with diabetes, in 
the presence and absence of clinical signs of DR.  
2.5 Diabetic retinopathy and its influence on retinal tissue 
thickness 
2.5.1 Introduction  
Diabetic retinopathy (DR) has been reported to confound full retinal and inner 
retinal thickness investigations. The purpose of this review is to enumerate the 
findings from previous studies that examined retinal tissue thicknesses using 
imaging techniques, both in the presence and the absence of DR.  
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Diabetic retinopathy (DR) remains the leading cause of visual impairment in 
working-age adults (Porta et al., 2002). The National Health and Medical 
Research Council (Australia) defines diabetic retinopathy by the presence of 
typical retinal microvascular lesions in a person with diabetes. Once the stage of 
severe retinopathy is established, any further improvement in glycaemic levels, 
as in pancreatic or renal transplantation, does not improve retinopathy (Ulbig et 
al., 1991). Therefore, it is vital to detect early signs and identify modifiable risk 
factors so as to prevent the worsening or to begin intervention in the early 
stages of diabetic retinopathy.  
The following section provides an introduction to the clinical features of 
diabetic retinopathy, the stages and the risk factors involved in the development 
and progression of retinopathy.  
2.5.2 Prevalence  
According to the American Diabetes Association, one-third of individuals with 
diabetes will develop DR at some stage. The National Health and Medical 
Research Council in its guidelines for management of DR (Mitchell et al., 2008), 
states that people with type 2 diabetes may have DR at the time of diagnosis, 
whereas in type 1 diabetes, DR is not so common within five years of diagnosis. 
An age-standardized prevalence has been reported to be 34.6% for 
preproliferative DR, 6.9% for proliferative DR, 6.1% for diabetic macular 
oedema, and 10.2% for vision-threatening DR in individuals with type 2 
diabetes (Yau et al., 2012). This was determined from a meta-analysis of 
prevalence rates of DR from 35 studies conducted worldwide.  
The prevalence rates of DR were calculated among those with type 1 diabetes; 
Roy and his group using the data from two population-based studies conducted 
in the United States, the New Jersey 725 study and the Wisconsin Epidemiologic 
study of diabetic retinopathy. The two studies examined people with type 1 
diabetes older than 18 years. Nearly 75% of African-Americans had some form 
of DR and 30% had vision-threatening retinopathy. Among Caucasians, 82% had 
some form of DR and 32% had sight-threatening DR (Roy et al., 2004).   
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It has been estimated that the number of people with any stage of DR would 
increase from 126.6 million in the year 2011 to 191 million by the year 2030, 
and the prevalence of vision-threatening DR would increase from 37.3 million to 
56.3 million if not attended to immediately (Zheng et al., 2010). Therefore, a 
clear understanding of the clinical features and risk factors involved in DR is 
essential for a timely intervention; this may help to slow down or decelerate the 
changes that lead to the development or the progression of diabetic retinopathy 
thus preserving the existing retinal anatomy and function and thereby maintain 
visual integrity. 
2.5.3 Clinical features and stages 
Based on the Airlie House classification (Davis et al., 1969), diabetic retinopathy 
can be broadly staged as follows: 
a. Background diabetic retinopathy (BGDR) 
b. Proliferative diabetic retinopathy (PDR) 
Background diabetic retinopathy (BGDR) - also called nonproliferative DR 
(NPDR) 
This represents an early stage of DR characterised by the appearance of 
microaneurysms, dot and blot haemorrhages, capillary occlusion and hard 
exudates (each of these signs is explained in detail below). NPDR can be further 
classified into mild, moderate, severe and very severe NPDR based on certain 
characteristics. A brief description has been provided in Table 1. 
Proliferative diabetic retinopathy (PDR) 
This is an advanced stage of DR characterised by the appearance of abnormal 
new blood vessels, fibrovascular tissue, vitreous haemorrhage, and tractional 
retinal detachment (Davis, 1992). 
The Early Treatment Diabetic Retinopathy Study (ETDRS) modification (Davis 
et al., 1998) of the Airlie House classification is employed as a staging system for 
Retinal degeneration in diabetes 
29 
 
the DR  in a majority of clinical trials. This has been used in the current research 
program to define the stages of retinopathy.  
Table 1 shows the ETDRS classification and staging system for diabetic 
retinopathy. 
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Table 1. ETDRS staging and classification system for diabetic retinopathy. Table derived from Davis 
et al., 1998 
Level Severity Definition 
10 No retinopathy Diabetic retinopathy absent 
20 Very mild NPDR Micro-aneurysms only 
35 Mild NPDR 
Hard exudates, cotton-wool spots, and/or mild retinal 
haemorrhages 
43 Moderate NPDR 
43A Retinal haemorrhages moderate (>photograph 
If) in four quadrants or severe 
(≥   t gra   2A) in  ne quadrant  3B Mi d I MA 
(<photograph 8A) in one to three quadrants 
47 A -D Moderate NPDR 
47A Both level 43 characteristics 
47B Mild IRMA in four quadrants 
47C Severe retinal haemorrhages in two to three 
quadrants 
47D Venous beading in one quadrant 
53 A-D Severe NPDR 
 3A ≥2 level 47 characteristics 
53B Severe retinal haemorrhages in four quadrants 
 3  M derate t  se ere I MA (≥   t gra   8A) in at 
least one quadrant 
53D Venous beading in at least two quadrants 
53E Very Severe NPDR ≥2  e e   3A-D characteristics 
61 Mild PDR NVE<0.5 disc area in one or more quadrants 
65 Moderate PDR 
  A NVE≥0.  dis  area in  ne  r  re quadrants 
65B NVD <photograph 10A (<0.25-0.33 disc area) 
71, 75 High-Risk PDR 
NVD ≥   t gra   10A   r NVD <   t gra   10A  r 
NVE<0.5 disc area plus VH or PRH, or VH or PRH 
  s uring ≥1 dis  area 
 
81, 85 Advanced PDR 
Fundus partially obscured by VH and either new 
vessels upgradable or retina detached at the centre of 
the macula 
 
NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; IRMA, 
intraretinal microvascular abnormalities; NVE, new vessels elsewhere; NVD, new vessels on or 
within 1-disc diameter of the optic disc; PRH, pre-retinal haemorrhage; VH, vitreous 
haemorrhage. (This classification does not cover macular oedema or photocoagulation) 
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The following are some of the features in diabetic retinopathy. The photographs 
were obtained from 
http://www.ucdenver.edu/academics/colleges/medicalschool/centers/Barbar
aDavis/Clinical/Pages/Ophthalmology.aspx 
Microaneurysms (MA) occur in the early stages of DR and appear as small red 
dots (Kohner, 1978). MA’s re resent  ut   u  ing  f t e  a i  ar      d  esse  
wall (Mahon et al., 1971) located in inner nuclear layer of the retina (Ashton, 
1969). These lesions are sometimes not distinguishable from the dot and blot 
 ae  rr ages. H we er  t e argins  f MA’s are   ear   de ar ated t an t  se 
of the haemorrhages. Figure 12 shows ETDRS Standard photograph 1 with 
microaneurysms. 
 
Figure 12. ETDRS Standard photograph 1.Microaneurysms 
 etina   ae  rr ages (H’s) re resent sites  f   eeding fr       d  esse   eit er 
from a ruptured aneurysm or from increased permeability of the blood vessel 
wall.  These haemorrhages can be a dot, blot (arising from venous end of 
capillaries that are essentially in the deeper retinal layers) or flame-shaped 
(arising from precapillary arteriole which are essentially in the retinal nerve 
fibre layer) (Ashton, 1949). Haemorrhages do not have distinct margins as do 
t e MA’s. H we er  d t  ae  rr ages tend t   a e   rders t at are   re 
distin t t an    t  ae  rr ages. H’s a  ta e 3  r    nt s t  res   e.  
MA 
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Distinguis ing  etween MA and H’s   ini a    is n t  ru ia   as t e    t  are 
present in early stages of DR. Figure 13 shows ETDRS standard photograph 2A 
t at  as   t   MA’s and H’s. 
 
Figure 13. ETDRS Standard photograph 2A. Retinal haemorrhages and microaneurysms 
Hard exudates (HE) represent deposition of lipids in the outer plexiform layer of 
the retina, due to leakage of plasma containing lipoprotein, crystalloid and 
water (Ferris et al., 1996) resulting from vasodilation. Exudates tend to be 
smaller ranging from 15-   μ . T e   ften accompany macular oedema where 
they arrange themselves in circinate or circular pattern (Bernard et al., 1995), at 
the junction of oedematous and normal retina (Singh et al., 2008). Figure 14 is 
the ETDRS Standard photograph 4 showing hard exudates.  
H 
MA 
Retinal degeneration in diabetes 
33 
 
 
Figure 14. ETDRS Standard photograph 4. Hard exudates 
ETDRS classified macular oedema as (1) clinically non-significant oedema and 
(2) clinically-significant macular oedema (CSME) (ETDRS, 1985); CSME is 
defined as one or more of the following:  
(i) retinal thickening at or within 500 μ   f t e  entre  f t e  a u a;  ard 
exudates at or within 500 μ   f t e  entre  f t e  a u a  if ass  iated 
with adjacent retinal thickening; 
(ii) a zone or zones of retinal thickening one disc area in size, at least part of 
which is within one disc diameter of the centre of the macula; 
(iii) thickening greater than 1 disk diameter in size, part of which is within 1 
disk diameter of centre or macula. 
Soft exudates or "cotton wool spots" (CWS) are white, cottony lesions that 
represent infarcts, or ischemic changes within the nerve fibre layer. Cotton wool 
spots often occur in association with intraretinal microvascular anomalies 
(IRMA) (discussed below).  
Intraretinal microvascular anomalies (IRMA) are spider-like branched vessels 
that appear generally in the later stages of NPDR. They are often tortuous and 
convoluted in appearance. IRMA is considered as either dilated capillaries that 
already exist or formation of new blood vessels within the retina.  
Venous Beading appears during the same stages like the IRMA, where the 
vessels lose their normal shape and they represent contracted columns 
Retinal degeneration in diabetes 
34 
 
resembling sausage-like segments. Figure 15 is the Standard photograph 6B 
showing IRMA and venous beading (ETDRS, 1985). 
 
Figure 15. ETDRS Standard photograph 6B. Venous beading, Intra retinal microvascular 
abnormalities 
New vessels defined as neovascularisation at the disc (NVD) and 
neovascularisation elsewhere (NVE) are the first of the proliferative lesions to 
appear. The theory is that during conditions of hypoxia, the retina compensates 
by growing new vessels in the areas lacking circulation. The new vessels are 
delicate and tend to grow on top of the retina rather than into it, making them 
prone to leakage and haemorrhage. They can cross over one or many major 
retinal blood vessels, but tend not to cross over themselves. They often appear 
in a blossom like a flower bud with the outside part of the NV more dilated than 
the inner NV. They can also appear as stringy and drawn out, but this 
presentation is not common (Davis, 1969). 
2.5.4 Risk factors for diabetic retinopathy  
People with diabetes will develop DR at some stage. Later stages of DR such as 
severe NPDR and clinically significant macular oedema have visual implications. 
Therefore, it is essential to monitor for the known and the modifiable risk 
factors. 
Duration of diabetes is one of the strong risk factors for the development and 
progression of DR, but it is not modifiable. Higher glycaemic level, poor blood 
VB 
IRMA 
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pressure control and dyslipidaemia are identified as strong risk factors in the 
development of DR (Ulbig et al., 1993) (Yau et al., 2012). Glycaemic level has 
been found to be positively related to the incidence and progression of 
retinopathy, after controlling for duration of diabetes, age, gender and baseline 
retinopathy findings (Klein et al., 1988). However, glycaemic level (HbA1c) is a 
modifiable risk factor for DR. There exists a possibility that the progression of 
DR can be slowed or prevented by achieving optimal glycaemic levels. The 
Australian Government, in its NHMRC guidelines (2008), recommends that the 
HbA1c levels be maintained below 7% for people with DR. In addition, blood 
pressure greater than 130/85 mmHg in people with diabetes is considered a 
risk factor for DR (Yam et al., 2007). Normalizing blood pressure and serum 
lipid levels has beneficial effects especially in cases of diabetic macular oedema 
in DR, (Ferris et al., 1996). Pregnancy, puberty and anaemia have been reported 
as other risk factors for DR (Agardh, 2002; Moloney et al., 1982; Sunness, 1988). 
There is also an ongoing debate about the role of nonhealing ulcers (Harris 
Nwanyanwu et al., 2013), obesity, smoking, alcohol consumption and physical 
inactivity (Mohamed et al., 2007) in the progression of DR.  
2.5.5 Monitoring and treatment  
Traditional methods of treatment include strict control of HbA1c levels, blood 
pressure and lipid levels and regular retinal evaluation and monitoring of 
retinopathy status  (Neely et al., 1998).  
Other forms of treatment include laser treatment, surgery for vitreous 
haemorrhage combined with complex retinal surgery as required. Advice on 
monitoring procedures depends on the severity of the condition. In minimal 
NPDR, procedures such as colour photography, fundus angiography or laser 
treatment is not advised. In mild NPDR, colour photography may be helpful for 
comparison with baseline findings, as there is a risk of progression to 
proliferative stage. For mild to moderate NPDR with CSME, OCT may be helpful 
in identifying subtle oedema or monitoring exiting CSME (American Academy of 
Ophthalmology Preferred Practice Guidelines).  
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2.5.6 Retinal degeneration in diabetic retinopathy 
Diabetes is associated with alterations in multiple layers of the retina (Imai et 
al., 2009).  For instance, there is evidence of loss of pericytes (de Oliveira, 1966) 
and vascular endothelial breakdown (Craitoiu et al., 2005) leading to vascular 
leakage (Aguilar et al., 2003; Antonetti et al., 1999; Feit-Leichman et al., 2005; 
Matsuura et al., 1976) and consequently diabetic retinopathy (Antonetti, et al., 
2006); the above changes may be related to glial cell dysfunction and glial cell 
loss consequently leading to neuronal cell death (Gaucher et al., 2007).  
Significance of glial cells 
The astrocytes, Müller cells and microglia constitute the glial cell population. 
Under normal conditions, the astrocytes stem from the optic nerve (Watanabe 
et al., 1988) and travel towards the internal limiting membrane; astrocytes 
closely associate with neural elements and blood vessels  (Gariano et al., 1996), 
protect the neurons from toxic (Chen et al., 2001) or anoxic (Vibulsreth et al., 
1987) environments and also play a role in the maintenance of the blood-retinal 
barrier (Abbott et al., 2006; Gardner et al., 1997). Muller cells extend radially to 
form the internal and the external limiting membranes; Müller cells associate 
with the neurons to provide nutrition (Newman, 1987) and also regulate 
synaptic release or the uptake of GABA and glutamate neurotransmitters 
(Mizutani et al., 1998). The microglia is derived from monocytes that play a vital 
role in immunity. These cells secrete inflammatory cytokines and some 
neuroprotective substances that provide immunological (Milder, 2006) and 
mechanical support to the neuronal and vascular cells (Zeng et al., 2000); 
together, the glial cells aid in nutritional, immunological, supportive and 
protective functions for the neurons and the associated blood vessels. 
Therefore, the glial cells constitute an integral part of normal functioning of 
neurons and blood vessels. The glial cells are destroyed in diabetes. This affects 
the normal functioning of the neurons (Gardner et al., 2002; Hogan et al., 1963). 
In addition, the thickness in the outer and inner nuclear layers are reduced in 
animal models of diabetes, as evidenced by significant thinning at 10 weeks 
after inducing diabetes in mice (Martin et al., 2004); atrophy of synaptic 
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terminals is also reported in diabetic rodents (Scott et al., 1986). In human 
diabetes, reduced nerve fibre diameter and degeneration of nerve fibre layer, 
possibly from atrophy of ganglion cells, the axons, and dendrites (Barber et al., 
1998; Lieth et al., 2000), have been observed.  
These changes may manifest as changes in the retinal thickness profile. The 
retinal anatomical changes may be associated with a compromise in visual 
function as the neural cells and glial cells are important for maintaining vision 
(Lasansky, 1965).  
2.5.6.1 Retinal structural and visual functional changes in diabetic 
retinopathy 
Optic nerve head in the presence of retinopathy 
Previous study observed that the size and shape of the optic disc, peripapillary 
atrophy and neuroretinal rim determined by morphometric analysis of optic 
disc photographs did not differ significantly in varying degrees of retinopathy 
when compared to that of those without diabetes (Königsreuther et al., 1995). 
However, a trend of decreased visibility of nerve fibre layer and increased disc 
pallor in eyes with increasing severity of retinopathy was noted; it was reported 
that optic disc in diabetic eyes can exhibit a non-glaucomatous appearance. The 
study had carefully excluded potential confounders such as high myopia -8.00 D 
or more, those diagnosed to have glaucoma as well as subjects with intra ocular 
pressure > 21 mmHg. Chihara et al (1998) compared optic nerve head (ONH) 
parameters in participants with and without diabetes. Despite the RNFL defects, 
individuals with diabetes had cup-disc ratios that were not significantly 
different when compared to that of individuals without diabetes (Chihara et al., 
1998). 
Visual function in the presence of retinopathy 
In patients with retinopathy, a blue-yellow colour vision defect was observed 
but only in less than three percent of their subjects. The total number of 
deviations from the normal colour sequence on the FM-100 Hue test increased 
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with increasing severity of DR (Green et al., 1985). Another study examined 
visual field sensitivity in people with and without DR. Among those eyes 
classified to have very mild and mild DR, only 4% of eyes had mean deviation 
(MD) values with a probability value worse than 5% (Henricsson et al., 1994), 
suggesting that a vast majority of subjects with and without DR had MD within 
normal limits. However, the number of abnormal test points became higher 
with greater severity of DR.  
Full retinal thickness in the presence of retinopathy 
The following studies utilized imaging techniques to examine the retinal 
thickness in individuals with diabetic retinopathy. The full retinal thickness is 
essentially the thickness from the retinal pigment epithelium up to the 
vitreoretinal layer (Sadda, et al., 2006). Previous studies have observed thicker 
fovea, nasal and temporal parafoveal retina (Goebel et al., 2002), greater 
thickness in at least two ETDRS zones (Massin et al., 2002), thicker overall 
macula (Oshima et al., 1999) and thicker central zone (within 1mm diameter 
that includes the fovea) (Cho et al., 2010) in people with DR compared to those 
without diabetes; a trend of increase in macular thickness with increasing 
severity of DR has also been observed (Lattanzio, et al., 2002; Park et al., 2011).  
It has been postulated that in DR, there could be leakage of serum proteins into 
the intraretinal spaces following increased vascular permeability (Ehrlich et al., 
2010). The increased vascular permeability may be one possible explanation for 
the increased macular thickness in DR (Davis, 1992).  
In contrast, a large multi-centric study examined the central subfield thickness 
(the average thickness at all points within 1 mm diameter of fovea) in people 
with diabetes with no or minimal DR in comparison to data published in 
literature on people without diabetes and observed similar thicknesses in both 
groups (Bressler, et al., 2008). The difference in results reported in literature 
may also reflect variations in the presentation of DR as no two individuals with 
DR have same clinical features nor do they progress similarly (Vaz, 2011).  
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Inner retinal thickness in the presence of retinopathy 
The inner retina predominantly comprises of neural elements such as neural 
cells, neurons and the glia (Barber et al., 1998). Histological sections of human 
cadaveric eyes with DR by Wolter (1961) and Bloodworth (1962) (as cited in 
Barber, 1998) showed neural degeneration and atrophy of ganglion cells and 
other neural elements with progressive loss of neural elements and a loss in 
visual function (Barber, et al., 1998).  
However, with the advent of imaging techniques, it has become possible to 
examine in-vivo, the structural changes in eyes with retinopathy. Inner retinal 
thickness is significantly thinner in people with type 1 diabetes with no or 
minimal DR in the zone immediately around the fovea in comparison to group 
without diabetes (van Dijk et al., 2009; van Dijk et al., 2010). With scanning 
laser polarimetry, retinal nerve fibre layer thinning has been observed in eyes 
with preproliferative retinopathy (Oshitari et al., 2009); these in-vivo studies 
suggest neurodegenerative changes despite only mild degrees of DR.  In 
addition, it was observed that the RNFL thinning worsens with more advanced 
degrees of retinopathy (Takahashi et al., 2006). With more recent versions of 
OCT where segmentation of various layers has become possible, in-vivo retinal 
examination reveals compromised ganglion cell and the inner plexiform layer 
thickness in people with minimal DR when compared to that of age and sex-
matched people without diabetes (Biallosterski et al., 2007) (van Dijk et al., 
2012). The compromised inner retinal thickness has been hypothesized as 
being related to hyperglycaemia-induced neuronal damage or ischaemic 
changes leading to consequent loss of ganglion cells in diabetic retinopathy 
(Park et al., 2010). 
Summary of section 2.5.6.1 
A frequently reported finding in literature is that in the presence of DR, the full 
retinal thickness increases with increasing severity of retinopathy, while, the 
inner retinal thickness decreases.  
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2.5.6.2 Retinal structural and visual functional changes in the absence of 
retinopathy 
Several studies (discussed below) demonstrated neuroretinal compromise in 
the absence of clinically visible signs of diabetic retinopathy. The following 
section discusses studies that have documented structural and functional 
deficits in the absence of clinical signs of DR.  
Optic nerve head in the absence of retinopathy 
The ONH features have been studied in eyes without retinopathy. The ONH 
volumetric parameters that included rim and cup measures and RNFL thickness 
measures obtained using scanning laser ophthalmoscope in diabetic eyes 
without DR were not significantly different to that of people without diabetes 
(Tekeli et al., 2008; Toprak et al., 2012). In addition, the mean cup-disc ratio 
(vertical & horizontal) in diabetic eyes was not different from that of the 
controls (Park, et al., 2011).  
Visual function in the absence of retinopathy 
The following independent studies observed disturbances in certain visual 
functional parameters assessed by means of colour vision, contrast sensitivity 
and visual field testing.  
Colour vision 
Individuals with diabetes but without DR had tritan (blue-yellow) colour vision 
defects (Ong et al., 2003). When compared to those without diabetes, the error 
in colour discrimination was significantly higher in a group of people with 
diabetes without DR (Green, et al., 1985) (Hardy et al., 1992). However, it is 
likely that the yellowing of the crystalline lens may have confounded the results 
as there is the increased absorption of wavelength at the blue end of the 
spectrum.  
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Contrast sensitivity 
In the absence of clinical signs of DR, contrast sensitivity (CS) has been reported 
to be compromised despite normal visual acuity in diabetic children 
(Georgakopoulos et al., 2011) and in diabetic adults (HyvÄRinen et al., 1983) 
(Heravian et al., 2010) (Trick et al., 1988); a trend of further reduction in CS was 
observed in individuals with early to more advanced DR (Ismail et al., 1998). 
The explanation behind impaired contrast sensitivity in diabetes is multi-fold; 
one of the several explanations being hyperglycaemia. Although no direct cause-
effect relationship could be established between hyperglycaemia and CS, 
increased retinal blood flow has been associated with impaired CS during 
alterations in blood glucose levels (Bursell et al., 1996), thus suggesting an 
indirect link between the higher glycaemic levels and CS. Another likely 
explanation could be alterations in retinal and choroidal blood supply in 
diabetes that have been linked with impaired CS (Shoshani et al., 2011). Loss in 
CS has been associated with capillary dropout observed in individuals with 
diabetes (Fletcher et al., 2005). Other likely explanations for impairment in CS 
in individuals with diabetes may be related to diffraction of light due to 
pupillary miosis or intraocular scattering of light due to cataractous lenses.    
Visual fields  
Early study by Roth (1969) reported scotomas in the visual fields in people with 
diabetes, with and without DR. In the DR group, the scotomas topographically 
corresponded to retinopathy lesions. However, in the no DR group, the presence 
of scotomas was considered as a pre-retinopathy sign and was thought to be 
related to disturbances in retinal blood circulation (Roth, 1969).  
Studies on type 2 diabetes have shown depressions in visual field with blue-on-
yellow perimetry but not with white-on-white perimetry (Nitta et al., 2006). 
However, the reduced blue-yellow sensitivities could also be due to yellowing of 
the crystalline lens. Also a recent study by Park et al (2011) showed that mean 
deviation values (representing the overall depression or sinking in the visual 
field) worsened with increasing severity of nonproliferative DR. The finding was 
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similar to that observed by Takahashi et al (2006) in the overall defect and 
pattern defect (indicates local defects) in people without DR (Takahashi, et al., 
2006).  
However researchers have used modified or alternate visual field techniques 
such as flicker perimerty; for instance, authors have successfully demonstrated 
de ressi n in  isua  fie d sensiti it  wit in  ˚ fr   fi ati n using f i  er 
perimetry in individuals with type 2 diabetes with no or minimal DR and also 
f r t  se wit  durati n  f dia etes ≤   rs (Stavrou et al., 2005). The rationale 
was that identification of flicker requires greater metabolic demand and 
therefore can detect visual field defects despite the absence of visible signs of 
DR (Lott et al., 2013; Scheiner et al., 1994). With the use of red-on-white 
perimetry, significantly greater visual field defects were demonstrated in 
patients with diabetes and because of the longer wavelength, it is not affected 
by the cataractous lens (Zele et al., 2008).   
Standard automated perimetry (SAP) has potential limitations in that it is a 
subjective technique. In addition, it has been demonstrated that there is already 
30-40% of retinal nerve fibre loss before any obvious field defect appears on 
standard perimetry (Quigley et al., 1982). With the advancement in imaging 
techniques, clinicians are now able to objectively assess the early changes in the 
human visual system. OCT has been demonstrated to have the ability to detect 
defects in the retinal nerve fibre layer when the standard automated perimetry 
results are normal (Kim et al., 2007). The current research program has utilized 
OCT for structural evaluation of the retina in diabetic participants. 
Frequency doubling perimetry  
Frequency doubling perimetry (FDP) was initially developed to test for the 
function of a subtype of ganglion cells. Realini et al (2004) observed diabetes to 
confound FDP results while screening for glaucoma. Participants in the diabetes 
group had higher test scores and took longer time than those without diabetes. 
However, impaired contrast sensitivity in diabetes may be an explanation for 
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the abnormal perimetry results (Realini et al., 2004)irrespective of neuronal 
loss in diabetes.  
Electroretinogram and visually evoked potentials 
Studies that measured the retinal electrophysiological responses observed 
abnormalities despite the absence of clinical signs of DR. Individuals with 
diabetes had reduced oscillatory potential amplitudes and delayed latencies 
(Barber, 2003), suggesting that the middle and inner retinal layers and possibly 
amacrine cells are susceptible to vascular insult even in the absence of signs of 
DR. The P100 latency of visual evoked potentials (representing 
electrophysiological responses of the nervous system and hence visual function) 
(Tobimatsu et al., 1991) was delayed in young people with diabetes without DR, 
which normalized following optimal metabolic control (Verrotti et al., 2000). 
Another study showed pattern ERG responses (a measure of central retinal 
function as well as ganglion cell function) were affected in glaucoma suspects 
with diabetes without DR as compared to glaucoma suspects without diabetes 
(Ventura et al., 2010). This could mean early changes in the inner retinal layers 
in diabetes despite the absence of clinical signs of retinopathy. These results 
indicate neuroretinal changes in the absence of visible vascular changes in the 
eye and can also suggest that the quality of some aspects of vision may become 
compromised in these eyes. Evaluating the structural integrity of the retina with 
imaging techniques will provide additional knowledge about the early changes 
in the retinal layers in diabetes. The current thesis examined the structural 
integrity in terms of retinal tissue thickness, in the presence and absence of 
clinical signs of retinopathy. 
Full retinal thickness in the absence of retinopathy 
The first part of this section provides a review of those studies that analysed the 
foveal thickness in diabetic people, in the absence of DR. Foveal thickness has 
been reported to increase with age in individuals with diabetes (Sánchez-Tocino 
et al., 2002, Fritsche et al., 2002, Kashani et al., 2010, Ooto et al., 2011) when 
compared to individuals without diabetes. However, there were differences in 
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mean age of individuals between the two groups; a mean difference of 4 years in 
the Sánchez-Tocino study and about 29 years older in the Fritsche study. This 
difference in age may have confounded the results, as the RPE metabolism has 
been reported to slow down with time. As a result, the degenerated cells and the 
outer segments of photoreceptors may accumulate over time (Ooto, et al., 
2011). This phenomenon might be exaggerated in diabetes. In contrast, another 
study found no significant differences in the thickness within the central 1mm 
zone between individuals without DR and those without diabetes (Alkuraya et 
al., 2005).  
Few other studies (described below) examined retinal thickness in the macular 
area. The retinal thickness in the parafovea (region just outside the fovea) was 
decreased in 29% of people with diabetes who also had subnormal Rarebit 
fovea test (Nilsson et al., 2007). Rarebit fovea test is reportedly used for testing 
of foveal function. Lower macular thickness has been reported in people with 
diabetes without DR compared to those without diabetes (Lattanzio, et al., 
2002) (Oshitari, et al., 2009) and a trend of increasing thickness with increasing 
severity of DR was observed.  In contrast, Sugimoto et al (2005) observed 
thicker retina in all quadrants with significantly thicker superior quadrant in 
people without DR than those without diabetes.  
Nevertheless, the following studies reported no difference in macular thickness 
between the groups with and without diabetes, but observed that sex of the 
individual can be a factor related to retinal thickness. A group of authors 
observed no significant differences in retinal thickness in people with diabetes 
without DR when compared to those without diabetes, after the groups were 
matched for  age and sex (Biallosterski et al., 2007) (Bressler et al., 2008). 
Browning et al (2007) reported macular volume data in addition to macular 
thicknesses for those without diabetes, individuals with diabetes but without 
DR, and other stages of DR. In normal eyes as well as in eyes without DR, the 
central subfield mean thickness (CSMT) was thicker and total macular volume 
was greater in men than in women. The mean between-gender difference was 
14 µm in people without diabetes and 12 µm in eyes without DR (Browning et 
al., 2008). Os itari et a  (2009)   ser ed t at  en in t e ‘n  D ’ gr u   ad 
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significantly thicker macular quadrants than women without DR. This suggests 
that sex of the individuals should be taken into account when examining retinal 
thickness in diabetes. 
Other studies observed compromised retinal thickness in individuals with 
longer duration of diabetes (Bressler et al., 2008, van Dijk et al., 2010) but 
observed no significant association with HbA1c levels (Asefzadeh et al., 2008).  
The inconsistencies in study results could be due to differences in age, sampling 
error, differences in male and female composition or the extent to which 
individual retinal layers are affected in diabetes. The collective evidence from 
previous studies indicates that DR, age, gender and duration of diabetes need to 
be taken into consideration while examining the retinal tissue thickness.  
Inner retinal thickness in the absence of retinopathy  
RNFL thickness has been documented to be reduced in people with diabetes 
without DR compared to those without diabetes, with scanning laser 
polarimetry, (Ozdek et al., 2002; Takahashi, et al., 2006). Nonetheless, it can be 
argued that scanning laser polarimetry gives only a measure of birefringence 
rather than the actual thickness profile. Recent versions of OCT with much 
higher resolution should provide a better understanding of the specific retinal 
layers affected in diabetes.  
The inner retinal thickness has been investigated in the following studies in 
people with diabetes in the absence of DR using OCT. Sugimoto et al (2005) 
observed slightly decreased superior quadrant RNFL thickness in a cohort of  
people without DR compared to those without diabetes. Another study found no 
significant differences in RNFL thickness between people with diabetes without 
DR and those without diabetes but observed significantly reduced superior GCC 
thickness (Park, et al., 2011). Recently, Verma et al (2012) demonstrated 
significantly decreased mean RNFL thickness in  people with diabetes without 
clinical evidence of retinopathy compared to  those without diabetes (Verma et 
al., 2012). Peng et al (2009) also observed reduced RNFL thicknesses in the 
superior and inferior sectors (between-gr u  differen e  f 8 μ ) and  in t e 
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 ean  NFL ( ean differen e  f   μ )  etween t  se wit  and wit  ut dia etes 
(Peng et al., 2009). On the other hand, two other studies observed no significant 
differences in RNFL or GCC thicknesses between the group of people without DR 
and those without diabetes (van Dijk, et al., 2009) (Oshitari et al., 2009).  
Recent investigators observed reduced inferior RNFL thickness to be related to 
increasing severity of neuropathy in people with type 2 diabetes that was not 
explained by DR (Shahidi et al., 2012).  This finding introduces the novel 
concept that reduced neural layer thickness in people with diabetes is explained 
by neuropathy rather than retinopathy. 
Other variables such as HbA1c levels and duration of diabetes and their 
relationship to inner retinal thickness have been investigated. Significant 
reduction in the RNFL thickness has been observed after 4 months of strict 
control of HbA1c levels (Sugimoto et al., 2010) suggesting a possible association 
with HbA1c levels. However, GCC thickness was not significantly explained by 
HbA1c levels when adjusted for age, sex, duration of diabetes and retinopathy 
(van Dijk et al., 2010).  
The inconsistencies in study results could be due to sampling error, the extent 
to which individual retinal layers are involved in diabetes or related to the 
presence or absence of neuropathy or in relation to glycaemic levels. Though 
there are differences in study results, it is likely that inner retinal thickness is 
reduced in the absence of retinopathy. To summarize, the full retinal and the 
inner retinal thickness is reduced in both, the presence and the absence of 
clinical signs of DR. In addition, factors such as duration of diabetes and HbA1c 
levels have to be taken into account while examining the full retinal and inner 
retinal thicknesses. 
This thesis presents a series of cross-sectional studies that investigated the full 
retinal and inner retinal thicknesses in individuals with diabetes, with and 
without neuropathy, adjusting for the known confounding factors such as DR, 
age, sex, duration of diabetes and HbA1c levels. Examining the full retinal and 
neural layer tissue thickness in relation to diabetic neuropathy is the main 
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objective of this research program. General methodology for these experiments 
is described in Chapter 3 and methodology specific to the experiment 
addressing each research question is described in subsequent chapters. 
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Chapter 3: Research program 
Summary of knowledge gaps  
Early studies (described in Chapter 2. section 2.5.6) attributed the compromise 
in full retinal and inner retinal thickness as being solely related to DR. Further 
studies observed compromised full retinal and inner retinal thicknesses even in 
the absence of clinical signs of DR suggesting that there might be another factor 
that explains this degeneration.  
1) Recent studies (elaborated in Chapter 1 and summarized below) reported 
that the neuroretinal layer thickness is significantly reduced in individuals with 
diabetes that was explained by peripheral neuropathy rather than DR (Shahidi 
et al., 2012). Therefore, it is likely that the retinal structural and visual 
functional compromise reported in literature may be confounded by diabetic 
peripheral neuropathy and therefore warrants investigation. 
2) It is reported that neuroretinal thickness (Shahidi et al (2012), retinal 
function (Lövestam-Adrian et al., 2012), visual field sensitivity (Sampson et al., 
2012) are compromised in relation to neuropathy. If RNFL thickness is 
compromised, it is likely that other retinal layers may be involved in diabetic 
peripheral neuropathy. In addition, if RNFL thickness is reduced in relation to 
neuropathy, GCC thickness may be reduced as well. It has been stated that the 
ganglion cell layer thickness can independently predict the visual function (van 
Dijk et al., 2011). Therefore, the integrity of other retinal layers, including that 
of the ganglion cell complex, requires investigation in relation to neuropathy.  
3) The integrity of the macula in relation to diabetic neuropathy is not known. 
As the macular and foveal integrity are crucial for visual function, the integrity 
of the macula needs to be examined in relation to diabetic neuropathy. 
4) Several independent studies demonstrate that retinal tissue thickness is 
influenced by a range of factors, namely age, sex of the individuals, ethnicity, 
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duration of diabetes, HbA1c  e e s and D . H we er  a ‘fu     de ’ a  r a   t  
account for these potential confounders has not been explored previously.  
One way to analyse these knowledge gaps is to determine the relationship 
between retinal tissue thickness and diabetic peripheral neuropathy, adjusting 
for the confounding variables.  
Therefore, the study by Shahidi et al (2012) was chosen as a foundation upon 
which further research questions were developed and explored in a 
comprehensive manner. 
Objective of this research program 
To determine the relationship between retinal tissue thickness and 
diabetic peripheral neuropathy 
Hypothesis 
It was hypothesized that the retinal tissue thickness is compromised in relation 
to diabetic peripheral neuropathy.  
 
The current study performed a comprehensive evaluation of the retinal tissue 
thickness parameters, namely: 
 
1) Full retinal thickness  
2) Macular and peripapillary inner retinal thickness assessed in terms of  
a. RNFL thickness  
b. GCC thickness and pattern-based GCC parameters,  
in a group with type 1 or type 2 diabetes and in those without diabetes or 
neuropathy (controls). 
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Key confounding variables that were taken into account include: 
 Diabetic retinopathy (indicating  clinically visible signs of 
retinopathy) 
 Age 
 Sex 
 Duration of diabetes 
 HbA1c levels 
 
The hypothesis was tested by a series of research questions in separate 
experiments. 
 
Research questions 
1. Is there is a relationship between the type of diabetes and retinal tissue 
thickness? 
2. Are the full retinal thickness and inner retinal thickness significantly related 
to the severity of diabetic neuropathy? 
3. Are the focal and global losses in GCC volume significantly related to diabetic 
peripheral neuropathy? 
Further explanation for the research questions are provided in respective 
chapters.  
It was expected that this research will provide new knowledge regarding retinal 
structural integrity in relation to diabetic peripheral neuropathy and will 
improve our understanding of the precise nature of retinal anatomical changes 
in diabetes, and how these relate to neural damage elsewhere in the body. This 
chapter describes the rationale for this research, followed by general 
methodology. The chapter discusses statistical analyses used in this research 
program. A more detailed discussion has been provided in subsequent chapters. 
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3.1 Rationale 
3.1.1 Rationale for including people with and without diabetic 
neuropathy 
Previous studies (referenced in Chapter 1, section 1.6) have demonstrated 
alterations to corneal nerve parameters in relation to diabetic neuropathy. 
Neuropathy has been proposed to be a microvascular complication (Malik et al., 
1995) and as a neural complication (Tomlinson, 2002) of diabetes. The 
observation that corneal nerves are affected in neuropathy, given that the 
cornea is avascular, provides an interesting dimension to this argument. The 
theory that neuropathy is a vascular complication of diabetes, may be subject to 
debate in view of the corneal nerve deficits. However, a likely proposition for 
corneal neuropathy as a microvascular complication in diabetes could be that 
the cornea is also nourished by the aqueous (Pirie et al., 1956) which derives its 
nutrients from the blood supply to the ciliary body. If the vessels supplying the 
ciliary body are compromised in diabetic neuropathy, the corneal nerves may 
not be properly nourished and hence may be subject to insult. Another 
explanation could be that the pathogenesis in diabetes and hence neuropathy 
involves several theories, of which, ischemia (the obvious vascular component) 
is only one of them.  The retina being a highly vascularised structure 
encompasses a wide range of neural components that play a vital role in vision; 
it is therefore crucial to evaluate the retinal integrity in relation to diabetic 
peripheral neuropathy. It is to be noted that the retinal nerve fibre layer 
thickness is reduced in association with diabetic neuropathy but not with 
retinopathy (Shahidi et al., 2012). In addition, literature that investigated retinal 
thickness in people with diabetes reported varying results. However, 
neuropathy status of the participants is not reported in those studies. Hence, 
there is a possibility that retinal layer changes observed in people with diabetes 
may be related to the presence of peripheral neuropathy. Therefore, this 
research project examined the full retinal and neural layer thickness in relation 
to diabetic neuropathy. 
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3.1.2 Rationale for examining participants with and without diabetic 
retinopathy 
Diabetic retinopathy has been recognised as a putative mechanism behind 
retinal tissue degeneration until few other studies reported retinal tissue 
compromise even in the absence of DR, suggesting the likelihood of another 
factor that may be related to the compromised retinal tissue thickness in 
diabetes. 
Recent studies have demonstrated reduced RNFL thickness (Shahidi et al., 
2012), decreased visual field sensitivity (Sampson et al., 2012) and 
compromised retinal ganglion cell function (Lövestam-Adrian et al., 2012) in 
relation to neuropathy rather than retinopathy, suggesting that neuropathy is a 
factor that may be more important than DR when assessing neural layer 
thickness, optic nerve function and mid-peripheral visual field sensitivity in 
people with diabetes. This could possibly suggest a local response of the 
generalised polyneuropathy rather than DR that may be exerting subtle neural 
changes in the eye. Therefore, participants with retinopathy were not 
specifically excluded but retinopathy status was accounted for in the statistical 
models, along with other factors namely age, HbA1c levels, duration of diabetes 
and sex of the individuals.  
Due to the prolonged nature of diabetes, it is also reasonable to expect that 
people with DR may have co-existing DPN or vice versa. If people with DR were 
excluded, people with co-existing DPN may also be excluded. Consequently, the 
cohort may not truly represent people with diabetic neuropathy. Therefore, 
people with DR were not specifically excluded.  
3.1.3 Rationale for examining full retinal thickness, RNFL and GCC 
thicknesses 
The reason that nearly one third of all the neurons that converge at the optic 
nerve originate from the macular area, suggests that, macular integrity is an 
important predictor of visual function (Apple, 1981). The macula has the 
highest density of cones and therefore has an increased metabolic demand 
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(Antonetti et al., 2006); the macular area may therefore be susceptible to 
microvascular or ischemic events. As a result, the integrity of macula may be 
challenged in diabetes. Therefore, this research project was designed to 
examine the structural integrity of the retina in terms of full retinal thickness 
and GCC thickness in the macular area. 
In addition, RNFL and GCC thicknesses have been studied extensively in the field 
of glaucoma for several years. Glaucoma is a disease process characterised by 
ganglion cell death and typical changes in the optic nerve head (Quigley, et al., 
1982). For the reason that the loss of neuroretinal cells is irreversible, focus has 
shifted to early detection and prevention of further damage. However, ganglion 
cell death may not be limited only to glaucoma (Quigley et al., 1995). Recently, 
researchers have observed compromise to peri-papillary neural layers in 
relation to diabetic peripheral neuropathy (as in Chapter 1, section 1.6). For the 
reason that ganglion cells are several layers thick in the macular area, loss of 
ganglion cells may be easier to detect in this area (Zeimer et al., 1998). However, 
to date, there is no literature pertaining to full retinal or ganglion cell complex 
thickness in the macular area in relation to diabetic peripheral neuropathy. 
Therefore, this research project investigated the full retinal thickness, GCC 
thickness at the macular area and in addition, the peri-papillary nerve fibre 
layer thickness in people with diabetes, with and without neuropathy. 
3.2 General methodology and research plan  
3.2.1 Participants 
Participants were recruited as a part of the LANDMark study conducted at 
Queensland University of Technology (QUT), Brisbane. Ethical clearances were 
obtained from QUT and Princess Alexandra Hospital Human Research Ethics 
Committees (Ref 0800000167 and 2008/058, respectively) (Appendix 1). 
Participants were recruited from Princess Alexandra Hospital and the broader 
Brisbane community by advertisements in magazines and newspapers. 
Participants provided written informed consent (Appendix 2).  
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The LANDMark study protocol 
The Longitudinal Assessment of Neuropathy in Diabetes using novel ophthalmic 
Markers (LANDMark) study is a 4-year, two-site study that is aimed at the 
identification and longitudinal assessment of ophthalmic markers for diabetic 
peripheral neuropathy. The LANDMark study enrolled a cohort comprising of 
315 participants at baseline visit; groups of individuals with diabetic 
neuropathy, without neuropathy and controls, were examined at baseline and 
are followed up annually for 4 consecutive years.   The study is ongoing, and is 
not expected to be completed until mid-2015. 
As a part of the LANDMark study research protocol, a large number of tests are 
being conducted. Several optometrists are involved in the ophthalmic 
examination of the study participants. A range of tests conducted as per the 
protocol are as follows:  
1) Detailed ophthalmic history 
2) Visual acuity assessment 
3) Slit lamp examination of the eye to assess ocular status of the 
participants 
4) Non-contact corneal aesthesiometry 
5) Corneal confocal microscopy 
6) Visual fields examination 
a. Medmont automated perimetry 
b. Frequency doubling perimetry (performed twice) 
7) Optical coherence tomography (acquisition of RNFL, GCC, macula and 
ONH scans) 
8) Fundus photography 
a. Colour 
b. Red-free 
9) Three consecutive intra ocular pressure measurements 
10) Slit lamp examination at the end of the examination 
11) Uploading the data on to the research group database  
12) Preparation of health care practitioner reports as needed 
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13) Follow-up calls to the participant the day after the visit to thank 
participants and seek assurance of no ill-effects of study participation. 
A more detailed description of the LANDMark study design as well as the 
baseline characteristic of participants with type 1 diabetes has been described 
elsewhere (Pritchard et al., in press). 
The work described in this thesis analyses a subset of the LANDMark dataset at 
the Brisbane site to address specific hypotheses relating to retinal thickness 
changes associated with DPN. 
Methodology specific to this research program of the candidate 
This research project comprised of a series of cross-sectional, observational 
studies to analyse the research questions. The presence and type of diabetes 
was by self-report or ascertained from their health care provider. Individuals 
identif ing as ‘wit  ut dia etes’   ad fasting   as a g u  se  e e  in t e n r a  
range per our local pathology provider. Anyone with a failed fasting plasma test 
underwent an oral glucose tolerance test; although the protocol allowed 
impaired fasting glucose, all individuals had fasting glucose in the normal range.  
Information about duration of diabetes and ethnicity was self-reported. 
Glycosylated haemoglobin level (HbA1c) was assessed on the day of the 
examination. Individuals underwent neuropathy evaluation (explained below) 
and were classified as with or without neuropathy according to NDS criteria. 
Medical and demographic data were collected by qualified and experienced 
personnel.  
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Participants were chosen based on the following inclusion and exclusion 
criteria. 
Inclusion criteria specific to this research program 
 Aged 40 years and above 
 Type 1 or type 2 diabetes, and no diabetes or neuropathy for 
control group 
 Best-corrected visual acuity equal to or better than 6/9 
 Spherical refractive error within ± 6 D, astigmatism within ± 3 D  
 Any stage of diabetic retinopathy defined using ETDRS scale 
Exclusion criteria specific to this research program 
 Coexisting ocular infection or inflammation 
 IOP > 22 mmHg 
 Individuals with a vertical and horizontal cup-disc ratio > 0.6 
 Cataract that prevents good view of posterior segment in fundus 
photography or conduct of OCT  
 History of systemic disease (e.g. malignant disease, diseases 
affecting o ti  ner e  u ti  e s  er sis   ar ins n’s disease  t at 
may affect the RNFL thickness) 
 History of neuropathy due to non-diabetic cause 
 Participating in any other interventional research trial 
For the control group, in addition to the above criteria, participants were 
excluded if they had any of the following criteria: 
Additional exclusion criteria for the control group 
 Diabetes 
 GADab (Anti-glutamic acid decarboxylase antibody) positive 
 Any neuropathy 
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Sample size calculation for the current research program 
As a preliminary step, the differences between the groups were analysed in the 
key variables and then in the retinal tissue thickness. Finally, the relationship 
between retinal tissue thickness and diabetic peripheral neuropathy was 
analysed. The GPower 3 software (Faul, Erdfelder, Lang & Buchner, 2007) was 
used to calculate the minimum difference to be detected between the groups: 
diabetes without neuropathy and diabetes with neuropathy. The desired power 
and significance level were set at 0.80 and 0.05, respectively and a priori 
analysis (sample size N has been computed as a function of power level 1-β  
signifi an e  e e  α  and t e effe t size) was a   ied. F r regressi n ana  sis  t e 
R squared deviation from zero was calculated. The hypothesis for each 
experiment is discussed in the respective sections of experiment. 
Sample size calculation for full retinal thickness  
To address the research question, 
Is the full retinal thickness in people with neuropathy different from those without 
neuropathy? 
For a mean difference of 10 microns with a SD of 17 microns (Sull et al., 2010), it 
was estimated that 47 in neuropathy group, 47 in the no neuropathy group and 
47 participants without diabetes or neuropathy (controls) will be required. 
Allowing 10% of drop-out rate, a total of 155 participants will be required. 
 
Sample size calculation for inner retinal thickness 
To address the research question, 
Are the RNFL and GCC thickness in people with neuropathy different from those 
without neuropathy? 
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RNFL thickness 
For a mean difference of 5 microns with a SD of 10 microns (Shahidi et al., 
2012), it was estimated that 71 in neuropathy group, 71 in the no neuropathy 
group and 71 in the control group will be required. Allowing 10% of drop-out 
rate, a total of 234 participants will be required. 
GCC thickness 
For a mean difference of 5 microns with a SD of 7 microns (Garas et al., 2012), it 
was estimated that 52 in neuropathy group, 52 in the no neuropathy group and 
52 in the control group will be required. Allowing 10% of drop-out rate, a total 
of 170 participants will be required. 
 
 
Sample size for regression analysis using deviation from R squared 
In a previous pilot study (Shahidi et al., 2012), with the RNFL thickness as the 
dependent variable, R squared was found to be 0.1 with 5 predictors in the 
model that analysed 82 individuals with type 2 diabetes. 
Research question 
Is there a relation between retinal tissue thickness (full retinal and inner retinal) 
and diabetic neuropathy? 
No previous data exists in relation to full retinal thickness. For the current 
research program, it was estimated that a total of eight predictors will be 
included in the model; the regression models will have four continuous 
independent variables and two categorical independent variables with two 
levels in each; a sample size of 69 is required for an R squared of 0.2 and a 
sample of 150 for an R squared of 0.1. In other words, a sample size between 70 
and 150 is required for an R squared of 0.1-0.2 at 80%   wer  α=0.0 .  
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Table 2 provides a summary of the parameters for the sample size calculation 
for the full retinal and inner retinal thicknesses.  
 
Table 2. Sample size parameters calculated using GPower software 
A priori calculation 
Full retinal 
thickness 
RNFL 
thickness 
GCC 
thickness 
Retinal tissue thickness 
Regression:  R2 deviation 
from zero 
Input: Tail(s) Two Two Two  
Effect size d 0.5882 0.4756 0.5555 f² = 0.1111 
α err prob 0.05 0.05 0.05 0.05 
Power (1-β err prob) 0.8 0.8 0.8 0.8 
Allocation ratio N2/N1 1 1 1 Number of predictors = 8-9 
Noncentrality parameter δ 2.8515 2.8340 2.8327 λ = 1 .9999 
Critical t 1.9860 1.9770 1.9834 F = 2.0076 
Df 92 140 102 Numerator df = 8 
Sample size group 1 47 71 52 Denominator df = 135 
Sample size group 2 47 71 52  
Actual power 0.8055 0.8036 0.8012 0.8030 
Total sample size 141 213 156 144 
 
The sample size for the RNFL thickness was the highest. Therefore this was 
taken as the minimum sample size required for the entire research program. 
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The following sections discuss the neuropathy and the ophthalmic tests that 
were performed. 
3.2.2 Neuropathy assessment 
In the current research program, neuropathy was defined using the NDS 
criteria. Individuals with and without diabetes also underwent comprehensive 
assessment for neuropathy. The following section provides a brief review of the 
tests used in the detection of diabetic peripheral neuropathy (as previously 
explained in detail in Chapter 1, section 1.5).  
3.2.2.1 Neuropathy disability score (NDS)   
The test involved neurological examination of three sensory modalities: 
vibration perception with a 128-Hz tuning fork on the great toe, sharp and blunt 
sensation using a Neurotip® device (Owen Mumford Ltd., Oxford, UK) on the 
plantar aspect of the great toe; and hot and cold temperature sensation was 
assessed on the arch of both feet using metal rods immersed in hot and cold 
water. A score of 0 was given for normal response and 1 for abnormal response 
for each individual test component.  
Additionally, the ankle reflex was assessed using a reflex hammer with the 
scores, 0 for normal, 1 for reinforcement and 2 for absent. Each foot can have 
maximum score of 5 resulting in a total score of 10 for both feet. An NDS 
 riteri n  f neur  at   was defined as NDS s  re ≥3  n a scale of 10 (Young et 
al., 1993), with higher scores indicating more advanced degrees of neuropathy. 
3.2.2.2 Diabetic neuropathy symptom score (DNSS)  
This is a questionnaire that contains four general questions regarding  
unsteadiness while walking, experience of burning, aching pain or tenderness in 
legs or feet, prickling sensation in legs or feet and places of numbness in legs or 
feet. A score of 1 was given for the presence of symptom and 0 for the absence 
of symptom. A score of 1 or more out of 4 was recorded as abnormal DNS score 
(Meijer, et al., 2002). 
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3.2.2.3 Nerve conduction/Electrophysiology    
Assessments were done on the peroneal, tibial or sural nerves in the lower limb 
on the hand-dominant side of the participants using the Nihon Kohden 
Neuropack S1; MS92a EMG (Medelec Limited, Old Working, Surrey UK). Nerve 
conduction velocities and amplitudes were compared with the age-related 
normal values (provided in Table 3). Peroneal nerve conduction velocities and 
amplitudes were analysed for all participants as the peroneal nerve parameters 
were recordable for almost all participants. Sural nerve measurements were 
obtainable in a minority of individuals, and are not reported here.  
Table 3 provides a summary of age-based normal values of conduction 
velocities according to LANDMark study in-house norms. 
Table 3. Criteria for abnormal nerve conduction velocities based on the age 
a. < 10th percentile for healthy individuals without neuropathy at Brisbane site. 
b. Nerve conduction (NC) is considered abnormal if either peroneal or sural nerve conduction 
velocity (NCV) is below age-reference cut-off values. 
c. If sural not present, NCV is considered abnormal if tibial NCV is below 43 m/s for any age. 
 
3.2.2.4 Quantitative sensory testing 
The thresholds for vibration, thermal and pain stimuli such as heat-induced and 
cold-induced pain were recorded and analysed. The Medoc Quantitative Sensory 
Analyser, Model TSA-II (Medoc Advanced Medical Systems, Ramat Yishai 30095, 
Israel) was utilized.  
 
Age < 54 
years 
Age ≥    
years 
Abnormal tibial conduction velocity < 43 m/s < 43 m/s 
Abnormal peroneal conduction velocity ankle to fibular head < 45 m/s < 42 m/s 
Abnormal sural conduction velocity calf to ankle < 40 m/s < 38 m/s 
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3.2.2.5 Monofilament test 
The 10g nylon monofilament test was utilized to assess touch perception by 
exerting a specific repeatable bending force on three test sites; the participant 
responded whether they felt it or not. The number of points felt out of three was 
recorded. 
3.2.3 Ophthalmic assessment 
The eye on the side of the dominant hand was tested unless contraindicated by 
the exclusion criteria, in which case, the eye on the non-dominant side was 
tested.  Participants underwent visual acuity assessment, slit lamp examination, 
intraocular pressure measurement and pupil dilation after confirming adequate 
anterior chamber depth by the van Herick method. Three-field fundus 
photographs were taken for colour and red-free evaluations (section 3.2.3.1). 
The full retinal and the inner retinal tissue thicknesses for RNFL around ONH 
and GCC thicknesses at macula were measured using spectral domain OCT 
(section 3.2.3.2). People who had undergone laser treatment were not included 
in the main experiments detailed in Chapters 4-5. However, the retinal tissue 
thickness in people who had undergone laser for DR has been examined and is 
discussed in Chapter 6.  
3.2.3.1 Fundus photography 
Three-field photographs were obtained, each 45 degrees, covering nasal, central 
and temporal retinal regions (Visucam Pro, Carl Zeiss Meditec Inc., Dublin, CA, 
USA). Diabetic retinopathy grading was performed using the Early Treatment 
Diabetic Retinopathy Study scale (ETDRS) by an Ophthalmologist who was 
masked to clinical information of the participants.  
3.2.3.2 Spectral domain optical coherence tomography  
Retinal evaluation in diabetes has been conventionally done with 
ophthalmoscopy, slit-lamp biomicroscopy, and sometimes with fundus 
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fluorescein angiography. Early detection of changes in ocular health has become 
essential for timely referral in order to initiate treatment.  
Imaging technologies have provided the gateway to assess structural changes in 
the ocular tissue. Optical coherence tomography (OCT) has become an 
indispensable technology for the clinicians to assess subtle changes in the 
retina. The spectral domain OCT (SD-OCT) aids in non-contact evaluation of 
retinal layers in-vivo at a near-microscopic resolution; the OCT provides 
thickness information of the layer of interest and has been employed in a 
number of studies. The current research program utilized RTVue SD-OCT 
(Optovue, model RT-100, ver.4.0, Fremont, CA, USA) (Figure 16) for 
investigating retinal tissue thickness.  
 
Figure 16. RTVue spectral domain OCT 
 
The principle has been described elsewhere (Schuman, 2008); however a brief 
review is provided here. The OCT employs a wavelength of 820 ± 10 nm from a 
super-luminescent diode. The beam is split into a reference arm that is sent to a 
mirror and the other that is sent to the ocular tissue. The reflected beam from 
the ocular tissue and that from the mirror create interference pattern, which is 
split by a grating into different wavelength components. Fourier transformation 
is then applied to give A-scans. The software acquires 26,000 A-scans in one 
se  nd wit  an a ia  res  uti n  f   μ  (Ada ted fr   t e  TVue User Manua   
ver.4.0). The MM6, RNFL, and GCC scan protocols (described below) were used 
to obtain thickness information.  
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Full retinal thickness  
The MM6 protocol of the RTVue OCT consists of 12 radial lines each 6mm long 
centred at the fovea to provide 1024 A-scans each. The full retinal thickness is 
reportedly measured from the vitreoretinal interface to the outer-inner 
segment layer of the photoreceptors (Figure 17) at three concentric zones: a 
circle of 1 mm diameter centred at the fovea, a parafoveal region that has inner 
diameter of 1mm and outer diameter of 3 mm and a perifoveal region that has 
an inner diameter of 3mm and outer diameter of 6 mm.  
                                             
Figure 17. The retinal thickness is measured from the internal limiting membrane to the IS-OS 
junction of the photoreceptors (indicated by the black line) 
 
Figures 18A and 18B illustrate the scanned retinal area and the three concentric 
zones: central zone, the parafovea and the perifovea  (American Diabetes 
Association, 1985) respectively. In addition to the overall thicknesses, the 
hemisphere thicknesses in the parafovea, perifovea as well as for inner retinal 
thickness were analysed. Figure 19 shows the hemisphere regions analysed in 
the current project. 
The rationale for examining as overall and as hemisphere thickness is that the 
inferior RNFL thickness (Shahidi et al., 2012), mfVEP amplitudes (Lövestam-
Adrian et al., 2012) in the lower nasal retinal quadrant, are compromised in 
relation to diabetic peripheral neuropathy. Also Harris et al (2003) reported 
that the blood flow per nerve fibre tissue volume may be reduced in the inferior 
retina compared to the superior retina and hence may be more vulnerable to 
vascular insults. Therefore, the current research project sought to examine 
retinal tissue thickness in the superior and inferior hemispheres as well apart 
from the overall thickness (Figure 19).  
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Figure 18. (A) The scanned area in the retina for retinal thickness (B) The three concentric zones, 
the central zone, the parafovea (inner macula) and the perifovea (outer macula) 
 
 
Figure 19. Retinal thickness in this project were further examined as overall thickness in the 
central zone, parafovea and perifovea as well as hemispheres of parafovea and perifovea 
 
A 
B 
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Repeatability of full retinal thickness measurements 
The variability in retinal thickness measurements in healthy populations have been 
reported in the literature. For instance, the test-retest variability for macular 
t i  ness  ara eters  as  een re  rted t   e  etween 2.8 μ  and  .  μ  f r t e 
inner  a u ar quadrants and  etween 2.8 μ  and  .2 μ  f r t e  uter  a u ar 
quadrants (Nakatani et al., 2011). The difference in retinal thickness between 
groups is expected to be greater than the repeatability of the measurements such 
that meaningful differences between groups can be elucidated. 
Inner retinal thickness 
Figure 20 is a representation of scanned areas for the RNFL and GCC thicknesses 
and their corresponding measured zones.  
RNFL parameters  
Peripapillary nerve fibre layer thickness (RNFL) is purportedly measured from 
the inner border of nerve fibre layer to outer border of the plexiform layer along 
a circle of 3.45 mm diameter centred at the optic nerve head. The macular inner 
retinal layer thickness is measured from inner plexiform layer to the nerve fibre 
layer at the macula.  
 
Figure 20. The top picture shows scanned areas for the inner retinal thickness. Bottom left picture 
shows the ganglion cell complex (GCC) scan. Bottom right picture shows retinal nerve fibre layer 
(RNFL) scan. 
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Retinal nerve fibre layer (RNFL) thickness around the ONH is provided as 16 
sectors that are colour coded for rapid visual inspection in comparison to the 
thickness values from the normative database. Overall RNFL is the mean of 
 NFLT (μ ) f r t e t ta  3 0˚ easuring  ir  e  f 3.     dia eter centred at 
t e ONH. Su eri r a erage  NFLT (μ ) is easured in t e su eri r  e is  ere 
 f t e easuring  ir  e. Inferi r a erage  NFLT (μ ) is easured in t e inferi r 
hemisphere of the measuring circle (Figure 21). 
 
Figure 21. RNFL scan in RTVue SD-OCT (A) RNFL thickness for the individual shown by black arrow 
(B) TSNIT graph showing the average RNFL thickness matched against that from normative 
database (C)  RNFL thickness divided into 16 sectors. For this research program, the overall RNFL 
and the averaged thicknesses in the superior and inferior hemispheres were analysed 
 
A 
B 
C 
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GCC parameters 
The ganglion cell complex (GCC) is a composite of retinal nerve fibre layer, 
ganglion cell layer and inner plexiform layer. The GCC protocol scans over a 7 
mm x 7 mm zone with 15 vertical lines and one horizontal line centred at 1 mm 
temporal to fovea so as to cover the maximum of macular area. The protocol 
provides 15,000 A-scans within 0.6 seconds. The output includes thickness map 
and the significance map that is derived from the deviation map (Figure 22)  
 
Figure 22. GCC scan in RTVue SD-OCT. (A) Summary of GCC parameter is given in the table on the 
left (B) Thickness map: warmer colours represent thicker regions and cooler colours represent 
thinner regions (C) Significance map at the bottom represents the significance of the difference in 
comparison to population norms 
 
Overall GCC thickness reflects the average of the superior and inferior GCC 
values. Superior hemisphere GCC is the thickness of all layers between the nerve 
fibre layer and the inner plexiform layer in the area above the horizontal 
meridian. Inferior hemisphere refers to thickness of all layers between the 
nerve fibre layer and the inner plexiform layer in the area below the horizontal 
meridian.  
A 
B 
C 
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Repeatability of measurements 
Garas et al (2010) have shown that the intratest (i.e within a series of test 
measures taken on the same occasion) variability for average RNFL thickness is 
2.91 µm and 3.45 µm and 3.11 µm for superior and inferior hemisphere GCC, 
respectively. The intertest (i.e between repeated test measures on different 
occasions) variability is 4.25 µm for the average RNFL and  4.51 µm and 3.93 µm 
for the superior and inferior GCC, respectively (Garas et al., 2010). Therefore, 
differences between the groups with and without neuropathy should be greater 
than the repeatability to be considered as meaningful differences between 
groups. 
Pattern-based GCC parameters 
The pattern-based GCC parameters include global loss volume (GLV), focal loss 
volume (FLV) and root mean square (RMS). These parameters have been 
summarised below.  
GLV indicates the global loss in GCC volume over the entire GCC map. The 
percentage decrease in thickness at each pixel compared to the population 
norms is calculated. The resulting map is called the fractional deviation map 
where the pixels with values < 0 are summed up and divided by the entire GCC 
area to give GLV (%).  
FLV indicates the focal loss in GCC volume over the entire GCC map. The 
thickness value at each pixel is compared to that of age-matched normative 
database from the machine to give a pattern map.  This map is then compared 
with the average pattern map from the age-matched normative database. The 
difference between the two maps is the pattern deviation map, which is colour 
coded and assigned significance values for the deviation. The pixel values in the 
pattern deviation map which had values < 0 in fractional deviation map are 
summed with those for a p < 5% from pattern deviation map and divided by the 
total area to give FLV.  
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RMS or root mean square represents the coefficient of variation. It is an index to 
show how well the fractional and pattern deviation maps of an individual fit the 
normal pattern. The higher the number, the poorer is the fit. For this research 
project, the FLV and GLV were analysed. 
Only well centered scans with signal strengths better than 35 were taken as 35 
is the minimum signal strength required to register a scan (Balasubramanian et 
al., 2009). If the desired signal strength is not achieved, the particular scan 
protocols were repeated.  One acceptable image with highest signal strength for 
each scan type was considered eligible for analyses.  
Final sample size eligible 
Figure 23 is a flow chart showing the number of participants in each sub-group. 
The eye on the hand-dominant side was chosen if ophthalmic data were eligible 
for that eye. If not, the other eye was included if eligible. 
 
Figure 23. The number of participants in each group. DR, diabetic retinopathy. Solid boxes 
represent final number of participants who were eligible 
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Data extraction and handling 
The retinal thickness data and fundus photographs were acquired from the OCT 
and the fundus camera respectively. The medical and neuropathy data were 
obtained from the online database of the research group where in, the data 
pertaining to medical, neuropathic and ophthalmic assessments is being 
routinely uploaded by registered nurses, electrophysiologist and optometrists.  
The eligibility pertaining to visual acuity, intra ocular pressure and spectacle 
prescription was assessed with reference to the data folder of every participant.  
Exporting OCT data 
The eligible eye of the participants was recorded. The OCT data was exported in 
‘   ’ f r at. Su sequent    t e t  e  f s an  f r instan e  ‘ NFL 3.  ’ was 
chosen. The participants and their visits were then were chosen based on the 
date of examination. This procedure was repeated separately for GCC thickness 
data and the macular thickness data. The exported data was then converted as 
Microsoft Excel datasheet and saved under a filename.  
Exported data was then reorganised in relation to specific retinal zones to 
facilitate subsequent data analysis. 
Data pertaining to history, medical and neuropathy assessments, fundus 
grading, retinal thickness measures, visual acuity and intra ocular pressures 
were all combined into one master Microsoft Excel datasheet so that every 
participant had a single row of data. The data sheet was then scanned for 
missing data points. In case of data that were missing, the same was obtained by 
examining the data folder for every participant and re-entered into the master 
excel sheet. 
Pilot study by Shahidi et al (2012)  
T e  re i us  i  t stud     S a idi (2012) entit ed “ etina  ner e fi re  a er 
t inning ass  iated wit  dia eti   eri  era  neur  at  ”    nstituted a 
collaborative effort from the LANDMark laboratory. A detailed description has 
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been presented in section 1.6.2. However, the study examined individuals with 
type 2 diabetes and controls only. The RNFL thickness was the only outcome 
variable assessed in the study. The current research program has taken a more 
comprehensive approach and has examined full retinal thickness, the RNFL 
thickness, GCC thickness and the pattern-based GCC parameters in relation to 
diabetic peripheral neuropathy. Individuals with type 1 or type 2 diabetes were 
examined. In addition, a larger number of controls were examined.  
Therefore, it is to be noted that there is a proportion of participants in the 
current project that were also included in the study presented by Shahidi et al 
(2012). The current study has used slightly different inclusion criteria. As a 
result, 67 individuals with type 2 diabetes in the current project represent 
a  ut 90%  f t  e 2     rt in  uded in S a idi’s stud . In t e   ntr   gr u   
 7%  f t e indi idua s in t e  urrent  r je t were a  art  f S a idi’s   ntr   
group. The current project has included 84 individuals with type 1 diabetes, 
who have not been examined so far. 
Contribution of the candidate towards the current research program and to the 
overall group research project  
As a member of the LANDMark research team, the candidate has been actively 
involved in examining participants over the entire duration of her PhD 
candidature. The candidate has been involved in  
(i) Examination of study participants, data collection, recording 
observations on the Case Report Forms. 
The candidate has examined about 290 participants over the duration of 
the PhD candidature; this total number is inclusive of some participants 
who were examined twice or even thrice by the candidate during the 
subsequent years. For the set of procedures conducted as per the 
LANDMark study protocol, the examination time was approximately 2 
hours per participant. 
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(ii) Data management and analysis (data export, uploading various data 
forms e.g. JPEG, mxf, pdfs to the study database). 
(iii) Contributing to scientific discussion regarding study design, analysis and 
outcomes of all aspects of the LANDMark study. 
(iv) Hospitality, e.g. greeting the participant, making them comfortable, to 
find their way in and out of study site, accompany the participants to the 
street and find them a cab. 
(v) Courtesy telephone calls after 24 hour of examinations to thank the 
participant for their time and to ensure there were no ill-effects of 
participation. These details are recorded in the study database. 
The involvement of the candidate in the data entry and management, 
preparation of referral letters and follow-up phone calls together 
constituted an additional 3 hours per participant-visit.   
Of the total 231 participants included in the current study (as in Figure 23), 
85% were examined by the candidate.  
To address the research questions for the current research program, all data 
were included except the perimetry and corneal tests. 
3.3 Statistical analyses  
Statistical Package for Social Sciences (IBM Corp. Released 2012. IBM SPSS 
Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp) was used for 
analyses.  
A summary of the variables included in the current research program has been 
provided in Table 4. 
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Table 4. Variables used for statistical analysis 
Variables  Variables of interest 
Outcome 
variable for 
analysis 
Retinal tissue thickness  
 
Full retinal thickness (µm) Continuous 
Inner retinal thickness (µm) Continuous 
Focal and global loss in ganglion cell volume 
(expressed as percentage loss, %) 
Continuous and 
Categorical 
Neuropathy measures 
Diabetic neuropathy symptom score Continuous 
Neuropathy disability score 
Continuous and 
Categorical 
Quantitative sensory testing: 
Temperature threshold: degree Celsius 
Vibration threshold: Hertz 
Continuous 
Peroneal nerve amplitude (millivolts) Continuous 
Peroneal nerve conduction velocity 
(meters/second) 
Continuous 
10g monofilament Continuous 
Demographic and 
general health variables 
Age (years) Continuous 
HbA1c (%), where, the HbA1c/total haemoglobin 
ratio is expressed as percentage HbA1c 
Continuous 
Duration of diabetes (years) Continuous 
Total cholesterol (mmol/L) Continuous 
Systolic and diastolic blood pressure (mmHg) Continuous 
Gender Categorical 
Ethnicity Categorical 
 
As a preliminary step, the assumptions of normality and homogeneity of 
variance were tested before any group comparisons were performed. If the 
assumptions of normality or the homogeneity of variance was violated, then a 
non-parametric test was utilized for group comparisons. Normally distributed 
data for two-group comparisons were analysed using two-tailed unpaired t-
tests. An analysis of variance (ANOVA) test was used for comparing three or 
more groups for normally distributed variables.  
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For instance, the group differences between type 1 diabetes, type 2 diabetes and 
the non-diabetic, no neuropathy group were analysed using ANOVA for 
normally distributed variables and with Kruskal-Wallis test for variables that 
did not follow normal distribution. For those variables where significant 
differences in means were noted with ANOVA, a post-hoc test was conducted 
using the Tukey HSD test. For the reason that there is a possibility of type I error 
due to multiple comparisons, a Bonferroni post-hoc test has also been 
performed to aid in the additional interpretation of the results.  
To analyse relationships between variables, general linear models were applied. 
A general linear model can account for main effects, and interactions between 
variables. For analysing the effects of clinical and demographical variables on a 
categorical outcome variable (Chapter 5), binary logistic regression model was 
utilized. A p-value of < 0.05 was considered statistically significant.   
In the entire thesis, the magnitude of the differences is discussed only for 
significantly different variables and their significance values are presented in 
the respective tables.  
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Chapter 4: Retinal tissue thickness and 
diabetic neuropathy 
4.1 Age, sex and retinal tissue thickness in the control group  
Chapter 2 discussed the literature from the general population demonstrating 
the relationship between retinal tissue thickness, age and sex of the individuals 
in the absence of diabetes. However, it is unclear if the presence of neuropathy 
was accounted for in those studies. In addition, there is discrepancy in literature 
regarding gender predilection for diabetic neuropathy. This is an important 
consideration for the reason that objective of this research program is to 
determine the relationship between retinal tissue thickness and diabetic 
neuropathy. 
Therefore, it is essential to examine for the effects of age and sex on the retinal 
tissue thickness in its pure form: which means, in the absence of diabetes and in 
the absence of neuropathy due to non-diabetic causes. Therefore, as a 
preliminary step, the first part of the study investigated the relative effects of 
age and sex on the full retinal and inner retinal thickness in individuals who do 
not have diabetes or neuropathy due to non-diabetic causes. This section 4.1 
presents the analyses in this group (control group). 
4.1.1 Purpose 
To explore the relationship between age, sex of the individuals and retinal tissue 
thickness in those without diabetes and without neuropathy 
4.1.2 Research question and hypothesis 
Is the retinal tissue thickness influenced by age and/or sex in individuals without 
diabetes or neuropathy? 
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It was hypothesized that age and sex of the individuals are significantly related 
to the retinal tissue thickness in those without diabetes and without 
neuropathy. 
4.1.3 Methods 
Participants who did not have diabetes were invited to participate in the study 
as previously described in Chapter 3. Individuals underwent a comprehensive 
ophthalmic, medical and neuropathy assessments to rule out diabetes as well as 
neuropathy. 
Forty-two individuals met the criteria. The full retinal and inner retinal 
thicknesses were examined.  
4.1.4 Statistical analysis 
The variables age and retinal thickness parameters were examined for 
normality of distribution. The mean ± SD are reported for normally distributed 
continuous data. As described earlier in Chapter 3, the group differences were 
analysed as a preliminary step for the key variables and also for the retinal 
tissue thickness to examine the participant characteristics. However to examine 
the relationship between variables such as age and sex of the individuals with 
the retinal thickness, univariate general linear regression was performed. Full 
retinal, the RNFL and GCC thickness were entered as dependent variables in 
separate regression models. Age and sex were entered as independent 
variables.  
4.1.5 Results 
Eighteen (42%) of the study participants were males. The mean age in the control 
group was 55.2 ± 9.5 years; age group examined was 40-73 years. Forty individuals 
(95%) were Caucasians. 
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Full retinal thickness in females and males  
 
Table 5 shows the retinal thickness in males and females in this control group. Figure 
24 presents the mean and the 95% CI for retinal thickness at various regions in 
females and males.  
 
Table 5. Full retinal thickness in females and males in the control group 
Full retinal thickness parameters (µm) 
Females 
n = 24 
Mean ± SD 
Min - Max 
Males 
n = 18 
Mean ± SD 
Min - Max 
Thickness within central 1 mm zone 
251 ± 25 260 ± 27 
180 - 313 194 - 296 
Overall  thickness at parafovea 
313 ± 13 317 ± 16 
287 - 341 277 - 336 
Retinal thickness in superior parafovea 
316 ± 13 321 ± 15 
285 - 339 285 - 341 
Retinal thickness in inferior parafovea 
309 ± 13 313 ±17 
288 - 342 269 - 336 
Overall  thickness at perifovea 
273 ± 12 270 ± 13 
245 - 301 236 - 293 
Retinal thickness in superior perifovea 
279 ± 12 277 ± 15 
251 - 306 242 - 304 
Retinal thickness in inferior perifovea 
266 ± 15 263 ± 17 
239 - 312 222 - 288 
 
 
 
 
 
 
 
 
Experiments 
79 
 
 
Figure 24. Full retinal thickness in females and males in the control group for (A) central 1mm zone (B) overall parafovea (C) superior hemisphere parafovea (D) inferior 
hemisphere parafovea (E) overall perifovea (F) superior hemisphere perifovea (G) inferior hemisphere perifovea. Marker indicates mean retinal thickness in µm. Error 
bars are 95% CI 
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Inner retinal thickness in males and females 
 
Table 6 shows summary statistics for the inner retinal thickness in females and 
males. Figure 25 presents the mean and the 95% CI for RNFL and GCC thickness in 
females and males. 
 
 
Table 6. Inner retinal thickness in females and males in the control group 
Inner retinal thickness (µm) 
parameters 
Females 
n = 24 
Mean ± SD 
Min - Max 
Males 
n = 18 
Mean ± SD 
Min - Max 
Overall RNFL thickness 
104 ± 12 100 ± 9 
74 - 132 80 - 119 
Superior hemisphere RNFL 
103 ± 15 101 ± 11 
66 - 135 77 - 128 
Inferior hemisphere RNFL 
104 ± 12 99 ± 12 
82 - 136 83 - 118 
Overall GCC thickness 
97 ± 6 95 ± 7 
83 - 108 76 - 106 
Superior hemisphere GCC 
97 ± 7 94 ± 8 
78 - 110 70 - 106 
Inferior hemisphere GCC 
97 ± 6 97 ± 7 
85 - 107 81 - 108 
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Figure 25. Inner retinal thickness in females and males in the control group for (A) overall RNFL (B) superior hemisphere RNFL (C) inferior hemisphere RNFL (D) overall 
GCC (E) superior hemisphere GCC (F) inferior hemisphere GCC. Marker indicates mean inner retinal thickness in µm. Error bars are 95% CI  
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Relationship between age, sex of the individuals and the retinal tissue 
thickness 
The relationship between age, sex of the individuals for the full retinal tissue 
thickness and the inner retinal tissue thickness were analysed for each region in 
separate regression models. The full retinal thickness within the central 1mm 
zone was not significantly related to age or sex of the individuals. However, the 
overall and the hemisphere thickness in the parafovea and perifoveal regions 
significantly reduced with advancing age at the rate of 0.58-0.67 µm and by 
0.65-0.78 µm respectively. Males had significantly thicker (8 µm) superior 
parafovea than females (p = 0.041) when adjusted for age. Other retinal regions 
did not show significant relation to sex of the individuals. Results for full retinal 
thicknesses are presented in Table 7. 
 
Table 7. Full retinal thickness with age and sex as variables in the model 
Full retinal thickness in                 
control group (µm) 
Variables 
entered in 
regression 
B SE(B) p-value 
Thickness within central 1 mm 
zone 
Age -0.476 0.400 0.240 
Males 11.143 7.830 0.162 
Overall  thickness at parafovea 
Age -0.588 0.204 0.006 
Males 6.935 3.941 0.086 
Retinal thickness in superior 
parafovea 
Age -0.670 0.203 0.002 
Males 8.318 3.944 0.041 
Retinal thickness in inferior 
parafovea 
Age -0.589 0.218 0.010 
Males 5.719 4.294 0.190 
Overall  thickness at perifovea 
Age -0.700 0.185 <0.001 
Males 0.178 3.715 0.962 
Retinal thickness in superior 
perifovea 
Age -0.788 0.183 <0.001 
Males 0.593 3.677 0.873 
Retinal thickness in inferior 
perifovea 
Age -0.651 0.237 0.009 
Males 1.080 3.677 0.822 
SE, standard error; B, slope 
 
 
 
Experiments 
83 
 
The overall and hemisphere RNFL and GCC thicknesses reduced significantly 
with advancing age but did not show significant relationship to sex of the 
individuals. The overall RNFL thickness reduced at the rate of 0.61 µm per year 
increase in age (0.68 µm per year and 0.53 µm per year for the superior and 
inferior hemispheres respectively). The overall GCC thickness reduced at the 
rate of 0.49 µm per year increase in age (0.53 µm per year and 0.46 µm per year 
reduction in GCC thickness for the superior and inferior hemispheres 
respectively). The results for the RNFL and GCC thickness parameters are 
presented in Table 8. 
 
Table 8. Inner retinal thickness with age and sex as variables in the model 
Inner retinal thickness in          
control group (µm) 
 
Variables entered in 
regression 
B SE(B) p-value 
Overall RNFL thickness 
Age -0.614 0.152 <0.001 
Males -1.872 2.998 0.536 
Superior hemisphere 
RNFL 
Age -0.689 0.189 0.001 
Males -0.040 3.741 0.992 
Inferior hemisphere 
RNFL 
Age -0.538 0.157 0.001 
Males -3.702 3.062 0.233 
Overall GCC thickness 
Age -0.496 0.085 <0.001 
Males -0.169 1.702 0.921 
Superior hemisphere GCC 
Age -0.532 0.098 <0.001 
Males -1.289 1.964 0.515 
Inferior hemisphere GCC 
Age -0.460 0.081 <0.001 
Males 0.936 1.61 0.564 
SE, standard error; B, slope 
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4.1.6 Discussion 
The study examined the relationship between age, sex of the individuals and the 
full retinal thickness and inner retinal thickness in a group of individuals 
without diabetes or neuropathy.  
The central zone thickness and age 
In a cohort of people without diabetes, belonging to the age group 40-73 years, 
retinal thickness within central 1mm was not significantly related to age or sex 
of the individuals. This is in agreement with past studies where the fovea did 
not show significant relationship with age (Wong et al., 2004, Chan et al., 2006). 
In contrast, Eriksson et al (2009) found that thickness within central 1mm zone 
reduced significantly at the rate of 0.26 µm per year increase in age. However, 
the participants belonged to age group 12 years to 74 years. This wider range of 
age group examined may be a possible explanation for the differences in effect 
due to age and therefore may explain differences in slope. Also, Eriksson and his 
group in their study, performed regression analysis for each ETDRS sector with 
age that were not adjusted for sex of the individuals. The current project used 
regression models that were adjusted for the effects of age and sex of the 
individuals.  
Full retinal thickness and age 
In the control group, thickness in the parafovea and perifovea reduced with 
advancing age. This is consistent with that reported by Fraser-Bell et al (2005). 
In the current study, thickness in the parafovea reduced at the rate of 0.58 µm 
per year (0.67 and 0.58 µm per year for the superior and inferior hemispheres 
respectively). The thickness in the overall perifovea reduced at the rate of 0.70 
µm per year increase in age (0.78 µm and 0.65 µm in the superior and inferior 
perifovea respectively). This is comparable to that reported by Alamouti et al 
(2003) who observed that the overall retinal thickness reduced at the rate of 
0.53 µm per year increase in age in those without diabetes. Eriksson et al (2009) 
observed that the retinal thickness reduced with age both in the parafovea (0.25 
µm and 0.35 µm reduction per year increase in age in superior and inferior 
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parafovea respectively) and in the perifovea (0.29 µm and 0.46 µm reduction in 
the superior and inferior perifovea respectively). However, the observations 
were unadjusted for sex of the individuals, which may be an explanation for the 
differing results when compared to the current study. 
Full retinal thickness in males and females 
In the current study, retinal thickness in the superior parafovea was 
significantly thicker (8 µm) in males compared to females, when adjusted for 
the effect of age. The other retinal regions were not significantly related to sex 
of the individuals. Studies from the past (Massin et al., 2004, Wong et al., 2004, 
Bressler et al., 2008, Huang et al., 2009) observed thicker retina in males 
compared to females. 
Wong et al (2004) studied 117 eyes in the age group 13-81 years and observed 
thickness within central 1mm zone to be greater (mean = 9 µm) for males than 
females. Therefore, in the current study, it is likely that a larger sample of 
individuals may have demonstrated significant differences between males and 
females in the central and the other retinal regions.  
Inner retinal thickness and age 
In this study, both the RNFL and GCC thicknesses reduced with increasing age 
but did not show significant relationship with sex of the individuals. The overall 
RNFL thickness reduced at the rate of 0.61 µm per year increase in age and the 
overall GCC thickness reduced at the rate of 0.49 µm per year increase in these 
individuals aged 40-73 years. Previous study reported that RNFL reduced at the 
rate of 0.2 µm per year in a group of people belonging to age group 18-85 years 
(Bundez et al., 2007). Another study observed that the GCC thickness reduced at 
a rate of 1.59 µm per decade belonging to the age group 22-84 years (Kim et al., 
2011).  It has been reported that retinal ganglionic axons are lost at the rate of 
2000 axons per year before the age of 50 years and at the rate of 7000 axons per 
year after the age of 50 years and on an average, about 5000 axons per year are 
lost from birth to death (Quigley et al., 1989). This may be a likely explanation 
f r t e differen es in t e agnitude  f t e ‘age effe t’   ser ed a r ss studies. 
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In the study by Bundez and his group, nearly 65% of the participants were 
Caucasians. In the study by Kim and his group regarding the GCC parameters, all 
participants examined were of Korean descent. The RNFL thickness is reported 
to be thicker in Asians and Hispanics compared to Caucasians (Bundez et al., 
2007). In the current study, 95% of individuals in the control group were 
Caucasians. Therefore, the results from the current project may not be 
applicable to other ethnic groups.  
4.1.7 Conclusion 
Full retinal thickness and inner retinal thicknesses decrease with increasing age, 
when adjusted for sex of the individuals, in this cohort of individuals without 
diabetes or neuropathy. The superior parafovea is thicker in males than in 
females. This control group predominantly comprised of Caucasians in the age 
group 40-73 years. Larger sample sizes may be required to demonstrate 
between-gender differences in thickness in the central zone and other retinal 
regions.  
With this knowledge, the variables age and sex were therefore included in 
subsequent analyses in the diabetic group for exploring the relationship 
between retinal thickness and certain key clinical variables.  
Examining the relationship between retinal tissue thickness and diabetic 
peripheral neuropathy in a group of individuals with diabetes was the main 
objective of this research program. Though data on the control group is also 
presented for comparison purposes, the following section 4.2 and onwards will 
specifically discuss the findings in individuals with diabetes. 
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4.2 Retinal tissue thickness: Type 1 versus type 2 diabetes 
Rationale  
The group with diabetes comprised of individuals belonging to either type 1 or 
type 2 diabetes. However, the two types of diabetes differ in their aetiology.  
Type 1 diabetes is an autoimmune process causing destruction to pancreatic 
beta cells, ultimately leading to absolute insulin deficiency; therefore, insulin is 
necessary for survival. The autoimmune process can be identified by the 
presence of antibodies against islet cell, insulin, or anti-glutamic acid 
decarboxylase (anti-GAD) (Zimmet et al., 1994).  
Type 2 diabetes is the most common form of diabetes. There is only a relative 
insulin deficiency in these individuals. Type 2 diabetes generally has no markers 
such as anti-GAD or insulin antibodies as are observed in type 1 diabetes. 
Individuals with this disorder either have insulin resistance or impaired 
secretion or both, which can be identified when the disease manifests. Exercise, 
weight reduction or oral hypoglycaemic agents may help to improve sensitivity 
of tissues to insulin (Joslin et al., 1936).  
Mitchell et al (2008) proposed that people with type 1 diabetes may have 
responded better to metabolic control. Hence, type 1 diabetes may be viewed as 
a metabolic disorder; however, most people with diabetes who died of 
cardiovascular and other vascular complication belonged to type 2 diabetes. 
Therefore, type 2 diabetes may be viewed as a vascular disorder (Fox, 2010). 
This raises the question whether they can be combined to represent one group 
of individuals with diabetes. 
One way to answer this research question is to explore the relationship between 
the type of diabetes and the retinal tissue thickness. Therefore, the first part of 
the experiment was modified to explore the effect of type of diabetes on the 
retinal tissue thickness. If the type of diabetes is significantly related to the 
retinal tissue thickness, then it would be rational to report results for type 1 and 
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type 2 diabetes separately. The following sections present a review of literature 
that report certain differences in type 1 and type 2 diabetes. 
There have been a limited number of studies (described below in section 4.2.1) 
that reported certain differences in ocular structure and visual function in 
individuals with type 1 diabetes compared to type 2 diabetes. The following 
section provides a review of those findings reported in the literature. 
4.2.1 Review of literature 
Clinical and demographic variables: type 1 versus type 2 diabetes 
In a recent study by Bronson-Castain et al (2012) that examined retinal function 
and structure using mfERG, retinal vessel diameter measurement and OCT in 
adolescent type 1 and type 2 diabetic people without DR, the authors observed 
that variables such as duration of diabetes (mean duration, 5.7 ± 3.6 years 
versus 2.1 ± 1.3 years) and HbA1c levels (9.6 ± 2.2% versus 7.6 ± 3.0%) were 
significantly higher in adolescents with type 1 than those with type 2 diabetes.  
On the other hand, those with type 2 diabetes had greater body mass index 
(BMI) compared to type 1 diabetes and those without diabetes (mean, 34.6 
kg/m2 versus 22.4 kg/m2 and 22.6 kg/m2 respectively), suggesting differences 
in clinical variables between the two groups. 
Neuropathy and the type of diabetes 
Prevalence of diabetic neuropathy  
A difference in the prevalence of neuropathy between the two types of diabetes 
has been observed. A study from the past observed prevalence of neuropathy in 
type2 diabetes (50%) to be twice as high as in type 1 diabetes (25%) (Van Acker 
et al., 2009). However, it is to be noted that the number of people with type 2 
diabetes examined was more than twice the number with type 1 diabetes (n = 
767 versus 344 respectively).  
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Sural nerve changes in diabetic neuropathy 
In the presence of hyperglycaemia, a significantly higher nerve fibre loss has 
been observed in the sural nerves in type 1 experimental diabetic rat models 
but not in type 2 models. The authors mention this as being related to axonal 
degeneration at the nodes caused by disruption of Na+/K+ - ATPase. This axonal 
change has been found to be correlated with subnormal conduction velocities in 
the sural nerves. This neuropathy-related structural change has been observed 
typically in type 1 rats but not in type 2 rats (Kamiya et al., 2005; Sima et al., 
2006). 
Ocular complications in type 1 and type 2 diabetes 
Anterior segment complications  
Corneal sensitivity was evaluated in a group of people with diabetes with 
proliferative retinopathy. Corneal sensitivity was significantly poorer in 
individuals with type 2 diabetes compared to those with type 1 diabetes and 
those without diabetes (Ruben, 1994). However, the results may have been 
confounded by the effect of patient age, in that individuals with type 2 diabetes 
were older than those in the other two groups (mean± SD, 58 ± 12 years versus 
46 ± 15 years; median age, 57 years versus 51 years).  
In individuals with type 1 diabetes, cataract with vacuoles and snow-flake like 
opacities with light scattering properties are seen. However, in those with type 
2 diabetes, the cataractous changes are similar in appearance to that of age-
related cataract (Bron et al., 1998). Both the groups were matched with respect 
to duration of diabetes.  
Retinal complications  
Prevalence of diabetic retinopathy  
Independent studies reported different prevalence rates for DR in the two types 
of diabetes. The data combined from two studies conducted in the US, the 
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WESDR and New Jersey 725 study, observed prevalence of DR to be 82% among 
people with type 1 diabetes (Roy et al., 2004).  
Analysis from pooled data from eight population-based studies in the US 
reported prevalence of DR to be 40% in people with type 2 diabetes above 40 
years of age (Kempen et al., 2004); two studies conducted in Indian 
subcontinent reported prevalence as 22% (Narendran et al., 2002) and 27% 
(Dandona et al., 1999) in people with type 2 diabetes above 50 years of age. 
Also, the visual impairment from DR in type 1 diabetes is most likely from 
proliferative DR, whereas in type 2 diabetes, it is more likely to be from macular 
oedema (Cunha-Vaz et al., 2012).  
Retinal tissue structure and function  
Metabolic control can influence both retinal structure and function. With 2 years 
of intensive metabolic control, the contrast sensitivity function in individuals 
with type 1 diabetes improved in those without DR and in mild DR when 
compared to baseline values (Verrotti et al., 1998). In a study by Sugimoto et al 
(2010) in people with type 2 diabetes, there was a significant reduction in 
superior retinal nerve fibre layer thickness after 4 months of strict metabolic 
control. The above two studies show retinal function and structural changes in 
response to strict metabolic control in individuals with type 1 diabetes and type 
2 diabetes respectively. This might possibly indicate differences in the way the 
two types of diabetes respond to strict metabolic control.   
Bronson-Castain et al (2012) analysed the frequency of abnormality (defined as 
equal to as or more than ± 2 z-score distributions) in the mfERG implicit times, 
mfERG amplitudes (which provide a measure of retinal function) and retinal 
thicknesses among adolescents with type 1 diabetes, type 2 diabetes and in 
participants without diabetes (control). The authors observed frequency of 
abnormality was greater in those with type 2 diabetes than those with type 1 
diabetes and control group, for all three parameters (Bronson-Castain et al., 
2009).  
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Longer duration of diabetes is more commonly observed in individuals with 
type 1 form than the type 2 form of diabetes. RNFL thickness has been reported 
to be inversely related to the duration of diabetes (Oshitari et al., 2009). If the 
nerve fibre layer thickness parameters are linked with the duration of diabetes, 
it is likely that the neural tissue thickness in people with type 1 diabetes may be 
reduced compared to that of people with type 2 diabetes.  
To summarize, there appears to be certain differences between type 1 and type 
2 diabetes. Given that the retinal tissue integrity has not been studied in detail 
in the two types of diabetes, examination of the full retinal and the inner retinal 
thicknesses in the two types of diabetes will provide a better understanding for 
further experiment. Therefore, the current research program sought to explore 
the association between the type of diabetes and retinal tissue thickness.  
4.2.2 Purpose 
The purpose of this part of the study was to examine the relationship between 
the type of diabetes and retinal tissue thickness 
4.2.3 Research question and hypothesis 
Is there a relationship between the type of diabetes and the retinal tissue 
thickness? 
 
It was hypothesised that the type of diabetes is significantly related to the 
retinal tissue thickness.  
4.2.4 Methods 
Information regarding the type of diabetes was self-reported or obtained from 
health care practitioner reports. After stratifying based on the type of diabetes, 
84 individuals were designated as having type 1 diabetes and 67 individuals had 
type 2 diabetes. There were 42 individuals in the control group. For the 
purposes of this experiment, individuals with type 1 diabetes are referred to as 
‘T1DM’ and t  se wit  t  e 2 dia etes as ‘T2DM’. 
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As a preliminary step, the key clinical and demographic variables of interest 
namely age, sex, NDS score, DR, duration of diabetes and HbA1c levels were 
analysed and compared between the three groups. The data for various other 
clinical and demographic variables were also compared between groups.  
The full retinal and inner retinal tissue thicknesses were compared between 
T1DM and T2DM and also with the control group. The relation between the type 
of diabetes and the retinal tissue thickness, adjusted for age, sex of the 
individuals, DR, NDS, duration of diabetes and HbA1c levels was subsequently 
explored.  
4.2.5 Statistical analysis 
The proportion of individuals with DR in the two groups of diabetes was 
analysed. A chi-square test of independence was performed to analyse the 
relation between DR and the type of diabetes. An analysis of variance test was 
used to compare continuous and normally distributed data between type 1 
diabetes, type 2 diabetes and the group without neuropathy or diabetes (named 
as t e ‘  ntr   gr u ’); a Tu e ’s HSD test was used after a signifi ant resu t in 
the analysis of variance test. These data are represented as mean, standard 
deviation (SD) and range. For the reason that there is a possibility of type I error 
due to multiple comparisons, a Bonferroni post-hoc test has also been 
performed and the significance values are shown in the respective tables, to aid 
in the additional interpretation of the results.  
For variables that did not follow a normal distribution, the group-differences 
were analysed using a Kruskal-Wallis test; a Mann-Whitney U test was 
performed after a significant Kruskal-Wallis test. These data are represented as 
median and inter-quartile range. 
To examine the relationship between the type of diabetes and retinal tissue 
thickness, a univariate general linear model was utilized. The overall retinal 
thickness, the RNFL and GCC thicknesses were entered as dependent variables 
and analysed in separate regression models. The type of diabetes, presence of 
diabetic retinopathy and sex of the individuals were coded and entered as 
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factors; age, NDS (entered as continuous variable), duration of diabetes and 
HbA1c levels were entered as covariates in each of the regression model.  
Main effects were assessed for type of diabetes, age, DR status, gender, NDS, 
duration of DM and HbA1c levels on the thicknesses of the overall fovea, 
parafovea, perifovea, and the RNFL and GCC thicknesses.  
Interactions were analysed between  
a) type of diabetes and age 
b) type of diabetes and NDS  
c) type of diabetes and duration of diabetes 
d) type of diabetes and DR 
4.2.6 Results 
Clinical and demographic variables  
Results are presented in Table 9. The magnitude of differences will be reported 
only for significantly different variables. 
People with T2DM were significantly older than those with T1DM and the 
control group (mean difference of about 6 years and 4.5 years respectively). The 
mean HbA1c levels were not significantly different, but, when compared to 
control group, both the groups with diabetes had significantly elevated HbA1c 
levels.  
Forty six percent of people with T1DM had DR compared to 35% among those 
with T2DM. A chi-square test of independence was performed to analyse the 
relationship between the type of diabetes and the proportion of people with 
retinopathy. There was no statistically significant relationship between the two, 
χ2 (1, 151) = 1.725, p = 0.189. There were 53% of males and 64% of males in T1DM 
and T2DM groups respectively and the relationship was not significant, p = 
0.189.  
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 Table 9. A summary of key clinical and demographic characteristics in groups with type 1 and type 
2 diabetes and in control group 
Clinical variables 
T1DM 
(A) 
Mean  ± SD 
n 
Min - Max 
T2DM 
(B) 
Mean  ± SD 
n 
Min - Max 
Controls(C) 
 
Mean  ± SD 
n 
Min - Max 
ANOVA 
F 
ANOVA 
p-values 
 
Bonferroni 
p-values 
Age 
53.6 ± 9.2 60.4 ± 8.1 55.9 ± 9.6 10.739 <0.001* A vs. B, <0.001 
84 67 42 B vs. C, 0.034 
40.1 - 77.3 41.4 - 72.1 40.7-72.6  
Males n (%) 
      
45 (53%) 43 (64%) 18 (42%)  0.189 ǁ  
      
HbA1c (%) 
8.0 ± 1.2 7.5 ± 1.4 5.4 ± 0.3 67.381 <0.001 § A vs. C,<0.001 
84 66 42 B vs. C,<0.001 
6 - 13 5 - 12 5 - 6  
DR (%) 
      
39 (46%) 24 (35%) n/a  0.189 ǁ  
      
Controls - no diabetes/neuropathy 
* Signifi ant differen es f r A  s. B and B  s.   wit  Tu e ’s HSD 
§ Significant differences between A,B vs. C with Tu e ’s HSD 
ǁ Signifi ant differen es wit  χ2 test for A vs. B 
n/a not applicable; DR, diabetic retinopathy (representing those with clinically visible signs of 
retinopathy) 
   Proportion of males in this table compared between T1DM and T2DM 
 
 
 
Table 10 shows duration of diabetes and NDS in the three groups using non-
parametric tests. Individuals with T1DM had significantly longer duration of 
diabetes (mean difference of 5 years) than T2DM group. The NDS scores were a 
unit higher NDS in the T2DM group compared to the T1DM group and was 2 
units greater when compared to that of the control group.  
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   Table 10. Duration of diabetes and NDS comparison with non-parametric tests 
Clinical variables 
T1DM (A) 
 
Median 
IQR 
Min-Max 
T2DM (B) 
 
Median 
IQR 
Min-Max 
Control(C) 
 
Median 
IQR 
Min-Max 
Kruskal-Wallis test 
χ2 df p-values 
Duration of 
diabetes (years) 
17 12  
<0.027 ‡ 26 12 n/a 
0 - 56 2 - 64  
NDS 
1 2 0 
28.55 2 <0.001 §‡ 2 5 1 
0 - 10 0 - 10 0 - 2 
T1DM, type 1 diabetes; T2DM, type 2 diabetes; Controls - no diabetes/neuropathy; NDS, 
neuropathy disability score, IQR, inter-quartile range 
‡ Signifi ant differen es  etween A and B  wit  Mann-Whitney U test  
§ Significant differences between A, B vs. C with Mann-Whitney U test 
 
 
The summary statistics for the other clinical and neuropathy related measures in 
the type 1, type 2 and control groups by non-parametric tests are presented in 
Table 11. The body mass index (BMI) was 4 kg/m2 higher in T2DM compared to 
T1DM and 5 kg/m2 higher than the control group. Among the neuropathy 
measures, those with T2DM had a unit higher DNSS than those with T1DM. The QST 
vibration threshold was 3.8 Hz higher in T2DM compared to the control group and 
3 Hz higher in T1DM group compared to the control group. Both the groups with 
diabetes had lower number of monofilament points detected than the control 
group. The QST warm sensation threshold, warm and cold-induced pain thresholds 
were similar in the three groups.  
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Table 11. Summary of other clinical and demographic characteristics in type 1, 2 diabetes and in 
control group using non-parametric tests 
Clinical variables 
T1DM (A) 
 
Median 
IQR 
Min-Max 
T2DM (B) 
 
Median 
IQR 
Min-Max 
Controls(C) 
 
Median 
IQR 
Min-Max 
Kruskal-Wallis test 
χ2 df p-values 
Body mass index 
(kg/m2) 
27.8 31.0 26.9 
28.16 2 <0.001 §‡ 5.4 6.8 4.3 
19 -  47 21 - 55 19 - 46 
DNSS 
0 1 0 
29.67 2 <0.001 §‡ 1 2 0 
0 - 3 0 - 4 0 - 1 
QST warm sensation 
(˚ ) 
39.7 39.2 37.2 
18.56 2 0.076 6.7 7.8 6.7 
33.1 - 50.0 19.4 - 50.0 30.5 - 47.0 
QST cold induced pain 
t res   d (˚ ) 
8.1 4.7 7.9 
0.05 2 0.975 17.8 19.7 17.9 
0.0 - 26.5 0.0 - 29.3 0.0 - 29.4 
QST warm induced 
 ain t res   d (˚ ) 
48.9 49.5 48.7 
1.60 2 0.448 3.3 3.0 4.0 
39.5 - 50.0 37.3 - 50.0 41.2 - 50.0 
QST vibration 
threshold (Hz) 
9.0 9.8 6.0 
12.84 2 0.002 § 16.4 19.1 7.6 
1.0 - 130.0 1.4 - 130.0 1.2 - 42.2 
Monofilament (no. of 
points detected out of 
3) 
3 3 3 
9.36 2 0.009 § 0 0 0 
0 - 3 0 - 3 2 - 3 
T1DM, type 1 diabetes; T2DM, type 2 diabetes; Controls - no diabetes/neuropathy; IQR, inter-quartile 
range; DNSS, diabetic neuropathy symptom score; QST, quantitative sensory testing  
‡ Signifi ant differen es f r T1DM versus T2DM by Mann-Whitney U test   
§ Significant differences between both T1DM, T2DM groups versus control group by Mann-Whitney U test 
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Table 12 presents a summary of other clinical and neuropathy measures. 
Individuals with T2DM had 0.8 mmol/L lower total cholesterol levels than the 
T1DM as about 63% of individuals in T2DM group and 49% in T1DM group 
were on lipid-lowering drugs compared to 7% in the control group. Both the 
groups with diabetes had significantly lower total cholesterol levels when 
compared to the control group (1.7 and 0.9 mmol/L respectively). Systolic and 
diastolic blood pressure was not significantly different in the three-group 
comparison. Among the neuropathy measures, T1DM and T2DM diabetic groups 
had lower peroneal nerve conduction velocities (3.9 m/s and 3.5 m/s 
res e ti e  ) and 3.  ˚    wer QST    d t res   ds     ared t    ntr   gr u . 
The peroneal nerve amplitudes did not differ significantly between groups.  
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Table 12. Other clinical and neuropathy measures in groups with type 1 and type2 diabetes and the control group 
Clinical variables and neuropathy 
measures 
 
 
T1DM (A) 
 
Mean  ± SD 
n 
Min - Max 
T2DM (B) 
 
Mean  ± SD 
n 
Min - Max 
Controls (C) 
 
Mean  ± SD 
n 
Min - Max 
ANOVA 
F 
 
 
ANOVA 
p-values 
 
 
Bonferroni 
p-values 
 
Total cholesterol 
(mmol/L) 
  
4.7 ± 1.0 3.9 ± 0.8 5.6 ± 1.0 43.067 <0.001 ‡§ A vs. C,<0.001 
84 66 42   B vs. C,<0.001 
3.0 - 8.6 2.6 - 6.2 4.2 - 9.2    
BP resting systolic (mmHg) 
  
  
128 ± 16 128 ± 14 126 ± 14 0.448 0.640  
84 67 42    
95 - 167 87 - 161 102 - 163    
BP resting diastolic (mmHg) 
  
  
78 ± 8 75 ± 8 79 ± 9 3.064 0.051  
84 67 42    
53 - 97 52 - 91 63 - 108    
Peroneal M amp ankle to EDB  
(millivolts)a 
  
3.6 ± 2.4 4.0 ± 2.6 4.2 ± 2.5 0.804 0.449  
83 67 42    
0.1 - 10.4 0.1 - 14.1 0.1 - 9.2    
Peroneal CV ankle to FH 
(meters/second) 
  
43.6 ± 5.6 44.0 ± 6.5 47.5 ± 7.4 5.873 0.003 § 
A vs. C, 0.004 
B vs. C, 0.015 
84 67 42    
20.0 - 52.3 20.0 - 57.1 20.0 - 59.0    
QST    d sensati n t res   d a erage (˚ ) 
  
  
24.7 ± 7.4 24.8 ± 7.4 28.2 ± 2.7 4.556 0.012 § A vs. C, <0.016 
84 67 42   B vs. C, <0.030 
0.0 - 31.3 0.0 - 31.3 19.6 - 33.2    
T1DM, type 1 diabetes; T2DM, type 2 diabetes; BP, Blood pressure; EDB, extensor digitorum brevis; FH, fossa head; Controls - no diabetes/neuropathy;   
§ Signifi ant differen es  etween T1DM and T2DM  ersus   ntr   gr u  wit  Tu e ’s HSD test 
‡ Signifi ant differen e  etween T1DM  ersus T2DM wit  Tu e ’s HSD test  
Where there was no response, the following substituted data were used: Peroneal amp:0.1 mV; Peroneal CV: 20 m/s reflecting lowest recorded value in our laboratory 
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The retinal tissue thicknesses analysis showed people with T2DM had reduced 
thickness in the overall parafovea, perifovea, the RNFL and GCC thickness when 
compared to individuals with T1DM. The mean differences were 6 µm, 7 µm, 6 
µm and 4 µm for the parafovea, perifovea, RNFL and GCC thicknesses 
respectively. Thickness within the central zone and parafovea in T2DM was 
further reduced when compared to the control group. Table 13 provides a 
summary of the full retinal thickness and in the three groups. 
Table 13. Retinal tissue thickness in groups with type 1 and type 2 diabetes and the control group 
Retinal variables 
(µm) 
 
 
 
 
T1DM 
(A) 
Mean  ± SD 
n 
Min - Max 
T2DM 
(B) 
Mean  ± SD 
n 
Min - Max 
Control (C) 
 
Mean  ± SD 
n 
Min - Max 
ANOVA 
F 
 
 
ANOVA 
p-values 
 
 
Bonferroni 
p-values 
 
 
Thickness within  
central 1mm  
  
249 ± 23 241 ± 24 254 ± 26 4.064 0.019 † B vs. C, 0.018 
84 66 42    
140 - 293 177 - 289 180 - 313    
Overall parafovea  
  
  
311 ± 16 305 ± 16 314 ± 14 5.291 0.00  †‡ B vs. C, 0.007 
84 66 42    
259 - 338 268 - 342 277 - 341    
Overall perifovea  
  
  
272 ± 13 265 ± 15 272 ± 13 5.081 0.007 ‡ A vs. B, 0.008 
84 66 42    
230 - 301 201 - 297 236 - 301    
Overall RNFL 
thickness  
  
  
105 ± 10 99 ± 12 102 ± 11 3.716 0.02  ‡ A vs. B, 0.021 
84 67 42    
82 - 132 71 - 136 74 - 132    
Overall GCC 
thickness  
  
  
97 ± 8 93 ± 8 96 ± 7 4.281 0.01  ‡ A vs. B, 0.013 
84 66 42    
77 - 117 71 - 113 76 - 108    
T1DM, type 1 diabetes; T2DM, type 2 diabetes; RNFL, retinal nerve fibre layer; GCC, ganglion cell complex 
† Signifi ant differen es  etween B and      Tu e ’s HSD 
‡ Signifi ant differen es  etween A and B    Tu e ’s HSD 
Controls - no diabetes/neuropathy 
 
For a better understanding of the relative effects of these variables, regression 
models were utilized.  
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Effect of the type of diabetes 
Regression was performed in the group with diabetes; NDS was included as a 
continuous variable from 0-10.  
It was observed that neither the interactions nor the main effect of the type of 
diabetes was significantly related to any of the retinal parameters. Although the 
main effect of the type of diabetes at the parafovea was p = 0.056, the 
relationship did not reach statistical significance. Therefore, the regression 
models were terminated at this stage. Table 14 presents the significance values 
of the main effects and the interactions between the type of diabetes and a 
range of variables namely, age, DR, duration of diabetes and NDS. 
 
Table 14. Significance values for the main effects of type of diabetes and interactions with a range of 
factors in the model 
Interactions between variables 
p-values for interactions and main effects at various retinal regions 
Thickness 
within the 
central 
1mm zone 
Thickness 
in the 
parafovea 
Thickness 
in the 
perifovea 
RNFL 
thickness 
GCC 
thickness 
Type of DM and age 0.655 0.180 0.467 0.314 0.511 
Type of DM and NDS 0.510 0.884 0.473 0.608 0.908 
Type of DM and duration of DM 0.330 0.909 0.632 0.905 0.547 
Type of DM and DR 0.222 0.397 0.290 0.635 0.841 
Main effect of the type of DM 0.160 0.056 0.085 0.688 0.165 
DM, diabetes mellitus; NDS, neuropathy disability score; DR, diabetic retinopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experiments 
101 
 
4.2.7 Discussion 
The study sought to explore the relationship between the type of diabetes and 
retinal tissue thickness parameters while adjusting for age, sex, DR, NDS, 
duration of diabetes and HbA1c levels. It was observed that individuals with 
T2DM showed a tendency for lower retinal tissue thickness than those with 
T1DM at the parafovea; however, this did not reach statistical significance, after 
adjusting for the aforementioned factors. Neither the main effect nor the 
interactions of type of diabetes with other variables were significantly related to 
retinal thickness parameters. To date, this is the first study to investigate the 
relationship between retinal tissue thicknesses and the type of diabetes.  
In the current study, analysis of clinical parameters showed that people with 
T2DM were older than T1DM. However, people with T1DM had a more 
prolonged duration of diabetes; this is sensible considering the nature of the 
disease and is also consistent with that reported in a past study (Van Acker et 
al., 2009). Although T1DM had a slightly greater proportion of people with DR 
than those with T2DM, the difference was not statistically significant. In the 
current study, there were differences in certain other clinical parameters and 
neuropathy measures between T1DM and T2DM groups. For instance, T2DM 
had higher NDS, DNS scores and elevated QST vibration thresholds compared to 
T1DM. The study by Van Acker et al (2009) observed the prevalence of 
neuropathy in T2DM to be twice as that observed in people with T1DM. These 
reported and observed differences may demonstrate certain dissimilarity in 
neuropathy measures between the two types of diabetes.  
The unadjusted thickness in the parafovea, perifovea, RNFL and GCC were lower 
in T2DM than T1DM, with a mean difference of 7 µm for the parafovea, 
perifovea, 6 µm for the RNFL and 4 µm for GCC thickness. This finding is broadly 
consistent with that reported by Bronson-Castain et al (2013). The authors 
observed retinal thickness to be reduced in T2DM in comparison to T1DM; 
however, the mean difference was 3 µm.  
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In the current study, T2DM were slightly older than T1DM as well as the control 
group; therefore there is a possibility of confounding due to differences in age. It 
is debatable that any reduction in retinal thickness in T2DM may be attributed 
to difference in age. In the study by Bronson-Castain (2009) that compared 
retinal thickness in T1DM, T2DM and control groups, retinal thickness in 
individuals with T2DM was lower than those with T1DM. However, it is 
interesting to note that all participants were adolescents (mean age = 16years) 
and the groups were age-matched. Therefore, any observation in T2DM cannot 
be argued as being related to older age. The results likely represent true 
differences due to the type of diabetes. The results from their study suggest 
evidence of structural neural degeneration and functional deficits in the retina 
of people with T2DM compared to people with T1DM. The current study 
findings are broadly in agreement with their study.  Although the differences in 
the current study are small but statistically significant, the clinical relevance of 
this difference is still debatable. Nevertheless, results from the literature and 
from the current study demonstrate certain differences in the structural aspects 
of retinal layers between T2DM and T1DM.  
A likely explanation for this relatively greater compromise in type 2 diabetic 
people could be that there may be an initial phase of reversible functional 
compromise due to greater neuro-plasticity and the possibility of reversal of 
changes with good metabolic control, especially in T1DM compared with T2DM. 
Following this, structural changes may become more permanent; this may no 
longer be reversible with metabolic control (Sima et al., 2006). Although the 
theory hypothesized by Sima et al was in relation to diabetic neuropathy in rats, 
the theory may hold true for ocular neural changes in humans. In addition, 
T2DM may remain unrecognized for several years (Goldstein et al., 2013). 
Therefore, it is likely that the retinal degeneration has already occurred and is 
possibly beyond any repair. 
Therefore, a broad understanding is that there are certain pathophysiological 
differences between the two types of diabetes but the type of diabetes did not 
show significant relationship to retinal thickness parameters when adjusted for 
certain key variables.  
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4.2.8 Conclusion 
People with T1DM and T2DM differ in certain clinical, demographic and 
neuropathy characteristics; however, the type of diabetes is not significantly 
related to retinal tissue thicknesses when adjusted for known confounding 
factors in this cohort of people with diabetes aged 40-77 years. Therefore, for 
exploring further research questions, the two groups of diabetes were combined 
to represent one group of people with diabetes.  
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4.3 Retinal tissue thickness and diabetic peripheral neuropathy  
The primary objective of this research program was to explore the relationship 
between retinal tissue thickness and diabetic peripheral neuropathy. The 
following section 4.3 discusses the analysis on the full retinal thickness and the 
inner retinal thickness in relation to diabetic neuropathy defined using NDS 
criteria. 
4.3.1 Purpose 
The purpose of this study was to explore the relationship between retinal tissue 
thickness and diabetic peripheral neuropathy defined using NDS criteria. 
4.3.2 Research question and hypothesis 
Are the full retinal thickness and inner retinal thickness significantly related to the 
severity of diabetic neuropathy, defined using NDS criteria? 
It was hypothesized that the full retinal thickness and the inner retinal thickness 
are significantly related to the severity of diabetic neuropathy defined using 
NDS criteria.   
4.3.3 Methods 
Full retinal thickness and the inner retinal thicknesses were measured with the 
OCT. When stratifying according to NDS criteria of neuropathy, 44 individuals 
were designated as having diabetic neuropathy, 107 individuals had diabetes 
but no neuropathy. There were 42 individuals in the control group. 
The key variables namely age, sex of the individuals, NDS, DR, duration of 
diabetes and HbA1c levels were analysed and compared as were the data for 
various other clinical and demographic variables.  
The full retinal and inner retinal tissue thicknesses were then compared 
between the groups with and without neuropathy and with that of the control 
group. Subsequently, the relationship between severity of diabetic peripheral 
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neuropathy and retinal tissue thickness was explored in the group of individuals 
with diabetes, adjusting for age, sex, DR, duration of diabetes and HbA1c levels. 
4.3.4 Statistical analysis 
The proportion of individuals with DR, proportion of males and females and 
ethnic composition were analysed using chi-square test of independence. The 
normality of the distribution was tested. An analysis of variance test was 
uti ized t      are n r a    distri uted data; a Tu e ’s HSD test was used after 
a significant result in the analysis of variance test. Data are represented as 
mean, standard deviation (SD) and range. There is a possibility of type I error 
due to multiple comparisons; therefore, a Bonferroni post-hoc test has also been 
performed and the significance values are presented in the respective tables to 
aid in the additional interpretation of results. For variables that did not follow a 
normal distribution, the group-differences were analysed using a Kruskal-Wallis 
test; a Mann-Whitney U test was performed after a significant Kruskal-Wallis 
test. These data are represented as median and inter-quartile range.  
The data for the key variables namely age, sex, duration of diabetes, HbA1c 
levels, DR, NDS, are discussed in detail; the results for the other clinical and 
neuropathy measures are presented in tables but are not discussed in detail.  
The relationship between severity of diabetic peripheral neuropathy and the 
retinal tissue thickness was explored in the group of individuals with diabetes, 
using a univariate general linear model, adjusting for age, sex, DR, duration of 
diabetes and HbA1c levels; the full retinal thickness and inner retinal thicknesses 
parameters were entered as the dependent variables in separate regression 
models. The presence or the absence of DR and sex of the individuals were 
coded and entered as factors in the model; age, duration of diabetes, NDS and 
HbA1c levels were entered as covariates. The models were then modified to 
achieve the most parsimonious model.  
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4.3.5 Results 
4.3.5.1 Ethnicity 
The ethnic composition is presented in Table 15. Majority of the participants 
(86%-95%) in the three groups were Caucasians. To assess the relationship 
between ethnicity and neuropathy in the group with diabetes, the individuals 
who were not Caucasians were combined into one group and were compared to 
the group comprising of Caucasians. A chi-square test of independence showed 
that the relationship was not significant, χ2 (1, 151) = 6.043, p = 0.418.   
 
Table 15. Ethnic composition in the groups stratified per NDS criteria and in control group 
 Neuropathy per 
NDS 
n (%) 
No neuropathy 
per NDS 
n (%) 
Controls 
 
n (%) 
Asian (e.g. Indian, Pakistani, Bangladeshi, 
Sri Lankan) 
1 (2.3%) 2 (1.9%) 0% 
Australian Aboriginal or Torres Strait 
Islander  
0% 1 (1%) 0% 
European (e.g. European Australian, 
English, German, Spanish) 
39 (88.6%) 92 (86.0%) 40 (95.2%) 
Middle Eastern (e.g. Iranian, Iraqi, 
Lebanese, Syrian) 
0% 2 (1.9%) 0% 
South East Asian (e.g. Chinese, Japanese, 
Korean, Indonesian, Thai, Malaysian) 
0% 5 (4.6%) 1 (2.4%) 
Other 
 
3 (6.8%) 5 (4.6%) 0% 
Not known 1 (2.3%) 0% 1 (2.4%) 
 
Controls - no diabetes/neuropathy 
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4.3.5.2 Summary of clinical, demographic and neuropathy measures in the 
groups stratified per NDS criteria and in control group 
Key variables 
Tables 16 and 17 provide a summary of the key variables. The magnitude of the 
differences is discussed only for those that are significantly different and their 
p-values are presented in Tables. People with neuropathy were significantly 
older than those without neuropathy and the control group (mean difference of 
4.5 years and 4 years respectively); also the individuals with neuropathy had 6 
years prolonged duration of diabetes than those without neuropathy. The 
proportion of males was similar in the groups with diabetes with and without 
neur  at    χ2 (1, 151) =2.505, p = 0.114. The HbA1c levels were not significantly 
different in the neuropathy group compared to no neuropathy group, but both 
the groups with diabetes had significantly higher levels compared to control 
group (mean difference of 2.6% and 2.3% respectively).  
The NDS was 4.5 units greater in the neuropathy group than the group without 
neuropathy. The proportion of people with DR was higher among individuals 
with neuropathy (61%) than those without neuropathy (34%). A chi-square test 
of independence was performed to determine the relationship between diabetic 
retin  at   and neur  at  . T e re ati ns i  was signifi ant  χ2 (1, 151) = 9.852,   
p = 0.002.  
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Table 16. Summary of key variables in the groups stratified per NDS criteria and in control group 
Variables 
Neuropathy  
per NDS (A) 
Mean ± SD 
n 
Min - Max 
No neuropathy 
per NDS (B) 
Mean ± SD 
n 
Min - Max 
Controls(C)  
 
Mean ± SD 
n 
Min - Max 
ANOVA 
F 
ANOVA 
p-values 
 
Bonferroni 
p-value 
Age 
 
59.9 ± 8.4 
44 
41.0 - 71.6 
55.2 ± 9.4 
107 
40.1 - 77.3 
55.9 ± 9.6 
42 
40.7 - 72.6 
3.94 0.021 ‡ 
A vs. B,  
0.018 
Males, n (%) 30 (68%) 58 (54%) 20 (44%)  0.114 ǁ  
HbA1c (%) 8.0 ± 1.3 
44 
7.7 ± 1.3 
106 
5.4 ± 0.3 
42 64.73 <0.001 § 
A vs. C, 
B vs. C, 
6 - 13 5 - 12 5 - 6 <0.001 
DR, n (%) 27 (61%) 36 (34%)   0.002 ǁ  
DR, diabetic retinopathy (representing those with clinically visible signs of retinopathy) 
‡ Signifi ant differen es  etween neur  at   and n  neur  at   gr u s wit  Tu e ’s HSD 
§ Signifi ant differen es  etween dia eti  and   ntr   gr u  wit  Tu e ’s HSD 
ǁ Significant with chi-square test 
Proportion of males in this table compared between the groups with and without neuropathy;  
Controls - no diabetes/neuropathy 
 
 
Table 17. Duration of diabetes and NDS in the groups stratified per NDS criteria and in control 
group 
Clinical and 
neuropathy 
variables 
  
Neuropathy per 
NDS 
Median 
IQR 
Min - Max 
No Neuropathy 
per NDS 
Median 
IQR 
Min - Max 
Controls 
 
Median 
IQR 
Min - Max 
Kruskal-Wallis 
χ2 df p-values 
Duration of 
diabetes 
(years) 
  
19 13  
 
<0.001 ǁ 
20 18 n/a 
6 - 64 1 - 53  
NDS 
  
4.5 0 0 
116.32 2 <0.001 * 4 1 1 
3 - 10 0 - 2 0 - 2 
NDS, neuropathy disability score 
ǁ Significant differences with Mann-Whitney U test 
* Significant differences between Neuropathy versus the other two groups with Mann-Whitney U test 
Controls - no diabetes/neuropathy 
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Other clinical and neuropathy variables 
Results are presented in Tables 18 and 19.  Differences were observed in other 
clinical variables and neuropathy measures. For instance, the systolic BP was 7 
mmHg higher in people with neuropathy compared to those without 
neuropathy and control group. Diastolic BP was similar in the three groups. The 
BMI in the neuropathy group was 3 kg/m2 higher when compared to no 
neuropathy group and about 4 kg/m2 higher when compared to control group.  
The group without neuropathy had 1.3 kg/m2 higher BMI than the control 
group. The total cholesterol in neuropathy group was similar to no neuropathy 
group but was 1.3 mmol/L less in both groups with diabetes compared to the 
control group, as 52% of individuals in the neuropathy group, 61% in the no 
neuropathy group were on lipid-lowering drugs as compared to only 7% in the 
control group. 
Individuals with neuropathy had a unit higher DNSS; the QST warm sensation 
t res   d was  .8 ˚   ig er     ared t  n  neur  at   gr u  and was  .9 ˚  
higher than the control group. QST warm-induced pain thresholds were 1.  ˚  
 ig er     ared t  n  neur  at   gr u  and a  ut 1.3 ˚   ig er     ared t  
control group; QST cold induced pain was similar in the three groups. QST cold 
sensati n t res   d was redu ed    a  ut  .  ˚  in t e neur  at   gr u  
compared to no neur  at   gr u   and was redu ed     .  ˚      ared t  t e 
control group. QST vibration thresholds were 11.6 Hz higher in the neuropathy 
group compared to no neuropathy group and about 13.4 Hz higher when 
compared to the control group. The number of monofilament points detected 
was one unit less in the neuropathy group than the no neuropathy group as well 
as the control group. The peroneal nerve amplitudes were reduced by 1.8 mV in 
the neuropathy group compared to the other two groups. The peroneal nerve 
conduction velocities were reduced by 5 m/s in the neuropathy group and 
reduced by 7 m/s when compared to the control group.  
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Table 18. Clinical and neuropathy measures in the groups stratified per NDS criteria and in control group 
Clinical variables and 
neuropathy measures 
Neuropathy  
per NDS (A) 
Mean ± SD 
n 
Min - Max 
No neuropathy 
per NDS (B) 
Mean ± SD 
n 
Min - Max 
Controls (C)  
 
Mean ± SD 
n 
Min - Max 
ANOVA 
F 
ANOVA 
p-values  
 
Bonferroni 
p-values 
Total cholesterol (mmol/L) 
4.3 ± 1.1 4.4 ± 0.9 5.6 ± 1.0 25.18 <0.001 * C vs. A,B, <0.001 
44 106 44    
2.6 - 7.4 2.8 - 8.6 4.2 - 9.2    
BP resting systolic (mmHg) 
133 ± 14 
44 
126 ± 15 
107 
126 ± 14 
44 
4.74 
 
0.010 § 
 
A vs. B, 0.011 
101 - 166 87 - 167 102 - 163   C vs. A, 0.04 
BP resting diastolic (mmHg) 
77 ± 8 
44 
76 ± 8 
107 
79 ± 9 
44 
1.28 0.279  
60 - 97 52 - 93 63 - 108    
QST cold sensation threshold 
average (°C) 
21.6 ± 9.5 
44 
26.0 ± 5.9 
107 
28.2 ± 2.7 
44 
11.46 <0.001 § A vs B,C, 0.001 
 
0.0 - 31.1 2.1 - 31.3 19.6 - 33.2    
Peroneal M amp ankle to EDB 
(millivolts) 
2.5 ± 2.0 
44 
4.3 ± 2.5 
106 
4.2 ± 2.5 
44 8.19 <0.001 § 
A vs. B, <0.001 
A vs. C, 0.004 
0.1 - 9.6 0.1 - 14.1 0.1 - 9.2  
Peroneal CV ankle to FH 
(meters/second) 
40.2 ± 6.5 
44 
45.2 ± 5.2 
106 
47.5 ± 7.4 
44 16.60 <0.001 § 
A vs. B, <0.001 
A vs. C, 0.001 
20.0 - 52.5 31.0 - 57.1 20.0 - 59.0  
BP, blood pressure; QST, quantitative sensory testing; amp, amplitude; EDB, Extensor digitorum brevis; CV, conduction velocity; FH, Fossa head  
* Signifi ant differen es  etween   t  dia eti  gr u s  ersus   ntr   gr u  wit  Tu e ’s HSD 
§ Signifi ant differen es  etween neur  at    ersus t e  t er tw  gr u s wit  Tu e ’s HSD 
Controls - no diabetes/neuropathy 
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Table 19. Descriptive statistics for clinical and neuropathy variables in the groups stratified per 
NDS criteria and in control group using non-parametric tests 
Clinical and 
neuropathy 
variables 
  
Neuropathy per 
NDS 
Median 
IQR 
Min - Max 
No Neuropathy 
per NDS 
Median 
IQR 
Min - Max 
Controls 
 
Median 
IQR 
Min - Max 
Kruskal-Wallis test 
χ2 df p-values 
BMI (kg/m2) 
  
31.3 28.2 26.9 23.62 2 <0.001 ǂ 
9.7 5.4 4.3    
21 - 55 19 - 44 19 - 46    
DNSS 
  
1 0 0 31.32 2 <0.001 ǂ 
3 1 0    
0 - 4 0 - 4 0 - 1    
QST warm 
sensation (°C) 
  
43.1 38.3 37.2 22.76 2 <0.001 * 
8.2 5.9 6.5    
32.8 - 50.0 19.4 - 49.2 30.5 - 45.4    
QST warm induced 
pain threshold 
(°C) 
  
50 48.5 48.7 14.53 2 0.001 * 
1.5 3.8 4.0    
45.1 - 50.0 37.3 - 50.0 41.2 - 50.0    
QST cold induced 
pain threshold 
(°C) 
  
2.7 9.7 7.9 4.92 2 0.085 
15.7 18.8 17.9    
00.0 – 24.5 0.0 - 29.3 0.0 - 29.4    
QST vibration 
threshold (Hz) 
  
19.4 7.8 6.0 30.73 2 <0.001 ǂ 
25.2 9.1 7.6    
1.0 - 130.0 1.1 - 51.1 1.2 - 42.2    
Monofilament (no. 
of points detected 
out of 3)  
2 3 3 57.25 2 <0.001 * 
2 0 0    
0 - 3 0 - 3 2 - 3    
BMI, body mass index; DNSS, diabetic neuropathy symptom score; QST, quantitative sensory testing; 
ǂ Significant differences between any two groups with Mann-Whitney U test 
* Significant differences between neuropathy versus the other two groups with Mann-Whitney U test 
Controls - no diabetes/neuropathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experiments 
112 
 
4.3.5.3 Full retinal thickness in the groups stratified by NDS and in the 
control group 
Results are presented in Table 20. The full retinal thickness analysis showed 
that the thickness within the central 1mm zone was not significantly different in 
the neuropathy group compared to the other two groups. The overall thickness, 
the superior and inferior hemisphere thicknesses in the perifovea was 
significantly lower in individuals with neuropathy compared to those without 
neuropathy. The mean difference in thickness was about 7 µm. When compared 
to control group, those in the neuropathy group had significantly lower retinal 
thickness in the parafovea (9-11 µm) and in perifovea (7-8 µm) except the 
inferior perifovea. Figure 26 shows full retinal thickness in the groups stratified 
per NDS criteria and in the control group. 
 
 
 
Table 20. Full retinal thickness in the groups stratified by NDS and in control group 
Full retinal thickness 
(µm) 
Neuropathy 
per NDS       
(A)                   
Mean ± SD 
Min - Max 
No 
neuropathy 
per NDS (B) 
Mean ± SD 
Min - Max 
Controls (C)             
 
 
Mean ± SD 
Min - Max 
ANOVA 
F 
ANOVA 
p-values 
Bonferroni 
p-values 
Thickness within central 
1mm zone (that 
includes fovea) 
246 ± 19 
207 - 286 
245 ± 26 
140 - 293 
254 ± 26 
180 - 313 
2.30 0.102 
 
 
Overall parafovea 
304 ± 14 
271 - 330 
310 ± 17 
259 - 342 
314 ± 14 
277 - 341 
4.54 0.012 † 
A vs. C, 
0.009 
Superior hemisphere 
parafovea 
307 ± 14 
274 - 332 
313 ± 17 
254 - 349 
318 ± 14 
285 - 341 
4.94 0.008 † 
A vs. C, 
0.006 
Inferior hemisphere 
parafovea 
302 ± 14 
262 - 328 
307 ± 17 
246 - 343 
311 ± 14 
269 - 342 
3.67 0.027 † 
A vs. C, 
0.024 
Overall perifovea 
264 ± 13 
233 - 289 
271 ± 15 
201 - 301 
272 ± 13 
236 - 301 
4.12 0.018 †‡ 
A vs. B 
0.024 
Superior hemisphere 
perifovea 
270 ± 15 
234 - 297 
277 ± 15 
228 - 313 
278 ± 13 
242 - 306 
3.74 0.02  †‡ 
A vs. C, 
0.040 
Inferior hemisphere 
perifovea 
258 ± 15 
207 - 285 
265 ± 16 
170 - 302 
265 ± 16 
222 - 312 
3.28 0.0 0 ‡ 
A vs. B 
0.039 
† Signifi ant differen es  etween neur  at   and   ntr   gr u s wit  Tu e ’s HSD 
‡ Signifi ant differen es  etween neur  at   and n  neur  at   gr u s wit  Tu e ’s HSD 
Controls - no diabetes/neuropathy 
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Figure 26. Full retinal thickness in the groups stratified per NDS and in control group for (A) central 1mm zone (B) overall parafovea (C) superior hemisphere parafovea 
(D) inferior hemisphere parafovea (E) overall perifovea (F) superior hemisphere perifovea (G) inferior hemisphere perifovea. Marker indicates mean retinal thickness 
in µm. Error bars are 95% CI. Asterisk represents significant difference   
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Retinal thickness was reduced in the perifovea in individuals with neuropathy 
compared to those without neuropathy. However, about 61% of participants 
with neuropathy had DR; therefore the relative effect of these variables on the 
retinal tissue thickness was explored.  
Relationship between full retinal thickness and NDS, DR status, age, sex, 
duration of diabetes and HbA1c levels in individuals with diabetes 
Regression was performed in the group of individuals with diabetes. In the 
regression models, NDS was included as a continuous variable from 0-10.  
Full retinal thickness and neuropathy by NDS criteria 
The reduced overall and hemisphere thickness in the perifovea was significantly 
related to the severity of neuropathy (ranged from 1.06 µm to 1.58 µm). In the 
inferior perifovea, for every unit increase in NDS score, retinal thickness 
reduced by 1.58 µm and this was not significantly related to age, sex, DR, 
duration of diabetes or the HbA1c levels. Neither the thickness in central zone (p 
≥ 0. 3 ) n r t at in  araf  ea (p ≥ 0.19 ) s  wed an  signifi ant re ati ns i  t  
NDS. Results are presented in Table 21.  
Relationship between full retinal thickness and other variables 
The overall as well as hemisphere retinal thickness in the parafovea reduced by 
7 µm to 8 µm, in the presence of DR; neither the thickness in the perifovea nor 
that in the other regions were significantly related to DR (p ≥ 0.0  ). 
Thickness within the central 1mm zone was about 10 µm greater in males when 
compared to females. The inferior parafovea showed a tendency for greater 
thickness in males than females and it approached statistical significance (p = 
0.051). Other retinal regions did not differ significantly between males and 
females (p ≥ 0.07 ).  
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The thickness within the central 1mm zone, in the overall and the hemisphere 
parafovea and perifovea reduced with increasing age, except the inferior 
perifovea (p = 0.077). 
Neither the duration of diabetes (p ≥ 0.13 ) n r t e H A1c levels (p ≥ 0. 2 ) 
showed any significant relationship to full retinal thickness. Results are 
presented in Table 21. 
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Table 21. Relationship between full retinal thickness and NDS, age, sex, DR, duration of diabetes and HbA1c levels in individuals with diabetes 
adjusted
SE B p-value SE B p-value SE B p-value SE B p-value SE B p-value SE B p-value R
2
Thickness in the central 1mm zone 0.207 -0.529 0.012 3.899 10.222 0.010 0.153 0.158 0.915 3.934 0.230 0.134 1.475 -4.320 0.274 0.885 0.692 0.436 0.068
overall parafovea 0.137 -0.455 0.001 2.575 4.603 0.076 0.102 -0.074 0.940 2.586 0.045 0.660 0.979 -7.554 0.004 0.578 -0.649 0.264 0.100
superior hemisphere parafovea 0.144 -0.463 0.002 2.718 4.060 0.137 0.107 0.212 0.836 2.721 0.034 0.751 1.026 -6.880 0.012 0.609 -0.795 0.194 0.085
inferior hemisphere parafovea 0.139 -0.447 0.002 2.618 5.146 0.051 0.104 -0.360 0.720 2.626 0.056 0.591 1.003 -8.221 0.002 0.589 -0.502 0.395 0.102
overall perifovea 0.132 -0.322 0.016 2.407 0.607 0.801 0.093 0.439 0.624 2.519 0.040 0.669 0.895 -2.142 0.397 0.506 -1.170 0.022 0.086
superior hemisphere perifovea 0.136 -0.458 0.001 2.547 0.663 0.795 0.098 0.416 0.657 1.014 0.035 0.724 0.930 1.014 0.707 0.539 -1.060 0.051 0.083
inferior hemisphere perifovea 0.150 -0.268 0.077 2.728 2.646 0.334 0.107 0.497 0.630 2.864 0.043 0.687 1.031 0.295 0.055 0.555 -1.583 0.005 0.060
NDSage males HbA1c levels duration of diabetes DR
 
DR, diabetic retinopathy; NDS, neuropathy disability score; SE, standard error 
 
The next section discusses the inner retinal layer thickness in relation to neuropathy per NDS criteria. 
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4.3.5.4 Inner retinal thickness in the groups stratified by NDS and in the 
control group 
Results are presented in Table 22. Individuals with neuropathy had significantly 
reduced overall and the hemisphere RNFL thicknesses when compared to those 
without neuropathy when stratified by NDS criteria. The reduction in RNFL 
thickness ranged from 6-8 µm. However, the difference in GCC thickness was 
statistically significant (p = 0.049); however, post-hoc group comparisons did 
not reach statistical significance. Figure 27 shows RNFL and GCC thicknesses in 
the groups stratified per NDS criteria and in control group. 
 
 
Table 22. Inner retinal thickness in the groups stratified by NDS and in control group 
Inner retinal 
thickness (µm) 
Neuropathy per 
NDS  
(A)                    
Mean ± SD 
Min - Max 
No 
neuropathy 
per NDS (B) 
Mean ± SD 
Min - Max 
Controls (C)             
 
 
Mean ± SD 
Min - Max 
ANOVA 
F 
ANOVA 
p-values 
Bonferroni 
p-values 
Overall RNFL  
97 ±  9 104 ± 11 102 ± 11 
6.30 0.002 ‡ 
A vs. B 
71 - 120 75-136 74-132 0.002 
Superior 
hemisphere RNFL 
98  ± 10 104  ± 12 102 ± 13 
3.71 0.02  ‡ 
A vs. B 
75 - 119 76 - 136 66 - 135 0.021 
Inferior 
hemisphere RNFL 
97 ± 9 105 ± 12 102 ± 12 
7.26 0.001 ‡ 
A vs. B 
75 - 119 74 - 137 82 - 136 0.001 
Overall GCC  
93 ± 7 96 ± 8 96 ± 7 
2.63 0.075 
 
77 - 112 71 - 117 76 - 108  
Superior 
hemisphere GCC 
93 ± 7 96 ± 8 95 ± 8 
2.18 0.115 
 
75 - 112 70 - 118 70 - 110  
Inferior 
hemisphere GCC 
93 ± 8 97 ± 8 97 ± 6 
3.06 0.049 * 
 
71 - 112 73 - 118 81 - 108  
‡ Signifi ant differen es  etween neur  at   and n  neur  at   gr u s wit  Tu e ’s HSD 
*  No significant differences with post-hoc analysis  in any group     aris ns wit  Tu e ’s HSD 
       Controls - no diabetes/neuropathy 
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Figure 27. Inner retinal thickness in the groups stratified per NDS criteria and in control group for (A) overall RNFL (B) superior hemisphere RNFL (C) inferior 
hemisphere RNFL (D) overall GCC (E) superior hemisphere GCC (F) inferior hemisphere GCC. Marker indicates mean inner retinal thickness in µm. Error bars are 95% CI. 
Asterisk represents significant difference 
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Relationship between inner retinal thickness and NDS, DR status, age, sex, 
duration of diabetes and HbA1c levels in individuals with diabetes 
In the regression models, NDS was included as a continuous variable from 0-10.  
Inner retinal thickness and neuropathy per NDS  
The overall as well as hemisphere RNFL thickness reduced with NDS or in other 
words, increasing severity of neuropathy, when adjusted for age, sex, DR, 
duration of diabetes and HbA1c levels. For every unit increase in NDS, the RNFL 
thickness decreased by 1.204 µm, 0.851 µm and 1.448 µm in the overall, 
superior hemisphere and inferior hemisphere respectively. GCC thickness was 
not significantly related to neuropathy (p ≥ 0.0  ). 
Relationship between inner retinal thickness and other variables 
The RNFL thickness and GCC thickness reduced with advancing age. Males with 
diabetes had significantly thinner RNFL in the inferior hemisphere than females 
(p = 0.03). Other regions did not show significant differences between males 
and females (p ≥ 0.178).  
Variables namely DR (p ≥ 0.3 7)  durati n  f dia etes (p ≥ 0.210)  H A1c levels 
(p ≥ 0.  2) were n t signifi ant   re ated t   NFL  r t e     t i  nesses. 
Results are presented in Table 23.     
 
 
 
 
 
 
 
 
 
 
Experiments 
120 
 
Table 23. Relationship between inner retinal thickness and NDS, age, sex, DR, duration of diabetes and HbA1c levels in individuals with diabetes 
adjusted
SE B p-value SE B p-value SE B p-value SE B p-value SE B p-value SE B p-value R2
overall RNFL 0.098 -0.325 0.001 1.779 2.406 0.178 0.066 -0.062 0.928 1.982 0.083 0.210 0.679 0.403 0.839 0.375 -1.204 0.002 0.161
superior hemisphere RNFL 0.108 -0.357 0.001 2.011 0.821 0.684 0.073 -0.331 0.652 2.226 0.085 0.242 0.733 0.911 0.683 0.413 -0.851 0.041 0.114
inferior hemisphere RNFL 0.106 -0.293 0.006 1.916 -4.203 0.030 0.071 0.284 0.694 1.965 0.078 0.275 0.721 -0.238 0.912 0.405 -1.448 <0.001 0.186
overall GCC 0.070 -0.271 <0.001 1.352 0.055 0.967 0.052 0.124 0.803 1.394 0.010 0.856 0.496 -1.156 0.408 0.280 -0.520 0.065 0.085
superior hemisphere GCC 0.070 -0.293 <0.001 1.333 -0.039 0.977 0.052 0.088 0.860 1.388 0.032 0.541 0.500 -0.965 0.488 0.278 -0.501 0.074 0.100
inferior hemisphere GCC 0.075 -0.250 0.001 1.444 -0.200 0.890 0.055 0.170 0.747 1.484 -0.007 0.906 0.527 -1.343 0.367 0.298 -0.539 0.073 0.064
NDSage males HbA1c levels duration of diabetes DR
 
RNFL, retinal nerve fibre layer; GCC, ganglion cell complex; DM, diabetes mellitus; DR, diabetic retinopathy; NDS, neuropathy disability score; SE, standard error  
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4.3.6 Discussion 
Full retinal thickness 
This research project examined for the relationship between diabetic 
neuropathy and retinal tissue thickness. The main finding was that the retinal 
thickness in the perifovea or in other words, the outer macula, reduced in 
relation to NDS scores or severity of neuropathy.  
The increasing severity of neuropathy was associated with reduced thickness in 
the perifovea but not in the parafovea. Diabetic peripheral neuropathy involves 
distal nerves first and then progresses to involve proximal nerves (e.g. in the 
legs) (Brown et al., 1980). With reference to the central zone, perifovea is distal 
or peripheral whereas parafovea is relatively proximal, indicating distal or more 
peripheral regions of retina affected. This appears similar to diabetic peripheral 
neuropathy, wherein, the distal nerves are affected first and then the proximal 
nerves are involved in later stages.  
Another likely explanation could be that the findings in perifovea may represent 
changes in the outer retinal layers as the perifovea mostly comprises of RPE and 
photoreceptors (Sernagor et al., 2001). Since neuropathy predominantly 
involves damage to the sensory receptors in the distal leg, changes in the 
perifovea may represent involvement of photoreceptors in the retina in relation 
to neuropathy. However, this supposition necessitates further investigation.  
The thickness in the perifovea was reduced with increasing severity of 
neuropathy and advancing age while that in the inferior perifovea was reduced 
with severity of neuropathy only. Another study reported significantly reduced 
multifocal visually evoked potential (mfVEP) amplitudes in the lower nasal 
retinal quadrant in people with neuropathy when compared to people without 
neuropathy (Lövestam-Adrian et al., 2012). A relatively common observation is 
that the inferior retinal region appears to be specifically compromised in 
relation to diabetic neuropathy. A likely explanation for this disturbance to the 
inferior retinal region could be the lower blood flow per nerve fibre tissue 
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volume in the normal human retina in the inferior region (Harris et al., 2003) 
and may be more prone to ischaemic insults; this effect may be exaggerated in 
diabetes. 
To date, this is the first study to examine the relationship between diabetic 
peripheral neuropathy and full retinal thickness; the reduced thickness in the 
perifovea was related to the severity of neuropathy. The magnitude of this 
difference in retinal thickness may appear smaller (1.06 -1.58 µm); however, 
this observed effect is after adjusting for potential confounding factors namely 
age, sex, DR, HbA1c levels and duration of diabetes. A likely explanation for the 
apparently small effect may be that 62% of individuals had mild neuropathy 
(NDS 3-5), 30% of individuals had moderate neuropathy (NDS 6-8) and only 
about 8% with severe neuropathy (NDS 9-10) based on the neuropathy severity 
grading proposed by Young et al (1993). Another explanation for the apparently 
small effect could be that the results demonstrate an association that is between 
local responses in the retina and neuropathy changes in the distal leg. 
Interestingly, after stratifying groups based on NDS criteria, retinal thickness 
was reduced by 7 µm; this resembles an age-related change of 25-40 years. In 
addition, in individuals without diabetes, retinal thickness decreased by 0.26-
0.46 µm, according to Ericksson et al (2009) and by 0.53 µm, according to 
Alamouti et al (2003) for a year increase in age. In the current study, with 
regression analysis, this reduction or compromise in relation to neuropathy was 
1.2 µm (1.06-1.58 µm), which is 5-7 times higher when compared to these 
reported age-related changes. Although the absolute effect of neuropathy on 
retinal thickness may appear small, it essentially reflects a physiologically 
relevant change. 
Diabetic retinopathy is a frequently reported factor associated with altered 
retinal tissue thickness. In the current study, thickness in the parafovea was 
reduced in the presence of DR.  Previous studies reported differing results. For 
instance, individuals with any stage of DR had greater retinal thickness (Goebel, 
et al., 2002) and a thicker central 2x2 mm2 area compared to those without 
diabetes (Oshima, et al., 1999); 30% of eyes with NPDR had greater thickness 
compared to those without diabetes in at least two ETDRS zones (Massin et al., 
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2002). A trend of increase in macular thickness with increasing severity of DR 
has also been observed with a vertical scan through the fovea (Cho et al., 2010) 
thicker macula (Lattanzio, et al., 2002; Park, et al., 2011). Few other studies 
observed similar thicknesses in the groups without DR (Massin et al., 2002) and 
with DR (Bressler et al., 2008; Cho, et al., 2010) when compared to those 
without diabetes. In contrast, few other studies observed reduced thickness in 
the parafovea in individuals with no DR (Nilsson, et al., 2007) and reduced 
overall macular thickness (Oshitari, et al., 2009) in comparison to those without 
diabetes.  The above studies differed in terms of their study objectives, scan 
protocols, the age group examined, differences in male-female composition and 
showed disparity in the consideration of factors such as the duration of diabetes 
and HbA1c levels. Also the neuropathy status of the participants was not taken 
into account. The current research program has utilized regression models and 
has accounted for the key variables namely age, sex, DR, duration of diabetes 
and HbA1c levels and neuropathy defined by NDS.  
In the current study, there were 63 (42%) individuals with DR and 88 (58%) 
individuals with diabetes but no DR. Amongst those with DR, the majority 
(88%) of individuals had very mild NPDR or mild NPDR and very few 
individuals with more advanced stages of DR. However, investigating retinal 
tissue thickness in varying severity of DR was not the primary focus of this 
research program. For this reason, the individuals with DR were grouped as one 
and presence of DR rather than the severity of DR were accounted for in the 
statistical models. It is relevant to note that diabetic retinopathy here 
represents only the clinically visible signs of retinopathy. There may be sub-
clinical or subtle retinopathy changes that are not clinically visible. The 
possibility of subtle retinopathy changes being related to any of the outcomes 
could not be ruled out and therefore requires caution when interpreting the 
results. 
Findings from the current study show that retinal thickness decreased with 
advancing age; an exception to this being the inferior perifovea which was 
significantly related to the severity of neuropathy but not with age. Previous 
studies reported reduction in retinal thickness with advancing age in 
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individuals without diabetes (Alamouti et al., 2003, Fraser-Bell et al., 2005, 
Eriksson et al., 2009). In contrast, studies conducted on individuals with 
diabetes observed increase in central thickness with age in people with diabetes 
with or without DR (Sánchez-Tocino et al., 2002, Fritsche et al., 2002). However, 
the individuals with diabetes were much older than the group without diabetes, 
with a difference as high as 29 years in the study by Fritsche and his group; 
therefore, the possibility of confounding due to age could not be ruled out. In 
addition, diabetic neuropathy was not taken into account. The current study 
adjusted for age, neuropathy status and other potential confounders. 
The thickness in the central zone was greater in males with diabetes than 
females with diabetes, when adjusted for age, DR, HbA1c levels and duration of 
diabetes. Previous studies observed greater thickness in the central zone and 
higher total macular volume in males with diabetes than females (Browning et 
al., 2008). Another study observed that the males in the diabetic group who did 
n t s  w   ini a  signs  f D   ad 12 μ  t i  er retina t an t e fe a es (Os itari 
et al., 2009); a between-gender differen e  f 1  μ  was   ser ed in individuals 
without diabetes. 
Although it is likely that the retinal thickness may be compromised in relation to 
prolonged duration of diabetes, glycaemic level is an important but also a 
modifiable risk factor. A previous study observed that the thickness in the 
macular region was inversely correlated to HbA1c levels (Moon et al., 2011). 
Other studies observed reduced visual function demonstrated by delayed P100 
latency of visual evoked potentials (Tobimatsu et al., 1991) in young people 
with diabetes without DR, which normalized following optimal metabolic 
control (Verrotti et al., 2000). In the current study, HbA1c levels were not 
significantly related to full retinal thickness when adjusted for duration of 
diabetes and other factors. This is consistent with a study by Asefzadeh et al 
(2008) who observed no significant relationship between retinal thickness and 
HbA1c levels. Although, Moon et al observed that the thickness in the macular 
region to be influenced by HbA1c levels, the relationship was assessed using 
correlations. The current research program used regression models to adjust 
for potential confounding variables. The lack of significant relationship to HbA1c 
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levels may be explained by the following; higher glycaemic levels have been 
reported to be related to development and progression of neuropathy (Tesfaye 
et al, 1996) and retinopathy (Diabetes Control and Complications Trial, 1995); 
however, a strict (more than 2% reduction) and an acute or rapid reduction in 
HbA1c levels were associated with worsening of DR (Funatsu et al., 1992) (Davis, 
1998); also after a 4 month-strict metabolic control, the RNFL thickness reduced 
further compared to baseline values (Sugimoto et al., 2010). The findings 
reported in previous studies and that from this study may indicate (i) a non-
linear relationship in retinal changes in response to alterations in HbA1c levels 
(ii) the extent or the percentage of reduction in glycaemic levels is equally 
important, in addition to the absolute values of HbA1c levels. The current study 
was cross-sectional; therefore, the previous HbA1c levels were not recorded.  
Inner retinal thickness  
The RNFL thickness was reduced in individuals with neuropathy compared to 
those without neuropathy; the reduced thickness was related to diabetic 
peripheral neuropathy when adjusted for DR status, sex, duration of diabetes 
and HbA1c levels. The difference in GCC thicknesses did not reach statistical 
significance. To date, this is the first study to investigate the relationship 
between macular inner retinal thickness (GCC) and neuropathy in a group of 
individuals with diabetes.  
The individuals with diabetic neuropathy were significantly older (mean = 4.5 
years) than individuals without neuropathy; the unadjusted group difference in 
RNFL thickness ranged from 8 to 9 µm. Given that the RNFL thickness decreases 
by 2 µm for a decade increase in age (Bundez et al., 2007), the difference noted 
in the current study was 8-9 µm for a 4.5 years difference in age; this decrease 
in thickness is greater than that expected due to age alone. Another way of 
looking at this is that people with neuropathy have neural changes that are 
similar to that seen in an individual 40-45 years older.  
In the current study, GCC thickness did not show significant relationship to 
neuropathy. The retinal nerve fibre layer thickness reduced with increasing 
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severity of neuropathy by 0.86 µm to 1.23 µm. Other variables such as HbA1c 
levels, duration of diabetes and retinopathy failed to explain the findings. The 
previous pilot study (Shahidi et al., 2012) that investigated the RNFL thickness 
in relationship to diabetic neuropathy observed inferior RNFL thickness to 
reduce by 1.5 µm for a unit increase in NDS in a group of individuals with type 2 
diabetes, when adjusted for age, duration of diabetes and retinopathy. The RNFL 
findings from the current study are not surprising, as the pilot study by Shahidi 
et al (2012) was expanded further. The current project took a comprehensive 
approach and examined the full retinal thickness, macular and the peripapillary 
nerve fibre layer thicknesses, in relation to diabetic peripheral neuropathy, in a 
higher sample size.  
Another interesting finding is that DR did not influence the RNFL or GCC 
thickness when neuropathy and other factors were taken into account. This is 
again in agreement with that reported by Lövestam-Adrian et al (2012) who 
also found retinal anatomical and functional changes in relation to neuropathy 
but not with DR. Degeneration of ganglion cell layers and inner plexiform layer 
and thinning of RNFL was a common observation in both, the presence (Wolter, 
1961, Bloodworth, 1962, Takahashi et al., 2006, Oshitari et al., 2009, van Dijk et 
al., 2009, van Dijk et al., 2010) and the absence of clinical signs of DR (Sugimoto 
et al., 2005, Peng et al., 2011, Verma et al., 2012,). In those studies, neuropathy 
may have been a contributing factor to the compromised neural layer 
thicknesses. In the current study, the GCC as well as the RNFL thickness, 
reduced with advancing age. This finding is consistent with that reported in 
previous studies (Bundez et al., 2007, Koh et al., 2012).   
In the current study, it was observed that the inferior RNFL thickness is about 4 
µm thinner in males in the group with diabetes compared to females when 
adjusted for other factors. Males with diabetes had a thicker inferior parafovea 
and a thinner inferior hemisphere RNFL. In contrast, in individuals without 
diabetes, Koh et al (2012) observed the ganglion cell complex-inner plexiform 
layer thickness to be thinner in females compared to males. In the current 
research program, the data did not appear to be influenced by any outliers. For 
that matter, this observation is also true for the control group, where in, males 
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showed a tendency for reduced RNFL thickness compared to females. Literature 
reports that there is a male preponderance in diabetic retinopathy (Bodansky et 
al., 1982; Zhang et al., 2010) and diabetic neuropathy (Booya et al., 2005). 
Therefore, the gender difference in the current study could be related to 
retinopathy or neuropathy. However, retinopathy did not show significant 
relationship to RNFL or the GCC thickness. Therefore, this gender difference in 
RNFL is less likely to be related to retinopathy. Interestingly, the RNFL thickness 
was significantly reduced in neuropathy. In addition, it is noteworthy that the 
proportion of males with neuropathy was higher (68%) compared to those 
without neuropathy (54%) though not statistically significantly (p =0.114). 
Therefore, this gender differences in RNFL may be linked to neuropathy. These 
findings demonstrate differences between males and females with respect to 
retinal region examined. However, this observation will require further 
exploration. 
In the current study, neither the retinal nerve fibre layer nor the GCC thickness 
showed any significant relationship to duration of diabetes or the HbA1c levels 
when including NDS, DR status, age and sex of the individuals into the models. A 
previous study observed a higher proportion of people with neuropathy among 
those with longer duration of diabetes (Tesfaye et al., 1996).  Interestingly, 
treatment of chronic hyperglycaemia was associated with improvement in 
neuronal function thus indicating a strong association with HbA1c levels 
(Boulton, 1982) and also the potential for neuropathy status to improve with 
intervention. Because of the cross-sectional design of the current study, 
previous HbA1c levels were not monitored. However, when including these 
factors into the statistical models, thickness differences in inner retinal layers 
was significantly related to peripheral neuropathy rather than the HbA1c levels 
or the duration of diabetes.  
Lack of significant relationship between neuropathy and GCC thickness may 
indicate the following (i) as the axons (representing the RNFL) from all over the 
retina converge at the optic nerve head, the changes happening in the axons of 
the retinal nerves (RNFL) may be more easily detectable around the optic nerve 
head as it purportedly represents a global measure of the RNFL thickness  (ii) 
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loss in the nerve cell bodies (ganglion cells) outside the 7 mm x 7 mm zone, if 
any, may have been missed by GCC protocol. This supposition is further 
strengthened by the observation that the relationship with GCC thickness was 
close but did not reach statistical significance. 
4.3.7 Conclusion 
Severity of neuropathy is associated with reduced thickness in the perifovea or 
the outer macula and the peripapillary nerve fibre layer. Retinopathy is 
associated with compromised thickness in the parafovea (inner macula). It 
appears that neuropathy and retinopathy involve different retinal regions.  
The inner retinal thickness was reduced in relation to diabetic peripheral 
neuropathy but did not show significant relationship to retinopathy, thus 
demonstrating that the neuroretinal degeneration in diabetes is significantly 
related to peripheral neuropathy rather than retinopathy. However, these are 
preliminary findings only and require further investigation.  
While the inner retinal layers comprise of neural elements that play a vital role 
in vision, a reduction in retinal layer thicknesses have important implications 
for a potential compromise in visual function. Future studies are indicated to 
examine the retinal tissue thickness and assess the visual function in people 
with neuropathy and also to investigate in individuals with mild versus more 
severe degrees of neuropathy. This will provide a better understanding of the 
associated visual implications for individuals with diabetic peripheral 
neuropathy. 
 
 
 
 
Experiments 
129 
 
Chapter 5: Pattern-based ganglion cell 
complex parameters in relation to diabetic 
neuropathy 
5.1 Background 
Results thus far from the current project demonstrate compromised full retinal 
thickness, RNFL thickness in relation to diabetic peripheral neuropathy. The 
GCC thickness showed a tendency to be reduced however this relationship did 
not reach statistical significance.  
It is interesting to note that in addition to the GCC thickness profile, there is also 
a pattern to this GCC loss. Previous studies in glaucoma (Tan et al., 2009) and 
macular degeneration (Garas et al., 2012) models have observed that this 
pattern-based GCC loss, namely focal and global loss in GCC volume, can detect 
more abnormalities than the GCC thickness profile. This provides a good 
platform to investigate for this loss in relation to diabetic peripheral 
neuropathy. Therefore, this part of the study investigated the pattern-based GCC 
parameters, namely the focal and global loss in GCC volume, in relation to 
diabetic peripheral neuropathy. It was expected that this part of the analysis 
will contribute to new knowledge regarding structural integrity of the inner 
retina at the macular area in relation to diabetic neuropathy.  
With the use of OCT, one can reportedly detect focal loss in ganglion cell volume 
(FLV) and global loss in ganglion cell volume (GLV) derived in comparison to 
population norms. The following section presents an overview of the calculation 
of FLV and GLV parameters. 
Calculation of GLV and FLV 
The ganglion cell complex thickness represents thickness from the inner 
plexiform layer to the nerve fibre layer, centred at the macula. Figure 28 shows 
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(A) the thickness map (B) the deviation map and (C) the significance map for a 
participant.  
 
Figure 28. Ganglion cell complex maps (A) the GCC thickness map (B) the GCC deviation map (C) the 
GCC significance map. The FLV and GLV are quantitative parameters estimated from these maps.  
 
The thickness map in Figure 28A displays thickness values at each pixel. 
Warmer colours represent thicker regions while cooler colours represent 
thinner regions. A deviation map, on the other hand, is derived by comparing 
each pixel with that of age-matched map from that of the general population. On 
a deviation map, cooler colours represent the thinner regions relative to the 
general population. The scale on the right side of the deviation map in Figure 28 
B shows pixels below 0; this represents thickness that is relatively lower in 
comparison to that of age-matched map from general population. From these 
maps, the GLV and FLV are calculated.  
 
The GLV indicates global loss in GCC volume over the entire GCC map. The 
percentage decrease in thickness at each pixel in comparison to the normative 
database is displayed on a map called the fractional deviation map. The pixels 
with values below 0 on this fractional deviation map are summed up and 
divided by the entire GCC area to provide the GLV. 
 
The FLV indicates focal loss in GCC volume over the entire GCC map. The 
thickness value at each pixel is compared to that of population norm to give a 
pattern map. This map for the participant is then compared with the average 
pattern map from the age-matched database. The difference between the two 
maps is the pattern deviation map, which is assigned significance values for the 
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de iati n. T e  i e   a ues  ess t an ‘0’ in t e fra ti na  de iati n  a  are 
summed along with those from the pattern deviation map that have loss at < 5% 
level and divided by the total area, to provide the FLV.   
 
Figure 29 shows GCC FLV and GLV parameters for another participant and the 
signifi an e  f t is   ss f agged. ‘N  signifi ant   ss’ w ere   ints  r regi ns are 
equal to or above 5% of the general population are represented by green. The 
measured value for the FLV or the GLV if outside the normal range, is 
 ig  ig ted in  e   w  r red. ‘B rder ine   ss’  f r instan e  is indi ated if t e 
measured value is below the 5% level when compared to that of the normative 
database, and the point or region is represented in yellow. Significance at < 5% 
indicates that one in 20 individuals in the general population will most likely 
exhibit this value or less. If the measured value is below the 1% level when 
compared to that of the general population, the point or region is represented in 
red indi ating ‘ utside n r a    ss’. Signifi an e at < 1% indi ates t at  ne in 
100 individuals in the general population will most likely exhibit this value or 
less.  
 
 
 
Figure 29. Significance map of another participant with greater abnormality. Significance of this 
loss is flagged. The FLV represented in green indicates ‘not a significant loss’ or probability > 5%; 
the GLV flagged in red indicates a significant loss at probability < 1%. This participant has ‘within 
normal’ FLV and an ‘outside normal’ GLV. 
 
In a previous study, the frequency of borderline and outside normal loss in GCC 
FLV and GLV has been assessed in eyes with subfoveal choroidal 
neovascularisation in comparison to that of non-diseased eyes (Garas et al., 
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2012). A greater proportion of eyes with subfoveal choroidal neovascularisation 
had significant focal loss in GCC volume than the non-diseased eyes. This 
provides a good platform to investigate this loss in relation to diabetic 
neuropathy. Therefore, this study sought to explore the focal and global loss in 
GCC volume, and the proportion of individuals with significant focal and global 
ganglion cell loss and the factors explaining this loss.  
5.2 Purpose 
The purpose of this study was to examine the focal and global loss in GCC 
volume in individuals with and without neuropathy, and also to compare with 
that of individuals without diabetes and without neuropathy (control group). 
The study also examined the proportion of individuals with significant focal and 
global loss in ganglion cell volume relative to population norms and the factors 
explaining the loss. 
Research question 
Are the focal and global losses in GCC volume significantly related to diabetic 
peripheral neuropathy? 
5.3 Methods  
The focal (FLV) and global (GLV) loss in GCC volume was examined in 
individuals with and without neuropathy defined by NDS criteria and in the 
control group. The FLV and GLV values are expressed in percentages. The 
proportion of individuals with borderline or outside normal limits loss in FLV 
and GLV was determined and compared to that of the control group. The 
outcome is represented as percentage. 
The relationship between the loss in GCC volume and diabetic neuropathy was 
then examined in the group of individuals with diabetes, taking into account, the 
presence of retinopathy, age, sex of the individuals, duration of diabetes and 
HbA1c levels.    
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5.4 Statistical analysis 
The FLV and GLV did not follow a normal distribution. Therefore, the group 
differences in FLV and GLV were assessed using a Kruskal-Wallis test; a Mann-
Whitney U test was performed for those with significant results on Kruskal-
Wallis test. To determine if loss in GCC volume is related to neuropathy, a binary 
logistic regression was performed in the group of individuals with diabetes. 
Indi idua s wit  signifi ant f  a    ss in        u e were   ded as ‘1’ and t  se 
wit  ‘n t a signifi ant   ss’ were   ded as ‘0’ and were entered as de endent 
variable in the regression. Variables namely age, HbA1c levels, duration of 
diabetes and NDS were entered as continuous variables; sex of the individuals 
and the presence of retinopathy were coded and entered as categorical 
variables. The models were then modified to obtain the most parsimonious 
model. The same procedure was followed for significant global loss in GCC 
volume. 
5.5 Results 
Table 24 presents the summary statistics and the group differences in FLV and 
GLV. Individuals with neuropathy had higher focal loss in GCC volume compared 
to those without neuropathy (p = 0.008), as well as when compared to that of 
the control group (p < 0.001); individuals in the no neuropathy group had 
higher FLV when compared to those in the control group (p = 0.044).  
With regards to the GLV, individuals with neuropathy had higher global loss in 
GCC volume when compared to those without neuropathy (p = 0.033), as well as 
with that of the control group (p = 0.008); however, the GLV in the no 
neuropathy group did not differ significantly when compared to that of the 
control group   (p = 0.406).  
 
 
 
 
 
 
 
Experiments 
134 
 
Table 24. Comparison of FLV and GLV in the neuropathy, no neuropathy and control groups 
  
  
  
  
Neuropathy 
 
Median 
IQR 
Min - Max 
No neuropathy 
 
Median 
IQR 
Min - Max 
No diabetes/ 
neuropathy(Controls) 
Median 
IQR 
Min - Max 
Kruskal-Wallis 
χ2 
  
df 
  
p-value 
 
GCC FLV 
(%) 
  
  
0.97 0.41 0.24 15.57 2  < 0.001 § 
2.99 1.43 0.67       
0.00 - 6.18 0.00 - 5.78 0.00 – 3.87       
GCC GLV 
(%) 
  
  
5.38 3.36 2.44 7.23 2 0.027 ‡ 
7.99 6.11 6.25       
0.02 – 21.48 0.00– 24.20 0.02 – 14.19       
§ Significant difference between any two groups with Mann-Whitney U test 
‡ Significant difference between neuropathy versus no neuropathy as well as the control group with Mann-
Whitney U test 
 
Focal loss in GCC volume 
Table 25 shows the proportion of individuals with borderline and outside 
normal FLV loss when stratified according to neuropathy status as well as in the 
control group.  
 
Table 25. Proportion of individuals with borderline or outside normal FLV loss stratified according 
to neuropathy status and in the control group 
Number of participants with FLV 
significant loss at: 
Neuropathy No neuropathy Controls 
Borderline loss in FLV 1 (2.3%) 6 (5.7%) 0 
Outside normal loss in FLV 10 (23.3%) 5 (4.8%) 2 (5%) 
Total no. with ‘significant FLV loss’ 11 (25.6%) 11 (10.5%) 2 (5%) 
 
About 25.6% of those with neuropathy, 10.5% of those with no neuropathy and 
5% in the control group had significant focal loss in GCC volume. Figure 30 
illustrates the proportion of individuals with FLV loss in the groups when 
stratified according to NDS criteria of neuropathy as well as in the control 
group. A chi-square test  f inde enden e was signifi ant  χ2 (2, 188) = 9.002,           
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p = 0.011, and the proportion of people with the FLV loss was significantly 
higher in the neuropathy group than the other two groups.  
 
The proportion in the control group is as expected when compared to the 
population norms. On the other hand, the group with diabetes show greater 
proportion of individuals with loss in comparison to population norms. 
Therefore, to determine the variable(s) explaining this loss, a regression 
analysis was performed only in the group with diabetes. 
 
 
Figure 30. Proportion of individuals with FLV loss when stratified according to neuropathy status 
and in the control group. The series in blue represent those with ‘significant FLV loss’ (probability   
< 5% or < 1%) 
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The relationship between significant focal loss in GCC volume and NDS, DR, 
age, sex, duration of diabetes and HbA1c levels, in individuals with diabetes 
 
Variables entered in the model are presented in Table 26. NDS was entered as a 
continuous variable from 0-10. Diabetic retinopathy was entered as presence or 
the absence of DR. This model was then modified to obtain the most 
parsimonious model. The final model is presented in Table 27. With every unit 
increase in NDS, the odds of having a significant focal loss in GCC volume 
increased by a multiplicative factor of 1.249, 95% CI [1.063, 1.468]; this loss is 
not significantly related to DR status, age, sex, duration of diabetes or the HbA1c 
levels.  
 
Table 26. Variables entered in logistic regression. Presence or the absence of significant focal loss 
in GCC volume was entered as dependent variable 
  B (SE) Wald df p-value Odds ratio 
Constant -0.665 (2.320)     
NDS 0.127 (0.096) 1.735 1 0.188 1.135 
Age 0.004 (0.030) 0.017 1 0.895 1.004 
Males -0.255 (0.496) 0.436 1 0.509 1.410 
Retinopathy 1.443 (0.570) 5.213 1 0.022 0.236 
HbA1c -0.112 (0.192) 0.342 1 0.559 0.894 
Duration of diabetes -0.013 (0.022) 0.369 1 0.544 0.987 
        SE, standard error; NDS, neuropathy disability score 
 
Table 27. Final regression model showing that significant focal loss in GCC volume is related to NDS, 
when adjusted for presence of DR, age, sex, duration of diabetes and HbA1c levels 
 B (SE) Wald df p-value Exp(B) 
95% CI for Exp(B) 
Lower Upper 
Constant -2.277 (0.338)       
NDS 0.222 (0.082) 7.280 1 0.007 1.249 1.063 1.468 
SE, standard error; NDS, neuropathy disability score 
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Global loss in GCC volume 
Table 28 shows the proportion of individuals with borderline and outside 
normal GLV loss when stratified according to neuropathy status and in the 
control group.  
 
Table 28. Proportion of individuals with borderline and outside normal GLV loss stratified 
according to neuropathy status and in the control group 
Number of participants classified to 
have significant GLV loss at: 
Neuropathy No neuropathy Controls 
Borderline loss in GLV 3 (7%) 2 (1.9%) 0 
Outside normal loss in GLV 3 (7%) 8 (7.6%) 1 (2.5%) 
Total no. with ‘significant GLV loss’ 6 (14%) 10 (9.5%) 1 (2.5%) 
 
 
For the GLV, 14% of individuals with neuropathy, 9.5% of those with no 
neuropathy and 2.5% of those in the control group had significant GLV loss. 
Figure 31 illustrates the proportion of individuals with GLV loss in the three 
groups. The chi-square test  f inde enden e was n t signifi ant  χ2 (2, 188) = 
3.372, p = 0.185. In the control group, the proportion of individuals with this 
significant loss is as expected when compared to the population norms. On the 
other hand, those in the group with diabetes show greater proportion of 
individuals with loss when compared to population norms. Although, the 
analysis of this loss indicated no statistically significant differences when 
stratified according to NDS, this loss may be related to other variable(s). 
Therefore, to determine the variable(s) that may explain this loss, a regression 
analysis was performed in the group with diabetes. 
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Figure 31. Proportion of individuals with GLV loss when stratified according to neuropathy status 
and in the control group. The series in blue represent those with ‘significant GLV loss’ (probability   
< 5% or < 1%) 
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The relationship between significant global loss in GCC volume and NDS, 
DR, age, sex, duration of diabetes and HbA1c levels, in individuals with 
diabetes 
 
The variables entered in the model are presented in Table 29. NDS was entered 
as a continuous variable from 0-10. This model was then modified to obtain the 
most parsimonious model. The final model is presented in Table 30. With every 
year increase in age, the odds of having a significant global loss in GCC volume 
increased by a multiplicative factor of 1.077, 95% CI [1.009, 1.149]; this loss 
was not significantly related to the severity of neuropathy, DR status, sex, 
duration of diabetes or the HbA1c levels.  
 
Table 29. Variables entered in logistic regression. Presence or the absence of significant global loss 
in GCC volume was entered as dependent variable 
 
   B (SE) Wald df p-value Odds ratio 
Constant -5.785 (2.983) 3.76 1 0.053 0.003 
NDS 0.083 (0.116) 0.506 1 0.477 1.086 
Age 0.082 (0.039) 4.41 1 0.036 1.086 
Males -0.578 (0.612) 0.891 1 0.345 1.782 
Retinopathy 0.683 (0.711) 0.923 1 0.337 0.505 
HbA1c -0.211 (0.236) 0.797 1 0.372 0.81 
Duration of diabetes 0.012 (0.023) 0.28 1 0.597 1.012 
SE, standard error; NDS, neuropathy disability score 
 
 
Table 30. Final regression model showing that significant global loss in GCC volume is related to 
advancing age, when adjusted for NDS, presence of DR, sex, duration of diabetes and HbA1c levels 
 B (SE) Wald df p-value Exp(B) 
95% CI for Exp(B) 
Lower Upper 
Constant -6.448 (2.040)       
Age 0.074 (0.033) 4.932 1 0.026 1.077 1.009 1.149 
SE, standard error;  
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5.6 Discussion 
This part of the study sought to explore the research question, if the focal loss 
(FLV) and global loss (GLV) in GCC volume is significantly related to diabetic 
peripheral neuropathy. Results from this research project demonstrate pockets 
of ganglion cell loss in individuals with diabetes that was related to the severity 
of neuropathy; individuals with diabetes also had generalized ganglion cell loss 
that was related to advancing age. It is interesting to note that these results 
were not significantly related to diabetic retinopathy or other factors such as 
duration of diabetes, HbA1c levels or sex of the individuals. Diabetic retinopathy 
did not show significant relationship to this loss, thus supporting the 
proposition that the previously reported visual field compromise (Stavrou et al., 
2005; Kern et al., 2008; Parravano et al., 2008) may be related to neural 
pathology elsewhere in the body in diabetes.  
The odds ratio for both FLV and GLV indicate that there is an association, 
although the lower limit of confidence interval may be argued as being just over 
1. However, the findings do suggest an association between focal GCC loss and 
diabetic neuropathy, as well as that between global GCC loss and age, 
independent of DR. 
To recall, the ganglion cell complex comprises of inner plexiform layer, ganglion 
cell layer and nerve fibre layer. The inner retina is also occupied by other cells 
such as astroglial cells, amacrine cells, horizontal and bipolar cells (Zeimer et al., 
1998). Therefore, loss in ganglion cell complex in the macular area may not be 
specific only to ganglion cells but can reflect loss in the above mentioned cells. 
The conventional GCC thickness profile examined in earlier experiment did not 
show statistically significant relationship with diabetic peripheral neuropathy. 
Interestingly, there is significantly greater focal loss in GCC volume in relation to 
the severity of neuropathy. These findings are similar to that reported in 
previous studies wherein, pattern-based GCC parameters detected more 
abnormalities than the GCC thickness profile in glaucoma (Tan et al., 2009) and 
macular degeneration models (Garas et al., 2012).  
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Functional significance of loss in GCC volume 
The scanned GCC area topographically corresponds to a 24-2 visual field plot of 
a Humphrey perimetry program. Figure 32 shows a Humphrey SITA Standard 
24-2 visual field plot. The region within the dotted line topographically 
corresponds to a GCC scan area, e tending 10˚ su eri r    inferi r   and nasa    
and 1 ˚ te   ra   .  
 
 
Figure 32. A visual field plot of a Humphrey 24-2 SITA standard program, adapted from Tan et al., 
2009. Area inside the dotted line represents topographical correspondence with GCC area.  
 
Therefore, loss of ganglion cells in the macular area may represent a significant 
threat to central visual field. Therefore, these findings warrant examination of 
central visual field. 
To date, this is the first study to demonstrate pockets of inner retinal volume 
loss in relation to the severity of diabetic peripheral neuropathy; however, it is 
believed that these findings may pose a significant threat to the central visual 
field. In the first instance, initial studies may be indicated to examine the 
functional correlate in relation to loss in GCC volume in individuals with severe 
and less severe degrees of neuropathy.  
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5.7 Conclusion 
The current research study demonstrated that individuals with diabetes have 
significant focal loss in GCC volume in relation to the severity of diabetic 
neuropathy, as well as a generalized GCC loss that is related to age. This loss is 
not significantly related to retinopathy, sex, duration of diabetes or the HbA1c 
levels. The results from this study calls for examination of visual function in 
people with and without focal GCC volume loss in relation to diabetic 
neuropathy. 
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Chapter 6: Retinal tissue thickness in 
individuals who had undergone laser 
photocoagulation 
6.1 Introduction  
The participants who had undergone laser treatment for DR were excluded 
from the main experiment for the reasons that the effect of laser treatment can 
confound retinal thickness measurements. The purpose of this analysis was to 
examine if laser treatment had any effect on the retinal tissue thickness in the 
individuals who had undergone laser treatment for DR when compared with 
those with DR who did not have any laser treatment.  
Laser photocoagulation is the standard treatment for severe NPDR and PDR 
(Neubauer et al., 2007). When laser is administered, the laser energy is 
absorbed by the RPE and photoreceptor layer and is converted to heat, resulting 
in coagulation or disruption to the RPE and photoreceptor layers. This in turn 
reduces the oxygen consumption and hence the demand. As a result, there is a 
decrease in the release of vascular endothelial growth factor, with a subsequent 
reduction in neovascularisation.  
The clinical outcome is a prominent RPE burn. Although the target tissue is RPE, 
thermal and mechanical damage to other retinal layers has been observed in 
response to laser exposure (Marshall, 1970). For instance, early study in rabbits 
reported RPE being subjected to thermal damage from the laser, whereas, 
neural layers are subject to more of mechanical disturbances due to shifting of 
cellular components (Marshall., 1970).  As an effect, the neural retina can 
sometimes be disturbed or damaged by heat conduction and can become 
oedematous and consequently lose its transparency. The temperature produced 
 an  e as  ig  as 100˚    eading t  denaturing  f  r teins. T e denatured 
proteins are then removed by phagocytosis and replaced by scar tissue (Berlien, 
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2003, p. 302) and this can have implications with regards to visual function 
(Marshall, 1970).  
6.2 Types of laser treatment 
Photocoagulation can be broadly classified into two (1) a scatter PRP, which 
involves a wide spread scatter (2) a focal laser for macular oedema.  
Scatter laser photocoagulation also called panretinal 
photocoagulation (PRP) is a standard procedure that is recommended 
for severe NPDR and for PDR to reduce the risk of vision loss. Argon laser 
is used to create tiny burns in the peripheral RPE, thus carefully avoiding 
the macula, papillomacular bundle, and the optic nerve head. Once 
complete, it may take about 8 weeks for the new vessels to regress.  
Focal laser photocoagulation is generally advised for diabetic macular 
oedema, after attempting optimal metabolic control. This can be either a 
focal treatment or a grid treatment. 
 
Focal treatment refers to treating a microaneurysm (MA) 
directly in the presence of macular oedema occurring within   
500-3000 μ  fr   t e  entre  f t e  a u a. Indi idua  MA’s are 
treated with small spot sizes outside the foveal avascular zone 
(FAZ). T e e udates disa  ear  n e t e MA’s are treated.  
 
Grid treatment is primarily used for non-ischemic diffuse 
leakage without any focal or point leakage. The entire macula 
minus the fovea is treated with a low power grid laser to enhance 
the absorption of oedema. Grid laser is generally advised as a 
treatment to preserve the existing vision rather than improving 
the vision (American Diabetes Association, 1985).  
 
Although recent techniques such as selective laser photocoagulation can be 
modified to produce the same effect on the retina with minimal damage to the 
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neighbouring tissues (Figueira et al., 2009), there is always some degree of 
damage.  
6.3 Adverse effects  
There is a risk of worsening of macular oedema, decrease in visual acuity and an 
increase in size of the lesion (Schatz H, 1991). Other side effects include 
inadvertent laser scarring at the fovea leading to central scotoma because of 
damage to photoreceptors (Framme et al., 2004), diminished night vision 
(Prskavec et al., 1986) and constriction of binocular peripheral visual fields 
(Pearson et al., 1998).  
6.4 Retinal tissue thickness in laser photocoagulation 
The RNFL thickness is reduced in eyes that have had laser when compared to 
that of eyes with DR without laser treatment (Cankaya et al., 2011; Hsu et al., 
2002; Kim et al., 2009; Lim et al., 2009). In the study by Muqit et al (2009), the 
mean and the temporal quadrant RNFL thicknesses at 10 weeks post laser 
showed a significant increase when compared to baseline values. However, at 6 
months, mean and temporal quadrant RNFL thicknesses reduced significantly to 
below baseline levels (Muqit et al., 2009). A recent study observed significantly 
increased RNFL thicknesses at 6 months after PRP but gradually decreased at 
24 months below baseline values. In contrast, RNFL thickness in the temporal 
quadrant increased significantly at 6 months and reduced at 24 months but 
remained higher than the baseline readings. Central zone thickness showed a 
significant increase at 3 months and remained significantly higher at 24 months 
when compared to baseline readings (Lee et al., 2012). Another study showed 
an increase in RNFL thickness at 2 and 6 months after PRP but the difference 
did not reach statistical significance. However, the optic nerve rim area showed 
a significant increase from baseline to 2 months and at 6 months post PRP 
(Ritenour et al., 2009). The RNFL thickness was examined in the previous 
studies at various time intervals. However, collective evidence suggests that 
with longer time interval from the laser treatment, the RNFL showed a tendency 
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to decrease in thickness and appear to drop below baseline levels, despite any 
transient increase in thickness.  
Optic nerve head photographs were examined in people with PDR just before 
and at one year after PRP; no difference was observed in the nerve head 
appearance (Johns et al., 1989). The visually evoked potential amplitudes did 
not show significant changes after PRP (Zhang et al., 2000). Photocoagulation 
was associated with an increase in the choroidal blood circulation (Takahashi et 
al., 2008) and a decrease in the retinal blood flow in eyes treated for PDR 
(Grunwald et al., 1989; Grunwald et al., 1986).  
It appears that the RNFL shows intermittent increase in thickness but 
eventually reduces in thickness to below baseline levels after laser treatment 
for DR. The varying results reported in the above studies may be likely 
explained by differing clinical laser settings used in each study. The outcome 
depends on factors such as differences in absorption properties of lasers 
(Blankenship, 1986), laser settings such as the spot size, duration (length of 
pulse), power, wavelength of laser beam (Marshall, 1973), frequency of 
treatment (Shimura et al., 2003), focal length of the converging lens,  absorption 
and the magnitude of the temperature increase in the tissue. This could be a 
likely explanation for the inconsistency in post-study changes.  
6.5 Purpose 
The purpose of this analysis was to explore the full retinal and inner retinal 
thickness in individuals who had undergone some form of laser treatment for 
DR, in comparison to individuals with DR who had not had laser treatment. The 
analysis was performed to determine if laser treatment significantly altered the 
retinal thickness. There were no criteria set for visual acuity or to any other 
parameter under consideration for either group. 
6.6 Methods 
The normality of distribution was tested. Clinical and neuropathy parameters 
were compared between individuals who had undergone laser treatment for DR 
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and that of people with DR using an independent samples t-test.  There were 
differences (2 times) in sample size between the two groups; therefore a 
Le ene’s test f r equa it   f  arian es was  erf r ed. In  ase  f  i  ati n  f 
Le ene’s test f r equa it   f  arian es  a t-test not assuming homogeneous 
variances was utilised.  
6.7 Results 
There were 38 eyes of 38 participants that underwent laser treatment and 63 
eyes of 63 participants with DR but had no laser treatment. For the purposes of 
t is d  u ent  t e gr u s are defined as ‘Laser gr u ’ and ‘D  gr u ’. 
Individuals in the laser group were on an average 6 years older (p = 0.005) and 
had 4 kg/m2 lower BMI (p = 0.002); the vibration threshold was 7.8 Hz higher in 
individuals in the laser group. Other clinical parameters namely HbA1c levels, 
duration of diabetes, total cholesterol, and blood pressure in the laser group 
were similar to that of DR group.  
Other neuropathy measures such as the NDS, DNSS, warm and cold thresholds, 
warm and cold induced pain thresholds, peroneal nerve conduction velocity and 
amplitude and the number of monofilament points detected in the laser group 
were similar to that of DR group. Results are presented in Tables 31-32.  
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Table 31. Summary of clinical variables in the laser group compared to those in DR group 
Variables Laser group 
Mean ± SD 
n 
Min - Max 
DR group 
Mean ± SD 
n 
Min - Max 
t 
 
 
 
df 
 
 
 
p-value 
 
 
 
  
  
  
Age 61.8 ± 9.3 55.8± 8.7 2.907 99 0.005 
  38 63       
  43.1 - 76.8 40.3 - 71.6       
Duration of diabetes (years) 24.4 ± 15.4 24.9 ± 13.3 -0.204 99 0.839 
  38 63       
  6 - 55 3 - 64       
BMI (kg/m2) 27.2 ± 5.1 31.2 ± 6.1 -3.262 99 0.002 
  38 63       
  19.2 - 38.4 22.5 - 55.5       
BP systolic (mmHg) 131 ± 20 129 ± 14 0.133 57 0.895 
  38 63       
  101 - 201 101 - 166       
BP diastolic (mmHg) 74 ± 9 76 ± 8 -1.094 99 0.277 
  38 63       
  61 - 95 58 - 97       
Total cholesterol (mmol/L) 4.6 ± 1.0 4.5 ± 1.1 0.401 98 0.689 
  37 63       
  30. - 7.0 2.6 - 8.6       
QST war  sensati n t res   d (˚ ) 41.7 ± 4.3 40.5 ± 4.6 1.588 99 0.115 
   38 63       
  33.3 - 49.4 32.8 - 50.0       
Peroneal M amp ankle to EDB (millivolts)  2.5 ± 2.1 2.9 ± 2.6 -0.600 98 0.550 
   37 63       
  0.1 - 8.1 0.1 - 14.1       
BMI, body mass index; BP, blood pressure; QST, quantitative sensory testing; amp, amplitude; 
EDB, extensor digitorum brevis 
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Table 32. Variables in the laser group compared to the DR group using non-parametric tests 
Variables Laser 
group 
Median 
IQR 
Min - Max 
DR group Mann-Whitney U test 
  Median p-values 
  IQR   
  Min - Max   
HbA1c (%) 7.5 8.1 0.251 
  1 2   
  6 - 14 6 - 13   
NDS 2 2 0.356 
  3 4   
  0 - 10 0 - 10   
DNSS 1 0 0.061 
  2 2   
  0 - 4 0 - 4   
Peroneal CV ankle to FH (meters/second)  41.8 41.7 0.498 
  9.6 7.5   
  20.0 - 50.0 20.0 - 56.6   
QST    d sensati n t res   d (˚ ) 23 26.5 0.077 
  10.1 8.2   
  0.0-31.2 0.0 - 31.3   
QST    d indu ed  ain t res   d (˚ ) 0.7 5.2 0.076 
  11.1 18.7   
  0.0 - 25.3 0.0 - 28.1   
QST vibration threshold (Hz) 21.4 13.6 0.023 
  34.9 20.4   
  1.4 - 128.4 2.1 - 130.0   
Monofilament no. of points detected out of 3 3 3 0.757 
   1 1   
  0 - 3 0 - 3   
IQR, inter-quartile range; NDS, neuropathy disability score; DNSS, diabetic neuropathy symptom 
score; CV, conduction velocity; FH, fossa head; QST, quantitative sensory testing 
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Retinal thickness in the laser group and the DR group 
The full retinal and inner retinal thickness in the laser group did not differ 
significantly from that of the DR group. Results are presented in Table 33. 
 
Table 33. Retinal thickness in the laser group compared to that of DR group 
Retinal tissue thickness (µm) Laser group DR group t df p-value 
  Mean ± SD Mean ± SD    
  Min - Max Min - Max    
Thickness in the central 1mm zone 248 ± 28 243 ± 25 0.512 96 0.610 
  183 - 309 140 - 293       
Overall parafovea 303 ± 26 304 ± 17 -0.264 54 0.793 
  218 - 339 259 - 337       
Overall perifovea 266 ± 19 267 ± 16 -0.220 96 0.826 
  229 - 307 201 - 301       
Overall RNFL 97 ± 12 102 ± 12 -1.402 97 0.164 
  65 - 117 71 - 132       
Overall GCC 94 ± 12 95 ± 8 0.075 53 0.941 
  65 - 119 77 - 117       
RNFL, retinal nerve fibre layer; GCC, ganglion cell complex 
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6.8 Discussion 
This analysis examined the full retinal and inner retinal thickness in individuals 
who had undergone laser in comparison to those with DR but have not had laser 
treatment. Initial analysis of clinical parameters showed that individuals in the 
laser group were significantly older and also had significantly lower BMI, and a 
higher vibration threshold than those in the DR group. The laser group differed 
from the DR group in terms of DNSS, cold sensation threshold and cold-induced 
pain threshold but the differences did not reach statistical significance. It is 
interesting to note that the full retinal and the inner retinal thickness in the 
laser group did not differ significantly compared to the DR group. However, the 
results are not surprising because several factors (described below) may have 
influenced the outcome.  
For instance, 
a) Clinical laser settings such as spot size, pulse duration, frequency of shots 
per sitting, number of sittings was not known. These settings can 
influence the extent of thermal damage at the level of retinal layers. This 
could have introduced some variability in the results as reported in 
literature. 
 
b) The stage of retinopathy before laser was not known. In general, scatter 
laser treatment is advised for severe NPDR and for PDR and a focal laser 
for macular oedema. In the current study, most participants in the DR 
group had individuals with very mild NPDR or mild NPDR. It is likely that 
the lack of difference between the two groups may be explained by these 
differences. For instance, it is possible that the retinal layers may be 
oedematous in the presence of retinopathy or may be thinner due to scar 
formation. Firstly, as demonstrated so far from the current project, the 
retinal layers are reduced in relation to neuropathy. However, in this 
part of the study, neuropathy measures in the laser group were not 
significantly different compared to the DR group, thus leaving a greater 
possibility of retinal tissue thickness being influenced by retinopathy 
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more than neuropathy in the laser group. Therefore, it is likely that the 
increased retinal thickness may be associated with higher degrees of DR 
as shown in previous literature (Chapter 2). Secondly, it is also likely that 
this effect may have been cancelled out by the thinning of the RNFL after 
laser.  
 
c) The laser group comprised of participants that had undergone focal laser 
or scatter laser. Both the groups were combined for this analysis. This 
may have attributed to some variations within the laser group and as a 
result, showed no significant differences between the two groups. 
 
d) OCT was not performed at pre-determined time points. As a result, the 
time interval between the date of laser and the date of OCT examination 
varied between participants. This could introduce variability in the result 
as reported in literature wherein, the RNFL shows intermittent increase 
in thickness but eventually reduces in thickness to below baseline levels. 
For the reason that OCT was not performed at fixed time points post-
laser, it is likely that this laser group have had some individuals with 
transient increase in RNFL thickness and some individuals with thinner 
RNFL and as a result, the combined effects may have cancelled each 
other. However, these are assumptions only.  
Therefore, the question whether laser treatment is a confounding factor for the 
retinal thickness measurements, is still unclear. Analysis of retinal tissue 
thickness in the same group before and after laser may contribute to more 
relevant information and may provide a more sound appreciation of the effect of 
laser on the retinal tissue thickness. However, this is not the objective of the 
current research program.  
Nevertheless, the observation that the individuals in the laser group had 
significantly higher vibration threshold is noteworthy because the individuals 
may be at risk of impending foot ulceration and hence require follow-up care. 
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6.9 Conclusion 
This supplementary analysis showed that the retinal tissue thickness in 
participants who had undergone laser treatment was not significantly different 
from those in the DR group. However, individuals in the laser group had 
significantly higher vibration threshold, which suggests that they may be at risk 
of foot ulceration. Shahidi et al (2012) observed that the inferior RNFL thickness 
is thinner in those at risk of foot ulceration. In the current study, although the 
retinal tissue thickness did not vary at the moment, these individuals need 
follow-up care to monitor especially the inner retinal thickness and the visual 
function. 
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Chapter 7: Summary, overall significance of 
this research 
This research program has demonstrated that retinal structural integrity as 
indicated by full retinal thickness, macular and the peripapillary inner retinal 
thickness is compromised in relation to diabetic peripheral neuropathy. This 
research program has investigated several important research questions which 
are addressed in this chapter. 
There is uncertainty as to whether the type of diabetes influences retinal tissue 
thickness. To understand this, the following research question was addressed. 
1. Is there is a relationship between the type of diabetes and retinal tissue 
thickness? 
No. The type of diabetes as well as the interactions between type of diabetes and 
age, sex, diabetic retinopathy, neuropathy disability score, duration of diabetes 
and HbA1c levels are not significantly related to the retinal tissue thickness. 
However, individuals with type 2 diabetes have a tendency for reduced retinal 
thicknesses compared to those with type 1 diabetes; therefore, individuals with 
type 2 diabetes may need close monitoring of the retinal tissue thickness 
integrity as well as examination of the associated visual function. Also, 
examination of other risk factors such as cardiovascular or nephropathy-related 
factors may need evaluation in order to understand the reasoning behind 
reduced retinal thickness in type 2 diabetes.  
2. Are the full retinal thickness and inner retinal thickness significantly 
related to the severity of diabetic neuropathy, defined using NDS criteria? 
Yes. Both the full retinal thickness and inner retinal thickness are reduced in 
individuals with advanced degrees of neuropathy. For instance, the retinal 
thickness in the perifovea is decreased in relation to diabetic peripheral 
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neuropathy. This may reflect a compromise in the photoreceptor layer. 
Furthermore, the thickness in the parafovea is reduced in the presence of DR. 
The RNFL is significantly thinner in individuals with advanced degrees of 
neuropathy. The GCC thickness showed a tendency to be reduced in relation to 
diabetic peripheral neuropathy. These findings may be reflected as compromised 
central and peripheral visual field sensitivity.  
3. Are the focal and global losses in GCC volume significantly related to 
diabetic peripheral neuropathy? 
Yes. In individuals with diabetes, there is significant focal loss in GCC volume that 
is related to the severity of neuropathy. There is a significant global loss in GCC 
volume associated with age. This may be mirrored as a reduction in visual field 
sensitivity in the central field or a compromise to the visual function and 
therefore warrants investigation.  
DR has been proposed as a putative mechanism behind neural apoptosis, loss of 
ganglion cell bodies and glial tissue in diabetes until recently where reduced 
retinal nerve fibre layer thickness has been reported to be related to diabetic 
peripheral neuropathy rather than retinopathy (Shahidi et al., 2012). This 
opened up the possibility that the ganglion cells and the other retinal layers may 
be involved in relation to diabetic peripheral neuropathy. In addition to reduced 
retinal nerve fibre layer thickness, this research program has demonstrated that 
there are focal losses in ganglion cells that are related to DPN rather than DR; 
these may indicate changes to the axon, axonal diameter, glial structure, 
extracellular volume, retinal vessel diameter or a combination of the above.  In 
fact, this further substantiates the hypothesis that retinal neuropathy in diabetes 
may be related to systemic neural injury, as a result of microvascular changes or 
that from chronic hyperglycaemia and may invovle multiple layers of the retina.  
Furthermore, the involvement of other cranial nerves suggests a multi-system 
involvement affecting all branches of the nervous system in diabetes. For 
example, extra ocular muscle palsies arising from damage to III, IV and VI cranial 
nerves, depletion of retinal nerve axons that form a part of II cranial nerve, 
alterations to corneal nerves  that constitute the V cranial nerve,    pupillary 
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defects (may indicate autonomic dysfunction) and so on. The findings from the 
current research program have important implications for the potential 
compromise to the central and peripheral visual field sensitivity. Therefore 
examination of visual fields in individuals with diabetes with neuropathy may be 
indicated. 
7.1 Limitations, overall strengths of this research program 
Visual function was not assessed as a part of this study. Therefore, the clinical 
significance of the observed retinal structural compromise is not well 
understood. This may be viewed as a limitation in this study. 
The strength of association between retinal structural thinning and diabetic 
neuropathy was not high, which could be regarded as a limitation in this study. 
The highest R2 observed was 19% for inferior RNFL thickness, indicating that 
one-fourth of the reduction in the RNFL thickness is related to the severity of 
diabetic neuropathy and age. This suggests that there are other variables yet to 
be explored, that may influence the retinal tissue thickness to a greater extent. A 
likely explanation for the weaker strength of association could be that, the study 
was started with a pre-defined resear     je ti e: ‘t  deter ine t e 
relationship between the retinal tissue thickness and diabetic peripheral 
neur  at  ’. T e ass  iati n was deter ined w i e adjusting f r t e  e  
variables namely DR, age, gender, duration of diabetes and the HbA1c levels. The 
rationale for choosing these variables was that these are consistently reported 
as risk factors for both DPN and DR and are related to the retinal tissue 
thickness as well.  Therefore, the results obtained are within the bounds of the 
research objective, taking into account, the pre-defined set of key variables. 
However, an exploratory analysis (model building) could have revealed 
additional variables that influence the retinal thickness. The method would 
involve analysing the retinal thicknesses and adding or removing variables that 
would significantly contribute to the overall statistical model by improving the 
adjusted R2. However, the sample size will also need to be higher to be able to 
include many independent variables into the model. A ratio of 20:1 may be 
considered as a guideline for the sample size needed to account for the number 
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of independent variables to be entered into the regression models. That way, 
the other micro- and macrovascular factors may also be studied. This 
exploratory analysis may lead to a better model with few other variables that 
might significantly influence the retinal tissue thickness. The current study can 
be considered as a foundation upon which, future studies can be developed, 
taking into account, the other cardiovascular and nephropathy related factors as 
well.  
In the current project, diabetic retinopathy (DR) did not show a significant 
relationship to the inner retinal thickness. It is pertinent to mention that DR 
 ere re resents ‘  ini a     isi  e signs’  n  .  T ere  a  a s   e su t e 
retinopathy changes that may be subclinical; therefore, the absence of clinical 
signs of DR does not necessarily rule out DR. Therefore, the results must be 
interpreted with caution. 
In addition, duration of diabetes was by self-report. The exact day of diagnosis 
cannot be firmly determined. Therefore, this fact needs to be taken into account. 
Despite any short comings, this research program has answered novel research 
questions within the constraints of the key variables assessed, and has 
contributed to new knowledge regarding the retinal anatomy in relation to 
diabetic peripheral neuropathy.  These findings have important implications to 
visual function, mobility and quality of life issues. 
Clinical significance of this research and contribution to new knowledge 
This is the first study to examine the association between the type of diabetes 
and retinal tissue thickness while adjusting for certain important confounding 
variables. To date, this study is the first to demonstrate compromised neural 
layer thickness in the macular and peripapillary regions, as well as reduced full 
retinal thicknesses, in relation to diabetic neuropathy. This research program 
has contributed to a deeper understanding of the changes to the retinal anatomy 
in relation to diabetic peripheral neuropathy. These anatomical changes may be 
mirrored as compromise to central and peripheral visual fields. This remains to 
be tested.  
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This is the first study to demonstrate pattern-based ganglion cell loss in relation 
to diabetic peripheral neuropathy that is not related to DR. This is a new 
observation but is also a critical finding in that, a compromise in the macular 
region can represent a significant threat to central visual field. Therefore, to 
understand the clinical implications of these structural deficits, examination of 
the central and peripheral visual fields, as well as assessment of ganglion cell 
function may be indicated. In addition, the observation that the perifoveal 
thickness is reduced may reflect changes to the photoreceptor layer. Therefore, 
this necessitates evaluation of the photoreceptors. The following sections 
provide a review of visual function tests that may be helpful in the assessment 
of structural compromise in diabetic neuropathy. 
7.2 Examination of the visual function 
Visual function is a broad terminology that includes measures such as visual 
acuity, contrast sensitivity function, hue discrimination, dark adaptation and 
visual fields (Nasralah et al., 2013). The following sections discuss the various 
attributes of visual function. 
It is of interest to note that foveal anatomy is suited for highest discriminative 
ability and colour perception. Assessment of visual acuity and colour vision may 
therefore be valuable. 
Visual acuity 
Visual acuity (VA) is a measure of spatial resolution of the retina. Visual acuity 
indicates resolving power of the eye, (Hartridge, 1922) and is typically assessed 
by visual recognition of letters on a chart. Visual acuity has been utilized as a 
measure of visual function to monitor and to record progression of disease in 
clinical trials, as well as to follow-up after treatment. However, in diseases like 
DR, VA deterioration is frequently observed in late stages of disease such as 
proliferative DR or in the presence of macular oedema (Antonetti et al., 2012). 
This suggests that visual acuity may not be the best measure of visual function 
especially in early stages of the disease. There are other measures of visual 
function that appear to be sensitive to subtle retinal changes such as colour 
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vision, contrast sensitivity, perimetry and electrophysiology (Jackson et al., 
2012). 
Colour vision  
Tritan (blue-yellow) colour vision defects have been observed in individuals 
with diabetes even in the absence of visible signs of DR (Ong, et al., 2003). When 
compared to those without diabetes, the error in colour discrimination was 
significantly higher in those with diabetes without DR (Green, et al., 1985) 
(Hardy, et al., 1992). Acquired macular diseases tend to be associated with blue-
yellow defects, whereas optic nerve lesions can produce red-green defects 
(Wright et al., 2007). The current project has demonstrated the involvement of 
both macular and peripapillary neuroretinal layers in relation to diabetic 
peripheral neuropathy. It would therefore be interesting to examine the colour 
vision defects in relation to diabetic peripheral neuropathy.  
The FM-100 hue test is a commonly used test that is sensitive for detecting 
defects in colour discrimination. The test consists of four boxes of coloured caps 
with fixed caps at either ends; the task for the individual is to arrange the caps 
as a gradual progression of the colours. The bottom of the caps has numbers 
printed for reference to indicate the correct sequence. The total number of 
deviations in the sequence is recorded as the total error score (Farnsworth et 
al., 1957). In the current research project, the reduction in perifoveal thickness 
indicates that the outer retinal layers may be involved. It is therefore likely that 
the photoreceptors are involved and this may manifest as blue-yellow or red-
green colour vision defect; this remains to be tested. The FM-100 hue test may 
be utilized to assess in-detail the nature of colour vision defects if any, in 
relation to diabetic peripheral neuropathy. 
Implications of defective colour vision in everyday life 
Problems in colour vision may pose challenges in everyday life. For instance, 
while cooking, individuals may have difficulty in determining if the meat is 
adequately cooked based on the colour; difficulties can rise in  choosing 
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wallpapers and cosmetics (Steward et al., 1989). Difficulty may arise while 
choosing fruits for their ripeness based on their colour; for instance, banana. 
Children are not spared when it comes to diabetic neuropathy (Blankenburg et 
al., 2012). Children are generally associated with a world of colours. Colour 
vision problems especially in children can be more problematic to deal with. 
Defective colour vision can make their food appear less appealing. As a result, 
they may dislike those foods that appear less colourful.  There can also be issues 
at school where there are creative projects involved such as drawing or crafty 
work (Neitz et al., 2000).  
Issues may arise in selecting clothing. Someone with defective colour vision may 
choose very bright or vibrant colours as they are not aware that they are 
brighter than normal.  Defective colour vision can interfere with occupational 
duties related to transportation, the food industry, textile industry and armed 
forces where, for example, interference with the interpretation of emergency 
flare, indicator lights can be problematic.  Earlier, it was thought that individuals 
with defective colour vision may not be able to drive vehicles because they may 
have difficulty following the traffic lights; however, individuals can still use 
other cues (Cole, 2004) such as the order of the light on a signal. However, this 
is not always the case. For instance, the lights can have arrows that change 
colours or may be arranged from left to right as in selected cities in the US. 
These can be challenging for a new driver or driver in a new zone. Therefore, 
assessing colour vision may be valuable so that individuals can be counselled 
accordingly.  
Photostress test 
The photostress test can differentiate macular involvement from an optic nerve 
involvement. The test involves exposing the macula to a bright source of light, 
like an ophthalmoscope or a penlight for about 10 seconds. This would bleach a 
significant proportion of visual pigments. The test is performed monocularly. 
After exposure to light, the time taken for the eye to read within a line from the 
previously read line is recorded. The response is considered normal if read 
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within 50-60 seconds. The rationale is that the return of normal retinal function 
and sensitivity depends on the regeneration of visual pigments. Disease 
affecting photore e t rs  Bru  ’s  e  rane     ri  a i  aries  r    r id  an 
prolong the visual recovery time. No such prolongation is seen in optic nerve 
conduction defects (Margrain et al., 2002). This test may show abnormality if 
the photoreceptors are involved in relation to reduced perifoveal thickness. 
Nevertheless, the test is not useful to quantify the extent of macular 
involvement. 
Contrast sensitivity 
Contrast sensitivity (CS) is defined as the ability of the visual system to 
distinguish an object from its background. If the visual acuity is reduced, the 
contrast sensitivity is reduced as well. On the contrary, CS may be reduced 
irrespective of the visual acuity. Therefore, if visual acuity alone is tested, the 
relative impairment in CS will be undefined.  
Contrast sensitivity may be affected early in a disease process. For instance, in 
the absence of clinical signs of DR, impaired contrast sensitivity has been 
reported in diabetic children (Georgakopoulos, et al., 2011) as well as in 
diabetic adults (Heravian, et al., 2010; HyvÄRinen, et al., 1983; Trick, et al., 
1988) while visual acuity was unaffected. A trend of further reduction in CS has 
been observed in individuals with early to advanced stages of DR (Ismail, et al., 
1998). The explanation for the impaired contrast sensitivity in diabetes is multi-
fold; one of them being hyperglycaemia. Although no direct cause-effect 
relationship could be established between hyperglycaemia and CS, impaired CS 
was found to be associated with increased retinal blood flow during alterations 
in blood glucose levels with glucose clamp technique (Bursell, et al., 1996), thus 
indicating an indirect link between the higher glycaemic levels and CS. Another 
likely explanation could be alterations in retinal and choroidal blood supply in 
diabetes that have been linked with impaired CS (Shoshani, et al., 2011). Loss in 
CS has been associated with capillary dropout in individuals with diabetes 
(Fletcher, et al., 2005). The above studies indicate that the contrast sensitivity 
function may be a sensitive tool for determining loss in visual function.  
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Contrast sensitivity may be assessed using a grating or an optotype (Mäntyjärvi 
et al., 2001). Grating indicates the spatial frequency or the number of dark-light 
cycles per visual angle. In early stages of macular diseases, there is marked 
impairment of CS function at intermediate and higher spatial frequencies 
(Sjostrand et al., 1977) and dramatically reduced CS across a wide range of 
frequencies in advanced stages of macular diseases. 
Contrast sensitivity chart such as Pelli-Robson chart may be also beneficial. The 
chart consists of 8 rows of letters of 20/60 equivalent that vary in their contrast 
from left to right. The set of letters with lowest contrast identified by the 
participant is recorded. A score of 2.0 indicates normal contrast sensitivity, 
while a score less than 1.5 indicates impaired contrast sensitivity function (Pelli 
et al., 1988). A combination of both optotype and grating may be utilized for 
contrast sensitivity testing. 
Implications of abnormal contrast sensitivity 
Abnormal CS can make objects appear foggy or washed out. Impaired contrast 
sensitivity can lead to problems in judging distances, climbing stairs, and 
recognising faces (Nema et al., 2010). Patients may bump into objects or may be 
prone to falls and fractures (de Boer et al., 2005). Patients with diminished CS 
can have driving-related problems despite normal visual acuity (Puell et al., 
2004). Driving can be difficult in low lighting conditions (Szlyk et al., 2005) such 
as during dawn, dusk, overcast days, rain and fog (Woods et al., 1995). Older 
drivers experience decreased ability to drive at night. Drivers with diminished 
contrast sensitivity function and a greater sensitivity to glare avoid night 
driving (Wood et al., 2002). Contrast sensitivity testing can therefore be 
beneficial so that appropriate measures can be taken to counsel and to educate 
the individuals about tasks involving contrast sensitivity. Yellow filters may be 
tried as a treatment option for improving the contrast (Lee et al., 2002).   
Visual fields  
Mid-peripheral visual field sensitivity is reduced in relation to diabetic 
peripheral neuropathy, and this was not explained by DR (Sampson et al., 2012). 
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Previous studies have demonstrated neuroretinal degeneration even in the 
absence of clinical signs of DR (detailed in Chapter 2). The results from the 
current study demonstrate that the compromise in neuroretinal layers is related 
to diabetic peripheral neuropathy. This emphasizes the importance of visual 
field assessment as part of routine eye examinations even in the absence of 
clinical signs of DR.  
Perimetry is a measurement of sensitivity to light across the retina. With 
manual kinetic perimetry, scotomas in the visual fields were detected in a group 
of individuals with and without DR (Roth, 1969). In the DR group, the scotomas 
topographically corresponded to retinopathy lesions. However, in the no DR 
group, the presence of scotomas was considered as a pre-retinopathy sign.  
In a study using static perimerty also called standard automated perimetry 
(SAP), about 4% of the eyes with very mild and mild DR had mean deviation 
(MD) values (overall depression or sinking of the visual field) with a probability 
value worse than 5% (Henricsson, et al., 1994), suggesting that a vast majority 
of subjects with and without DR had MD within normal limits. However, the 
number of abnormal test points became higher with greater severity of DR. A 
similar trend was observed by Park et al (2011) where the mean deviation 
values increased with the severity of DR.  
A limitation with the use of white-on-white perimetry is that there is already 
30-40% loss in retinal nerve fibre axons before any obvious field defect appears 
(Quigley, et al., 1982). However, blue-on-yellow perimetry (blue target on a 
yellow background) has been found to be superior in detecting depressions in 
visual field, when white-on-white perimetry results were normal (Nitta, et al., 
2006). Nevertheless, the reduced sensitivities on blue-on-yellow perimetry 
could also be due to yellowing of the crystalline lens. Interestingly, with the use 
of red-on-white perimetry, significantly greater visual field defects were 
demonstrated and because of the longer wavelength, it is not affected by 
cataract or yellowing of the lens (Zele, et al., 2008).   
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With the use of alternate visual field techniques, such as flicker perimetry, 
researchers have successfully demonstrated reduction in visual field sensitivity 
wit in  ˚ fr   fi ati n  in indi idua s without DR and also in those with early 
stages of DR (Stavrou, et al., 2005). These defects were not detected by the static 
white-on-white perimetry. Flicker perimetry can be performed using critical 
fusion frequency (CFF) or temporal modulated perimetry (TMP) techniques 
(Stavrou & Wood, 2005). The CFF involves measuring the threshold frequency 
by presenting alternating or flickering dark and light bars at a fixed level of 
contrast. The highest temporal frequency detected is recorded as the threshold. 
The TMP involves measuring the threshold at varying levels of contrast that 
flicker at a constant rate. The stimulus with lowest contrast detected is recorded 
as the threshold.  The rationale is that identification of flicker requires greater 
metabolic demand and therefore can show  greater abnormality in the presence 
of vascular compromise (Scheiner, et al., 1994). In addition, flicker sensitivity 
also depends on the integrity of photoreceptor and their metabolism. When 
compared to the two techniques, the TMP technique is reported to be more 
effective than the CFF in separating glaucoma patients from normal non-
glaucomatous healthy individuals (Yoshiyama et al., 1997). 
Other perimetry techniques namely frequency doubling perimetry and 
microperimetry has been in use in clinical settings.  
Frequency doubling perimetry  
Frequency doubling perimetry (FDP) was initially developed based on the 
hypothesis that when a low spatial frequency grating is allowed to undergo 
counterphase flicker, the spatial frequency appears to be doubled (Kelly, 1966; 
Zeppieri et al., 2008). It was hypothesized that this illusion is a property of a 
subset of ganglion cells that is involved in detection of movement and flicker 
(Derrington et al., 1984). The FDP was reported to be superior to standard 
automated perimetry (SAP) in detecting early neuronal loss in glaucoma disease 
models. Also participants with diabetes had higher test scores and took longer 
testing time compared to those without diabetes, when SAP results were 
normal, suggesting neural degeneration in diabetes. However, impaired contrast 
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sensitivity can confound the FDP results independent of any neuronal loss 
(Realini, et al., 2004).  
Interestingly, recent study has reported that a Goldman size III stimulus may be 
more effective than frequency doubling technology in testing a specific subtype 
of ganglion cells (Swanson et al., 2011). However, the threshold measurements 
from the standard automated perimetry represent responses of multiple levels 
of the visual pathway.  
Microperimetry 
Microperimetry is advancement in perimetry technique with which, clinicians 
are able to map the retinal sensitivity with a real time topographical 
correspondence with the retina. Microperimetry detected greater number of 
individuals with visual field defects compared to that with standard automated 
perimetry (Lima et al., 2010).  
There are two types of technology available in microperimetry. One technology 
uses digital fundus photography and computerized perimetry; the other uses 
scanning laser ophthalmoscope to combine SD-OCT with microperimetry for the 
 entra  20˚  f t e retina  fie d  f  iew. A d tted  ig t is  r je ted dire t    nt  
the retina through the pupil at certain intensity at predefined points on the 
retina. The patient is asked about the perception of the light at certain 
brightness. By changing the light intensity, the differential light sensitivity or 
threshold at the retinal points can be determined. When compared to the 
conventional perimetry, microperimetry provides a real time ophthalmoscopic 
imaging and point to point topographical correlation of functional deficits with 
the fundus pathology (Sunness et al., 1995) and can detect areas of reduced 
retinal sensitivity in the presence of normal standard automated perimetry  
(Lima et al., 2010) in individuals with glaucoma. 
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Implications of compromised visual field sensitivity 
Loss in visual field sensitivity can result from neuroretinal compromise (Quigley 
et al., 1982) as well as from damage or death of the photoreceptors (Milam et al., 
1998).  
A GCC scan corresponds to a Humphrey 10-2 visual field program. Loss in the 
ganglion cell complex in this region may be mirrored as loss in the very central 
portion of the visual field. This can present as difficulty in reading, as the central 
10˚  f t e  isual field is crucial for reading and is represented by 50% of the 
primary visual cortex (Demb et al., 1997). Visual field sensitivity loss can lead to 
disturbances in mobility and problems in climbing stairs can lead to falls 
(Freeman et al., 2007); difficulty in recognizing road signs (Wood et al., 2010), 
changing lanes, and manoeuvring (Johnson et al., 1983) and also difficulty in 
tracking moving objects (Owsley et al., 1995) may be observed. Constriction of 
useful visual field is associated with an increased risk of crash among elderly 
drivers (Owsley et al., 1999). Involvement of RNFL, GCC and photoreceptors can 
be a source of scotomas in the visual field as well as impaired dark-light 
adaptation (Framme et al., 2004).  
Limitations of perimetry techniques 
Perimetry techniques do have certain limitations. Collective evidence from 
glaucoma disease models have demonstrated that the structure versus function 
correspondence can depend upon a number of factors (Wood et al., 2000). The 
responses may vary due to discrepancy between the type or the extent of 
ganglion cell involvement and the nature of visual field testing system utilized 
(for example static versus flicker perimetry or white-on-white perimetry versus 
blue-on-white perimetry and so on).  
Furthermore, there is a possibility that the structural damage may occur much 
earlier than a demonstrable functional loss, as in glaucoma disease models. For 
instance, nearly 70% loss in the ganglion cells in the parafoveal retina is 
required to demonstrate a 3-5 dB loss in visual field sensitivity (Harwerth et al., 
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1999; Harwerth et al., 2004). As a result, perimetry techniques may not be 
sensitive to detect early losses in ganglion cells.  
Various other techniques such as electrodiagnostics are available that can be 
utilized to objectively measure the visual function and they also exhibit 
topographical correspondence with retinal regions examined. 
Electrodiagnostic tests 
Electroretinogram (ERG) 
Full-field ERG represents the mass electrical response from the entire retina 
that constitutes rod and cone-mediated responses. Studies that measured the 
retinal electrophysiological responses in individuals with diabetes observed 
reduced oscillatory potential amplitudes and delayed latencies (Barber, 2003) 
in the absence of signs of DR; this suggests susceptibility of the middle and inner 
retinal layers (Kern et al., 2008) and possibly amacrine cells to vascular insult. 
However, unless about 20% of the retina is affected, the full-field ERG responses 
are generally normal (Hood et al., 2008). Therefore, full-field ERG may not be 
suited for assessing focal retinal function or macular function.  
The multifocal ERG (mfERG) on the other hand, provides a topographical 
 easure  f t e retina  fun ti n fr   t e  entra     ˚  f t e retina (Hood et al., 
2012). The responses are essentially cone-driven, elicited from the foveal, 
macular and paramacular regions. The outcomes of mfERG are a result of 
mathematical extraction and are recorded as a waveform represented as 5 
rings. The waveform has a first negative deflection called N1, followed by a first 
positive P1 and then a second negative N2. Similar to a full-field ERG, the N1, P1 
and N2 represent responses from photoreceptors, bipolar and amacrine cells as 
in full-field ERG. Interpretation involves assessment of amplitudes and implicit 
times in comparison to age-related normal values. The mfERG amplitude is 
measured from trough to peak and the implicit time is measured as the time at 
which P1 occurs. The advantage of mfERG over full-field ERG is that the 
responses can be localized to separate retinal regions such that, loss of signal 
can be localized to dysfunction in that region. A reduction in the mfERG 
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amplitudes with delayed implicit times may suggest ischaemic or hypoxic 
effects; however, the technique requires central fixation. More importantly, the 
retinal ganglion cells have little contribution to the mfERG responses (Hood, 
2000). 
Another variation of ERG technique is the pattern ERG (PERG). Pattern ERG 
responses represent a measure of ganglion cell function (Holder et al., 2007) 
fr   a 1  ˚ fie d (Neveu et al., 2006). The retinal response is obtained by having 
the patient view a checker board pattern stimulus that is based on temporal 
modulation. Reduced amplitude and or a delay in the implicit time may 
represent disease process affecting the outer plexiform layer and bipolar cells 
that connect with the ganglion cells. The PERG responses were affected in 
individuals with diabetes with and without DR (Coupland, 1987; Falsini et al., 
1989; Fortune et al., 1999; Ghirlanda et al., 1991; Prager et al., 1990) thus 
supporting the hypothesis that neural degeneration may be possibly related to 
diabetic peripheral neuropathy. This indicates that PREG can detect early 
neuroretinal changes in diabetes. Therefore, PERG may prove to be beneficial in 
demonstrating peripheral neuropathy related compromise in ganglion cell 
function, irrespective of DR.  
Visual evoked potentials (VEP) 
Visual evoked potentials represent electrophysiological responses recorded 
from the visual cortex, by attachment of electrodes to the scalp. The VEP 
represent an objective method of assessing optic nerve function. Flash VEP and 
pattern VEP are the two commonly performed VEP techniques. Flash VEP is 
performed to assess the visual function wherein, visual acuity is not a main 
requirement for the conduct of the test. Pattern-reversal VEP on the other hand 
requires the participant to view checkerboard stimuli that alternates. Pattern 
VEP responses depend on central fixation and hence visual acuity. The 
waveform has the first negative deflection, the N75, followed by the P100; P100 
is the first positive rise on the response waveform. This is followed by N135 
which is the second negative. The latency and the amplitude of P100 are mostly 
of interest. The latency of this P100 has been demonstrated to be delayed in 
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people with diabetes in the absence of clinical signs of DR, which normalized 
following optimal metabolic control (Verrotti, et al., 2000). The amplitude is 
generally contributed by the axonal numbers, and the latency is an attribute of 
the myelin status of the entire visual pathway (Daube. et al., 2009). About 65% 
of the response from pattern VEP represents that from the central 2 degrees of 
fixation indicating that it is not particularly useful for measuring peripheral 
retinal function. In addition, pattern VEP is subject to high variability between 
subjects (Baseler et al., 1994) and is limited by the reduced ability to localize the 
defects in space (Danesh et al., 2006).  
The multifocal VEP (mfVEP) involves objective evaluation of retina, optic nerve 
function and visual cortex; tests up to 26 degree eccentricity (Klistorner et al., 
1998); has better repeatability compared to that of standard automated 
perimetry (Fortune et al., 2006). However, the responses can be confounded by 
background noise due to the morphology of the visual cortex (Hoffmann, 2008); 
mfVEP also has been reported to have greater variability with increasing 
eccentricity as well as a greater inter-test variability (Klistorner et al., 2005).  
Assessment of visual function in diabetic neuropathy 
Individuals with neuropathy and foot complications may have gait problems. 
They may bump into objects because of unsteadiness while walking. This may 
become more problematic especially in dim illumination. Therefore evaluation 
of contrast sensitivity may reveal useful information.  
In the current study, a significant reduction in the full retinal thickness and 
neural layer thickness in the macular area and focal loss in ganglion cells is 
observed in individuals with diabetic peripheral neuropathy. Macular integrity 
is crucial as it subserves central visual field. Therefore, objective evaluation of 
both central and peripheral visual field sensitivity is indicated for such patients. 
Although microperimetry is a subjective technique, it represents an innovative 
technology among the perimetry techniques in that, it provides a topographical 
correspondence with the OCT scanned area as well as with ocular fundus 
images; therefore, the SD-OCT combined with microperimetry may prove to be 
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beneficial in this scenario. A pattern ERG may be utilized for assessment of 
ganglion cell function. The observation that the thickness in the perifovea is 
reduced could mean that the photoreceptors are involved; the results therefore 
call for examination of colour vision. 
From the above tests, a comprehensive evaluation that includes colour vision 
test, contrast sensitivity evaluation, SD-OCT combined with microperimetry, 
and pattern ERG evaluation, may prove to be beneficial in mapping the visual 
function in individuals with diabetes with and without neuropathy. New 
technologies are developed in an effort to overcome the limitations of 
techniques, but essentially all tests of visual function are subject to certain 
limitations. Eye care professionals to choose the most appropriate test 
depending on the objective of the testing. 
7.3 A potential marker for diabetic peripheral neuropathy 
T e ter  ‘ i  ar er’  as  een defined    Hu  a and     eagues (1990) as 
“ e  u ar   i   e i a   r    e u ar a ternati ns t at are  easura  e in 
 i   gi a   edia su   as  u an tissues   e  s  r f uids” (Hulka, 1991); for 
example, glucose levels in diabetes and blood pressure in hypertension. The 
main characteristic of a biomarker is that it should be specifically associated 
with a particular disease or disease state; must be capable of predicting the 
occurrence of the disease and be able to differentiate between similar 
physiological conditions. The Food and Drug Administration recommends that 
an ideal marker must be rapid, simple, accurate and an inexpensive measure.  
The biomarker identification process may involve direct or indirect 
measurements of the proposed parameter. Direct sampling includes 
examination of the biological fluids such as blood or tears. Indirect sampling 
involves detection of changes to biological tissues by imaging techniques 
(Mayeux, 2004). Markers that represent a characteristic or feature identified in 
an image that is relevant to the diagnosis of the patient are called imaging 
markers (Thrall, 2003). Corneal nerve fibre pathology is an example of a marker 
where the images can be used to assess diabetic peripheral neuropathy 
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(Edwards et al., 2012; Edwards et al., 2012; Efron et al., 2010; Pritchard et al., 
2010; Pritchard et al., 2011; Pritchard et al., 2012). Biomarkers can also be 
diagnostic or predictive (Jain, 2010). 
Markers for diabetic peripheral neuropathy 
There have been several breakthroughs in biomarkers research in various fields 
of medicine. For instance, samples of tissues such as the nerves, skin and 
muscles have been examined to understand the nature of the neurological 
disease process, as well as for developing effective treatment strategies.  
Sural nerve biopsy and skin biopsy are the traditional tests for detecting small 
fibre neuropathy (Tavee et al., 2009). However, the biopsy technique is 
minimally invasive and therefore uncomfortable for the individual (Polydefkis 
et al., 2001); also the results cannot be obtained immediately. Magnetic 
resonance imaging of the spine can reveal nerve damage (Thakkar et al., 2012) 
but this technique is not cost-effective and is also not feasible in a clinical 
scenario. Other methods such as nerve conduction studies provide with an 
objective evaluation of nerve fibres but of predominantly large nerve fibres. 
Techniques such as quantitative sensory testing involve evaluation of both large 
and small nerve fibres (Vinik et al., 1995); however, this is a subjective test and 
also requires the use of sophisticated equipment. In addition, these techniques 
could not demonstrate nerve regeneration in the peripheral limbs (Hsieh, 
2010). The eye serves as a suitable platform wherein, the nerve fibre 
involvement can be assessed non-invasively, with instant results.  
Corneal nerve fibre morphology evaluated by corneal confocal microscopy 
(CCM), has been identified as an ophthalmic biomarker for diabetic peripheral 
neuropathy. The nerve fibre density in both the epidermis and cornea were 
significantly reduced in individuals with neuropathy compared with those 
without neuropathy (Quattrini et al., 2007). The CCM can differentiate between 
various degrees of neuropathy (Tavakoli et al., 2011) and can detect corneal 
nerve fibre regeneration after pancreatic transplantation (Mehra, et al., 2007) 
thus demonstrating that CCM is a potential surrogate marker for diabetic 
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peripheral neuropathy (Malik, et al., 2003). In addition, corneal sensitivity 
evaluated by means of non-contact corneal aesthesiometry is a useful marker 
and a threshold of 0.66 millibars or greater indicates the presence of 
neuropathy (Pritchard, et al., 2012; Pritchard, et al., 2010). Thus CCM has been 
proven to be successful in identification of diabetic neuropathy changes as 
reduced corneal nerve fibre length even in early stages of the disease (Edwards 
et al., 2012; Edwards et al., 2012; Efron et al., 2010), thus indicating that this 
may have the potential to serve as a quick screening tool. 
Retinal markers for diabetic peripheral neuropathy are currently under 
investigation. The inferior RNFL thickness is compromised in individuals with 
neuropathy especially in those at risk of foot ulceration (Shahidi et al., 2012). 
Further to this, the current project has demonstrated that the full retinal 
thickness, macular and peripapillary nerve fibre layer thickness is compromised 
in relation to diabetic peripheral neuropathy. There is a greater focal loss in 
ganglion cell volume in individuals with neuropathy and it is worse in 
individuals with advanced degrees of neuropathy. Interestingly, focal loss in 
GCC volume does not show significant relationship to DR, age, duration of 
diabetes or the HbA1c levels. Thus the retinal parameters already exhibit the 
characteristics of a prospective biomarker for diabetic peripheral neuropathy. 
These findings are novel. As a subsequent step, the visual function needs to be 
assessed. Thereafter, the retinal thickness and visual functional parameters 
together require validation as potential biomarkers (Stem et al., 2013) for 
diabetic peripheral neuropathy.  
Validation of the biomarker 
The FDA recommends that a potential biomarker needs to be assessed for 
sensitivity, specificity, reliability and variability of the measurements. 
Sensitivity and specificity are measures of validity. An example of validity in this 
context would be if the RTVue OCT measures the correct retinal thickness 
(validity) and if it is consistent (reliability). A measurement is said to be reliable 
if it shows minimal variations. Inter- and intra-observer variability indicates the 
variability in measurements between operators and within individuals, 
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respectively. Retinal thickness measures have been evaluated for reliability, 
variability and diagnostic capability as described below. Retinal thickness 
measures demonstrated high correlation with the histological measurements 
indicating that the measurements are true retinal tissue thickness (Fukuchi et 
al., 2001; Knott et al., 2011; Koinzer et al., 2013; Michalewski et al., 2007). The 
reproducibility of RTVue retinal tissue thickness measures are equivalent to 
other commercially available instruments (Wolf-Schnurrbusch et al., 2009) and 
has similar diagnostic capability to other commercial instruments (Leite et al., 
2011). Sensitivity indicates the ability of the test to correctly identify the 
number of people who actually have the disease. Specificity indicates the ability 
 f t e test t    rre t   identif  t  se w   d n’t  a e t e disease. Positive 
predictive value is the percentage of people with a positive test who actually 
have the disease. Negative predictive value is the percentage of people with a 
negati e test resu t w   d n’t  a e t e disease (Parikh et al., 2008). These 
statistics need to be determined for retinal thickness assessment if such 
parameters are to serve as valid biomarkers for diabetic peripheral neuropathy.  
The current research program has demonstrated the retinal thickness measures 
are significantly associated with the NDS. As a subsequent step, the relationship 
with the electrophysiology measures may be assessed; furthermore, the 
sensitivity, specificity, inter-observer and the intra-observer variability of 
retinal thickness measurements and the predictive capability assessment in 
individuals with and without neuropathy and in various stages of neuropathy 
may be valuable. A receiver operating characteristic curve analysis can be 
performed to determine the diagnostic capability and validity of retinal tissue 
thickness measurement and visual function loss.  
It is to be noted that there is currently no single, effective, valid means to 
diagnose diabetic peripheral neuropathy. It is possible that ophthalmic markers 
may ultimately outperform the current screening methods for DPN and may 
decrease the need for painful, expensive and invasive procedures such as skin 
or nerve biopsies (Efron, 2011). 
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7.4 Future directions of this research 
An important follow-on from this study will be a longitudinal study assessing 
the retinal tissue thickness in relation to the natural history of diabetic 
neuropathy. This will provide a better understanding of these changes in 
relation to neural pathology occurring elsewhere in the body in individuals with 
diabetes. Investigation of other factors such as cardiovascular and nephropathy 
related factors in relation to retinal tissue thickness may be of interest. The 
current study may be a foundation to understand the risk of other micro and 
macrovascular complications of diabetes in relation to retinal tissue thickness. 
In addition, examination of the relationship between retinal tissue thickness 
and factors such as smoking and alcohol intake may be useful. 
Exploring other cranial nerves in relation to diabetic peripheral neuropathy 
Diabetic peripheral neuropathy has been thought as involving the peripheral 
nerves only, until studies demonstrated that the disease process can extend 
beyond the peripheral nerves (Eaton et al., 2001). The corneal nerve structure 
measured as nerve fibre length, count, branching, beading, width, tortuosity, 
orientation and reflectivity is compromised in relation to diabetic peripheral 
neuropathy (discussed in Chapter 1). Corneal nerves constitute the ophthalmic 
division of trigeminal nerve, which is the fifth cranial nerve. This opens up the 
possibility that diabetic peripheral neuropathy also involves the central nervous 
system. The RNFL thickness is compromised in relation to diabetic neuropathy 
(Shahidi et al., 2012) and this finding has been reiterated in the current research 
program. Consequently, the involvement of the second cranial nerve has been 
authenticated. It is also likely that the other cranial nerves may be involved in 
relation to diabetic peripheral neuropathy. The following sections provide an 
overview of the cranial nerves and methods of clinical assessment. 
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Testing for the other cranial nerves 
Cranial nerve I (Olfactory nerve) 
This nerve governs the sense of smell or olfaction. The assessment is performed 
by asking the patient to identify different aromas. The testing is performed for 
each nostril separately (Clark et al., 1990). 
Cranial nerves II, III, IV and VI  
The axons of the retinal nerve fibres represent cranial nerve II. Autonomic 
neuropathy may manifest as pupillary miosis or sudden extraocular muscle 
palsy thus indicating the involvement of III (Oculomotor nerve) and possibly IV 
(Trochlear nerve) and VI (Abducens nerve) cranial nerves (Fite et al., 1990). 
The extra ocular movements can be tested by the broad H test. Extraocular 
muscles can be tested for saccades (rapid eye movements) and pursuits (slow 
following movements) as well as the ability to converge and diverge. The 
assessment of eye deviations and the ability of the eyes to maintain fixation can 
be tested with cover tests. Pupillary reflex tests can be performed to evaluate 
the sympathetic and parasympathetic innervation.  
Cranial nerve V (Trigeminal nerve) 
The cornea receives its sensory innervation from the ophthalmic division of the 
trigeminal nerve. The non-ophthalmic component of the trigeminal nerve serves 
the sensory component of the face as well as motor supply to the muscles of 
mastication. Tests for sensory innervation include assessment of sensation to 
light touch and pin prick sensation with cotton wool and pins on both sides of 
the face along the three divisions of the trigeminal nerve. To examine the 
muscles of mastication, the patient is asked to clench the jaw and the examiner 
should feel equal muscle bulk on both sides of the jaw and temple (Walker et al., 
1990).  
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Cranial nerve VII (Facial nerve)  
This nerve governs the sensation on the skin of the face, motor control to the 
muscles in the face and also the anterior 2/3rds of the tongue. Motor control is 
assessed by simply asking the patient to wrinkle their eyebrows. It should be 
symmetrical on both sides. The patient is asked to show their teeth and to pop 
out their cheeks. Facial nerve supplies the orbicularis muscle that helps in 
closure of the eyelids. The nerve involvement can be tested by Bell’s 
phenomenon; the patient is asked to close his or her eyes tightly while the 
examiner tries to open the eyes. It is expected that the eye balls should be 
covered after eye lid closure. Any asymmetry or incomplete closure or lack of 
resistance to forced opening of the eyelid is abnormal (Walker, 1990). Absence 
 f Be  ’s  henomenon may lead to exposure of the cornea resulting in exposure 
keratitis (Brown, 1982). 
Cranial nerve VIII (Auditory and Vestibular nerves)  
This nerve governs hearing and balance. Weber test involves placing a tuning 
fork on the forehead. The normal response is to hear the tuning fork in both the 
ears. Rhine test involves placing a vibrating tuning fork on the mastoid process. 
The patient is asked to report when they cannot hear anymore. Following this, 
the other end of the tuning fork is brought to the front of the ear. The tuning 
fork would still be ringing because the air conduction pathway is more sensitive 
than the bone conduction pathway. This test can reportedly detect conductive 
hearing defect (Sanders et al., 2010). 
Cranial nerve IX nerve (Glossopharyngeal nerve)  
This nerve serves the taste sensation in the posterior 1/3rd of the tongue and 
also gag reflex. The gag reflex is tested by touching the palate with a tongue 
blade and observing for ipsilateral tongue contraction (Dodds, 1989).  
 
 
Summary and Conclusions 
177 
 
Cranial nerve X (Vagus nerve)  
This nerve serves muscles that aid in swallowing and in parasympathetic 
responses of the heart. The patient can be given water to drink, as a test for 
swallowing. Difficulty in swallowing may result in coughing (Dodds, 1989). 
Parasympathetic heart responses are assessed as beat-beat variations in heart 
rate with deep breathing, valsalva manoeuvre and postural changes in blood 
pressure. 
Cranial nerve XI (Spinal Accessory nerve)  
The nerve supplies the sternomastoid muscle. Testing is performed by asking 
the patient to turn the head sideways and if they can hold like that against 
resistance applied with the palm of the examiner. The examiner looks for 
stiffening of the neck muscle (sternomastoid muscle) on the opposite side (Gillig 
et al., 2010). 
Cranial nerve XII (Hypoglossal nerve)  
This nerve aids in motor control of the tongue. The muscle can be tested by 
asking the person to protrude their tongue and also observing tongue 
movements to the left and to the right. Evaluation can be as simple as looking 
inside the mouth of the patient to know if the tongue is steady or fasciculating 
(Gillig et al., 2010).  
Implications for patients with diabetic neuropathy 
Individuals with diabetic neuropathy especially with foot complications may 
have gait problems (Allet et al., 2008; Katoulis et al., 1997) either due to loss of 
sensation or due to painful symptoms in the feet. This may become significant 
and more complicated in the presence of reduced visual field sensitivity 
(Sampson et al., 2012). As a consequence, they are may be more prone to bump 
into objects especially in dim illumination, making them more susceptible to 
foot injury or even falls (Gabell et al., 1985; Richardson et al., 1995).  Patients 
can have defective colour vision that interferes with the quality of life, difficulty 
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in driving and face recognition. Other micro and macrovascular complications 
and amputation may complicate existing health conditions. For the reason that 
diabetic peripheral neuropathy is a debilitating disorder for which there is no 
effective treatment, it is crucial that the disease be screened and identified in its 
early stages so as to intervene as early as possible, and thereby prevent 
avoidable complications. 
Implications for eye care practitioner 
The eye care practitioners must note that the absence of diabetic retinopathy 
does not rule out any retinal complications. Individuals can have undiagnosed 
diabetic peripheral neuropathy and its associated neuroretinal complications. 
Due to the transparent nature of the retinal nerve fibre layer, a compromise to 
the neural layers may or may not be noticeable during a routine eye 
examination. Therefore, these individuals need to be referred to their health 
care provider for appropriate follow-up so as to detect undiagnosed disease or 
other micro and macrovascular complications of diabetes. This would help in 
intervening at the early stages so that any avoidable complications can be 
prevented. Conversely, once these retinal findings have been established as 
markers, ophthalmic screening may detect a previously undiagnosed 
neuropathy. The patients can be subsequently referred to a specialist for a 
comprehensive evaluation. 
Implications for endocrinologist 
Peripheral neuropathy is a debilitating complication of diabetes for which there 
is no effective treatment. Therefore, the emphasis here is on prevention or 
slowing down the progression of neuropathy. Although clinical trials tested 
aldose reductase inhibitors, antioxidants and nerve growth factors as treatment 
options for diabetic neuropathy, the results were disappointing (Habib et al., 
2010). The only aspect that showed promising outcomes was optimal glycaemic 
levels. Endocrinologists can play a significant role in working with the patients 
to achieve optimal glycaemic levels as well as in counselling the patient in 
recording the everyday levels. In addition, podiatrists can assist by educating 
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patients about the importance of regular health check-up and proper foot care. 
Counselling and advice regarding proper fitting shoes and protection of 
sensitive areas in the feet should be emphasized.  
If the various ophthalmic markers of diabetic neuropathy such as the retinal 
markers investigated in this thesis are eventually validated, then eye care 
practitioners may become an important part of multidisciplinary teams 
(Gardner et al., 2011), including diabetic physicians and podiatrists, in 
identifying and monitoring patients with diabetic peripheral neuropathy. A 
timely referral and management plan can prevent or delay unnecessary 
consequences. 
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Certificate serves as your written notice that the proposal has met the requirements of the National Statement on 
Research involving Human Participation and has been approved on that basis.  You are therefore authorised to 
commence activities as outlined in your proposal application, subject to any specific and standard conditions        
detailed in this document.
Within this Approval Certificate are:
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                    * Participant Details
                    * Conditions of Approval (Specific and Standard)
Researchers should report to the UHREC, via the Research Ethics Coordinator, events that might affect 
continued ethical acceptability of the project, including, but not limited to:
   (a) serious or unexpected adverse effects on participants; and
   (b) proposed significant changes in the conduct, the participant profile or the risks of the  
          proposed research.
Further information regarding your ongoing obligations regarding human based research can be found via the 
Research Ethics website http://www.research.qut.edu.au/ethics/ or by contacting the Research Ethics 
Coordinator on 07 3138 2091 or ethicscontact@qut.edu.au
If any details within this Approval Certificate are incorrect please advise the Research Ethics Unit within 10 days 
of receipt of this certificate.
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Category of Approval:
Approved From: 28/05/2013
Approval Number: 0800000167
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Project Title:
Approved Until:28/05/2008 (subject to annual reports)
Ophthalmic markers of diabetic neuropathy
Experiment Summary: Employ novel non-invasive ophthalmic markers of peripheral nerve dysfunction to 
investigate peripheral nerve morphology and function in Type 1 and 2 diabetic patients 
with and without neuropathy.
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Specific Conditions of Approval:
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5. Stop any involvement of any participant if continuation of the research may be harmful to that person, and 
immediately advise the Research Ethics Coordinator of this action;
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continued ethical acceptability of the project;
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1. Conduct the project in accordance with University policy, NHMRC / AVCC guidelines and regulations, and the 
provisions of any relevant State / Territory or Commonwealth regulations or legislation;
2. Respond to the requests and instructions of the University Human Research Ethics Committee (UHREC); 
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7. Report on the progress of the approved project at least annually, or at intervals determined by the Committee;
8. (Where the research is publicly or privately funded) publish the results of the project is such a way to permit 
scrutiny and contribute to public knowledge; and
9. Ensure that the results of the research are made available to the participants.
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Participant Information and Consent Form 
for a joint project by Princess Alexandra Hospital 
 and Queensland University of Technology  
Project Title (official): Ophthalmic Markers of Diabetic Neuropathy 
Project Title (simplified):  Examining the eyes to diagnose nerve problems in patients with 
diabetes. 
Principal Researcher: Prof Nathan Efron1 
Associates: Prof Andrew Boulton2, Prof Rayaz Malik2, Prof John Prins3, Dr Anthony 
Russell3, Nicola Pritchard1 , Katie Edwards1 , AProf Andrew Cotterill4 
1 Queensland University of Technology, 2 University of Manchester, 3 Princess Alexandra 
Hospital, 4 Mater Children’s Hospital 
1. Introduction 
You (or your child or the person you are responsible for) are invited to take part in this 
research project. This is because you (or your child or the person you are responsible for) 
are in the age range of 14-75 years and either have a history of diabetes, or have no history 
of disease that might affect the nerves of the eye or the body. People who have had eye 
injury or surgery, other eye diseases (e.g. glaucoma), other general health diseases which 
may affect the front ‘clear window’ of the eye, known as the cornea (e.g. keratoconus) or 
body (e.g. carcinoma, leukemia), large fibre neuropathy (damage to the large nerve fibres), 
congestive heart failure (weakening of the hearts pumping ability), major mental health 
problems, HIV-AIDS or diabetic foot ulcer or infection, or those participating in any other 
research trial will not be eligible. 
The research project is aiming to investigate relationship between the nerves of the eye and 
a condition which involves the peripheral nerves of the body in people with and without 
diabetes.  We hope to determine if some of the measures of the nerves in the eye and the 
sensitivity of the eye are reduced in people with peripheral nerve damage due to diabetes. 
This Participant Information and Consent Form tells you (and your child or the person you 
are responsible for) about the research project. It explains the procedures involved. Knowing 
what is involved will help you (or your child or the person you are responsible for) decide if 
you (or they) want to take part in the research. 
Please read this information carefully. Ask questions about anything that you (or your child or 
the person you are responsible for) don’t understand or want to know more about. Before 
deciding whether or not to take part, you (or they) might want to talk about it with a relative, 
friend or healthcare worker. 
Participation in this research is voluntary. If you (or your child or the person you are 
responsible for) don’t wish to take part, you (or they) don’t have to. You (or your child or the 
person you are responsible for) will receive the best possible care whether you (or they) take 
part or not. 
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If you (or your child or the person you are responsible for) decide you (or they) want to take 
part in the research project, you (or they) will be asked to sign the consent section. By 
signing it you (or they) are telling us that you (or they): 
 understand what you (or they) have read;  
 consent to take part in the research project; 
 consent to participate in the research processes that are described; 
 consent to the use of your (or their) personal and health information as described 
You (or your child or the person you are responsible for) will be given a copy of this 
Participant Information and Consent Form to keep. 
If you are the parent or guardian of a child or young person, as the ‘person responsible’ for 
the patient, you are invited to consider the patient’s participation in this research project. Both 
the child/young person and the ‘person responsible’ must consent to participation in the 
study. If you (or they) decide to take part and later change your mind, you (or they) are free 
to withdraw from the project at any stage for any reason (stated or unstated) without 
comment or penalty. 
2. What is the purpose of this research project? 
This research project focuses on patients with different types of diabetes. As you (or your 
child or the person you are responsible for) may know, diabetes is associated with high sugar 
levels in the blood due to the body not producing enough insulin to convert this sugar into 
energy.  We think there might be some differences in the nerves of the eyes of people who 
have different types of diabetes and we can measure this by using new, simple methods that 
measure the actual nerves and nerve function.  These are the eye tests:  corneal confocal 
microscopy (CCM; high magnification microscope) can be used to look at the nerves in the 
front of the eye; and corneal non-contact aesthesiometry (NCCA) is used to measure the 
sensitivity of the front of the eye; ocular coherence tomography (OCT) is used to assess the 
nerves and tissues at the back of the eye and flicker perimetry (FP) measures how well you 
can see dim lights (both these techniques are described in Section 3).  The measures of 
nerves and nerve function made by these techniques are thought to be related to diabetic 
neuropathy, the damage of nerves in the peripheral limbs associated in some patients with 
diabetes.  In the research project we aim to investigate the following:  
 Changes in corneal (front of eye) nerve counts and corneal sensitivity over time. 
 Changes in retinal (back of eye) nerve layer thickness and sensitivity to light over time. 
 The relationship between the progression of nerve damage with the results of other 
traditional nerve tests such as electrophysiology, measuring electrical signals from the 
body), measuring how easily you can detect vibration and temperature sensitivity and  
assessment of level of pain and discomfort in people with different types of diabetes. 
 The ability of these eye tests to detect nerve damage earlier than traditional means. 
 Identify risk factors associated with changes in nerves and nerve function in people 
with different types of diabetes; these may include age, height, weight, duration of 
diabetes, blood pressure, smoking, and poor blood-sugar control. 
Understanding these aspects of the nerves may provide healthcare professionals with a 
quick, simple, cost-effective and repeatable means to identify patients at risk, anticipate and 
monitor deterioration, and assess new treatments.   
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Diabetic nerve damage is a significant clinical problem that currently has no effective 
treatment, and in advanced cases, it is a major cause of ill-health and death worldwide.  If left 
unmanaged, diabetic nerve damage can lead to foot ulceration and ultimately, in some 
cases, foot amputation. It is therefore important to have the capacity to detect this condition 
early, monitor its progression and assess the benefits of any treatments. 
The results of this study will develop a better understanding of small fibre peripheral nerves 
in the arms and legs in patients suffering from diabetic nerve damage, and will determine the 
extent to which these changes are associated with the clinical signs and symptoms of the 
condition.  The significance of this study is that it will reveal the potential for these eye tests 
to serve as sensitive, rapid, repeatable, ‘patient-friendly’ eye tests for the detection, diagnosis 
and monitoring of the progression of diabetic nerve damage. This information will provide a 
sound basis for the design of trials of treatments for diabetic nerve damage.  Data will also 
be generated which will reveal the importance (or otherwise) of blood sugar control and other 
metabolic abnormalities and lifestyle factors which may impact on the progression of nerve 
damage in diabetic patients. 
A total of 298 participants will take part in this study at the Institute of Health and Biomedical 
Innovation (IHBI) at QUT in Brisbane and a further 202 at the University of Manchester in the 
United Kingdom.   
Five groups of people will be recruited in Brisbane:  
Group 1: Patients with Type 1 diabetes and without nerve damage 
Group 2: Patients with Type 1 diabetes with nerve damage 
Group 3: Patients with latent autoimmune diabetes in adults (LADA; similar to Type 1 
diabetes but occurring later in life) with nerve damage 
Group 4: Patients with Type 2 diabetes with and without nerve damage  
Group 5: Non-diabetic participants without nerve damage.   
Some of the results of this research will be used by the researchers Ayda Moavenshahididi 
and Nicola Pritchard to obtain Doctor or Philosophy degrees. 
This research is a collaborative project between researchers at QUT, Princess Alexandra 
Hospital (PAH) and University of Manchester (UM). It has been initiated by the investigators 
Professors Nathan Efron (QUT), Rayaz Malik, Andrew Boulton (UM), and John Prins (PAH); 
Dr Anthony Russell (PAH) and optometrists Nicola Pritchard and Dr Katie Edwards (QUT). 
This research has been funded in part by the Juvenile Diabetes Research Foundation 
International and Australia’s National Health & Medical Research Council and the George 
Weaber Foundation (to support Ms Moavenshahidi). 
3. What does participation in this research project involve? 
Your participation (or that of your child or the person you are responsible for) will involve 
asking you (or they) to reveal eye and past medical problems, and undergo an examination 
of the front part of the eye using a high powered microscope, read letters on an eye chart, 
and have the pressure of the eyes measured.  We will ask you (or your child or the person 
you are responsible for) to complete a questionnaire about pain in your (or their) lower limbs, 
and undergo simple tests of your (or their) sensations of pain/touch, vibration and 
temperature.  The tests are quick and involve use of a pointed tip, a tuning fork and warm 
and cool metal rods to test these three sensations. The presence of absence of the reflexes 
in your knees and ankles using a small hammer will be tested. Your (or their) height, weight 
and blood pressure will also be measured and a picture will be taken of the back of the eye. 
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Another high powered microscope, known as a corneal confocal microscope (CCM) will be 
used to examine the number of nerves at the front part of the eye, the cornea.  A drop of 
anaesthetic is applied to numb the front of the eye and you (or they) will be asked to sit at an 
instrument and look a target while several images are captured.  Initially the drop may sting 
for 1 or 2 seconds.  Because the drop numbs the eye it is possible to scratch the eye without 
noticing it.  Therefore please do not rub the eyes for at least 45 minutes after the drop has 
been placed in the eye.  
Another test of your (or their) ability to feel different sensations will be done using an 
instrument that can measure when you (or they) just notice sensations of cool, warm and 
vibration on the foot.  For example, for the coolness test you (or they) may feel like “a pulse 
of cooling” has touched the foot. It is important that before these tests no sedatives, 
tranquillisers, opiates, or stimulants have been taken in the preceding 12 hours, and not 
more than one hot drink has been consumed prior to the test.   
Another test that can reveal alterations to the nerves is a test of heart rate variability.  A 
measure of heart rate variability will also be conducted to show how the heart responds to 
deep breathing and to changes in blood pressure and posture.  
Corneal non-contact aesthesiometry (NCCA) will be conducted to measure the sensitivity of 
the cornea.  The smallest noticeable air pressure is determined by directing gentle, almost 
imperceptible puffs of air to the eye, and you (or they) indicate whether the air on the eye can 
be felt or not. We will also take a small sample of tears (50µl) to examine the proteins; this 
involves holding a tiny glass tube near the eye for a few seconds.   A swab of the conjunctiva 
(the white part of the eye) will be taken to investigate how diabetes affects the normal 
microbiota (microscopic living organisms) of the eye.  
The speed the nerves conduct messages will also be tested as a measure of nerve damage.  
Nerve conduction velocity will be measured by putting sensors on the ankle, wrist and elbow.  
The limb will be kept warm with a heat lamp if necessary. A small electrical current will be 
applied to the sensor which may feel like a tingling sensation and it may be uncomfortable for 
you (or them). You (or they) should feel no discomfort once the test is finished.  
Ocular coherence tomography (OCT) involves having a drop inserted into one eye to dilate 
the pupil. Then you (or they) will be asked to fixate a target while seated at the instrument, 
and at least two OCT images are captured.  A photograph of the back of the eye will also be 
taken using a specialised digital camera.  Due to the increased size of the pupil, your (or 
their) sensitivity to glare may be increased for 4 to 6 hours, so you (or they) may wish to wear 
dark glasses when outside and/or have someone drive or escort you (or them) home.    
Flicker perimetry (FP) involves viewing a light stimulus of varying intensity, and sometimes 
flickering, which appears in different parts of the visual field.  You (or your child or the person 
you are responsible for) will be required to click a button if you (or they) see the light while 
looking at a central spot.   
At the end of the study procedures the eye will be examined again; follow-up appointments 
will be made if the investigator believes it is in your (or their) best interests. This study will be 
carried out at IHBI at QUT. 
We expect the visit will be approximately 3 to 5 hours at IBHI at QUT, Kelvin Grove at a time 
suitable to you.  You (or they) will not be paid for participation in this research, but will be 
provided transport to and from QUT (e.g. parking / vouchers for petrol or cab vouchers will be 
provided up to approximately $40) and will receive light refreshments during the visit 
(approximate value $10). 
4. What will happen to my test samples? 
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You (or your child or the person you are responsible for) will be asked to provide consent for 
the collection of your (or their) blood (approximately 30-35ml, or 3-4 tubes) and urine 
(approximately 10ml) during the research project. From these samples the levels of protein, 
glucose, lipid and a test for antibodies for glutamic acid decardoxylase (GADAb) and 
antibodies to islet cells (ICAb) will be determined and recorded. This will help investigators 
decide which group to assign you (or them) to. All samples will be individually identifiable at 
the time of collection, analysis and report; a re-identifiable code will be assigned your (or 
their) blood results.  All blood and urine samples will be assessed through a contracted 
pathology service and samples are usually destroyed 7 days after collection. Separate 
consent will be obtained regarding storage of blood samples.  Unused tear and swab 
samples will be destroyed typically within 7 days of collection.  
5. What are the possible benefits? 
There will be no direct benefit to you (or your child or the person you are responsible for) 
from your (or their) participation in this research. However, it may benefit the many people 
who have problems with diabetic neuropathy, because with these instruments and 
techniques we are able to look at the tissues of the eye under very high magnification.  Also 
these new technologies may reveal features that have not, to date, been discovered but 
which might serve as sensitive, rapid and useful techniques for the detection, quantification 
and monitoring of the progression of nerve disease in patients with diabetes as well as other 
diseases where the nerves of the body are affected. Some people find the opportunity to 
learn and be a part of something new an interesting experience. 
We can provide you (or your child or the person you are responsible for) with state-of-the-art 
images of your (or their) eye if you (or they) would like them. 
6. What are the possible risks? 
The risks associated with participation in this study are minimal, and similar to routine 
diabetic and primary eye care. Minimal scratching the front surface of the eye can occur with 
corneal confocal microscopy, similar to that which might occur if you (or they) rub the eyes 
too hard; however, in our experience it is like that noted with normal daily wear of contact 
wearers.  This type of abrasion heals quickly, without intervention, typically within 12 hours. 
Having a blood taken may cause some discomfort or bruising. Sometimes, the blood vessel 
may swell, or blood may clot in the blood vessel, or the spot from which tissue is taken could 
become inflamed. Rarely, there could be a minor infection or bleeding. If this happens, it can 
be easily treated.  
Nerve conduction tests involve applying a small electrical current to the limb which may feel 
like a tingling sensation; this may be uncomfortable for you (or them). You (or they) should 
feel no discomfort once the test is finished. 
If you (or your child or the person you are responsible for) become upset or distressed as a 
result of your (or their) participation in the research, the researcher is able to arrange for 
counselling or other appropriate support. Any counselling or support will be provided by staff 
who are not members of the research team. In addition, you (or they) may prefer to suspend 
or end participation in the research if distress occurs without comment or penalty. 
There may be additional risks that the researchers do not expect or do not know about. Tell a 
member of the research team immediately about any new or unusual symptoms that you (or 
they) get. 
7. What if new information arises during this research project? 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you (or your child or the person you are 
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responsible for) will be told about this new information and the researcher will discuss 
whether this new information affects you (or them).  
8. Can I have other treatments during this research project? 
It is important to tell your (or their) doctor and the research staff about any treatments or 
medications you (or they) may be taking, including over-the-counter medications, vitamins or 
herbal remedies, acupuncture or other alternative treatments. You should also tell your (or 
their) doctor and the researchers about any changes to these during participation in the 
research. 
9. Are there alternatives to participation? 
Since this study does not involve any treatments, you (or your child or the person you are 
responsible for) will receive the best possible care whether you (or they) take part or not.  
Participation in the study does not replace full eye or medical care. You (or they) may also 
request that your (or their) general practitioner be informed of participation in the study. 
10. Do I have to take part in this research project? 
Participation in any research project is voluntary. If you (or they) do not wish to take part you 
(or they) don’t have to. If you (or they) decide to take part and later change your mind, you 
(or they) are free to withdraw from the project at any stage for any reason (stated or 
unstated) without comment or penalty. 
The decision whether to take part or not to take part, or to take part and then withdraw, will 
not affect your (or their) routine treatment, your relationship with those treating you (or them), 
nor your (or their) relationship with Princess Alexandra Hospital or Queensland University of 
Technology. 
11. What do I need to do if I decide to withdraw from this research project? 
If you (or your child or the person you are responsible for) decide to withdraw, please notify a 
member of the research team before you (or they) withdraw.  
If you (or they) decide to leave the project, the researchers would like to keep the personal 
and health information about you (or them) and your (or their) blood results that have been 
collected. This is to help them make sure that the results of the research can be measured 
properly. If you (or they) do not want them to do this, you (or they) must tell them before 
joining the research project. 
12. Could this research project be stopped unexpectedly? 
There are no foreseeable reasons why this research project would be terminated before 
completion.  In the unlikely event this did occur, you (or they) will be informed in writing and 
asked to attend a final study visit. 
13. How will I be informed of the results of this research project? 
The research team will provide regular newsletters on the progress of the study.  You (or 
your child or the person you are responsible for) will also receive a copy of any publications 
that are generated as a result of this study.  We expect this research project to be completed 
in approximately 5 years and a full summary of the results will be provided to you (or them) 
then. Results from the tests we perform will be sent, with your (or their) permission, directly 
to your (or their) medical practitioners. 
We would like to receive your feedback about your participation and may ask you (or the 
person you’re responsible for) to complete a questionnaire after the visit.  These responses 
will be matched to your visit dates by a team member who has no interaction with you.  This 
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means that the results of these questionnaires will be anonymous to the staff you meet at 
your visits. 
14. What else do I need to know? 
Any information obtained in connection with this research project that can identify you (or 
your child or the person you are responsible for) will remain confidential and will only be used 
for the purpose of this research project. It will only be disclosed with your (or their) 
permission, except as required by law. Information about you (or them) may be obtained 
from your (or their) health records held at PAH (where applicable) for the purposes of this 
research e.g. additional blood results related to your (or their) PAH clinic visit. If you attend 
another clinic we will seek your (or the person you’re responsible for) permission to obtain 
your (or their) blood results from your (their) doctor.  
Data is stored on paper records in locked filing cabinets at QUT, and the data in electronic 
form (i.e. entered into a computer) is only available to the research team members and is 
kept secure by using password-protected limited-access environment to protect your privacy.  
Data is stored during the project in an identifiable format i.e. with your name attached.  In any 
publication and/or presentation, information will be provided in such a way that you (or they) 
cannot be identified, except with your (and/or their) permission.  This will be done by only 
using the code number assigned to you (or them) for the purpose of this study; this will 
provide anonymity.  
At completion of the project your (or their) data will be decoded, or de-identified, such that it 
will not be possible to determine which data belong to which participant.  Data for this project 
will be kept for a minimum of 15 years or 5 years after the last publication, and de-identified 
data may be shared with national and international data registries.  Paper files will,be 
shredded.  
Information about your (or their) participation in this research project may be recorded in your 
(or their) health records. 
How can I access my information? 
In accordance with relevant Australian privacy and other relevant laws, you have the right to 
access the information collected and stored by the researchers about you (or your child or 
the person you are responsible for). You also have the right to request that any information, 
with which you disagree, be corrected. Please contact one of the researchers named at the 
end of this document if you (or they) would like to access your (or their) information. 
What happens if I am injured as a result of participating in this research project? 
If you (or they) suffer an injury as a result of participating in this research project, hospital 
care and treatment will be provided by the public health service at no extra cost to you (or 
them) if you (or they) elect to be treated as a public patient. 
Is this research project approved? 
The ethical aspects of this research project have been approved by the Human Research 
Ethics Committee of the Princess Alexandra Hospital and Queensland University of 
Technology.   
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007) produced by the National Health and Medical Research Council of 
Australia. This statement has been developed to protect the interests of people who agree to 
participate in human research studies. 
 Participant Information & Consent Form, Version 6, Date: 4 May 2010 PI&CF Page 8 of 9 
15. Consent 
I have read, or have had read to me in a language that I understand, this document and I 
understand the purposes, procedures and risks of this research project as described within it. 
I give permission for my doctors, other health professionals, hospitals or laboratories outside 
this hospital to release information to Queensland University of Technology concerning my 
health and treatment that is needed for this project. I understand that such information will 
remain confidential.  
I consent to the use of blood samples taken from me for use in this specific research project 
only, as described in Section 4 of this document. 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
I freely agree to participate in this research project as described.  
I understand that I will be given a signed copy of this document to keep. 
Participant’s name (printed)  ______________________________________________  
Signature __________________________________________ Date ______________ 
 
Declaration by parent, guardian or person responsible (where appropriate): I agree for my 
child/young person or the person named above who I am responsible for to participate in this 
research and I believe that they have understood the explanation of the study, its procedures 
and risks. 
Name of parent/guardian to participant’s (printed)  _____________________________   
Signature __________________________________________ Date ______________ 
 
Name of witness to participant’s signature (printed)  ____________________________   
Signature __________________________________________ Date ______________ 
Declaration by researcher*: I have given a verbal explanation of the research project, its 
procedures and risks and I believe that the participant has understood that explanation. 
Researcher’s name (printed)  ______________________________________________  
Signature __________________________________________ Date ______________ 
* A senior member of the research team must provide the explanation and provision of 
information concerning the research project.  
Note: All parties signing the consent section must date their own signature. 
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16. Who can I contact? 
Who you (or your child or the person you are responsible for) may need to contact will 
depend on the nature of your (or their) query; therefore, please note the following: 
For further information or appointments: 
Landmark Study  Email:   landmark@qut.edu.au or  Katie Edwards, Ph: 07 3138 6154, Email: 
katie.edwards@qut.edu.au. 
If you (or they) have any medical problems which may be related to your (or their) 
involvement in the project (for example, any side effects), you can contact Dr Anthony 
Russell Ph: 07 3240 5914 If you (or they) want any further information concerning this project 
you can contact the following people: 
Katie Edwards 
Ph: 07 3138 6154 
Email: 
katie.edwards@qut.edu.au 
Nicola Pritchard 
Ph: 07 3138 6414 
E-mail: 
n.pritchard@qut.edu.au 
Prof.Nathan Efron 
Ph: 07 3138 6401 
E-mail: 
n.efron@qut.edu.au 
If you (or they) feel emergency medical care is required, then go to the nearest hospital 
Emergency Department.  
For complaints:  
If you (or they) have any complaints about any aspect of the project, the way it is being 
conducted or any questions about being a research participant in general, then you (or they) 
may contact:   
Ethics Manager 
Princess Alexandra Hospital Human Research 
Ethics Committee 
Ph: (07) 3240 5856 
Email: PAH_Ethics_Research@health.qld.gov.au 
QUT Research Ethics Officer 
Queensland University of Technology Human 
Research Ethics Committee 
Ph: (07) 3138 2340 
E-mail: ethicscontact@qut.edu.au 
Researcher Ethics Officers/Managers are not connected with the research project and can 
facilitate a resolution to your (or their) concern in an impartial manner. 
 
